2022/12/01 更新

写真a

イシカワ タカシ
石川 卓
ISHIKAWA Takashi
所属
医歯学総合病院 医療情報部 准教授
職名
准教授
外部リンク

代表的な業績

    • 【論文】 In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.  2009年10月

    • 【論文】 Neoadjuvant therapy for gastrointestinal stromal tumor.  2018年

    • 【講演・口頭発表等】 胃癌に対する腹腔内三部位洗浄細胞診の有用性  2014年3月

学位

  • 博士(医学) ( 2010年3月   新潟大学 )

研究キーワード

  • 消化管間質腫瘍

  • 消化器外科

  • 医療情報学

  • 胃癌

  • 食道癌

研究分野

  • ライフサイエンス / 消化器外科学

経歴(researchmap)

  • 新潟大学医歯学総合病院   医療情報部   准教授

    2015年4月 - 現在

      詳細を見る

  • 新潟大学医歯学総合病院   光学医療診療部   助教

    2013年5月 - 2015年3月

      詳細を見る

  • 新潟大学医歯学総合病院   腫瘍センター   特任助教

    2010年4月 - 2013年4月

      詳細を見る

経歴

  • 新潟大学   医歯学総合病院 医療情報部   准教授

    2015年4月 - 現在

  • 新潟大学   医歯学総合病院 光学医療診療部   助教

    2013年5月 - 2015年3月

  • 新潟大学   医歯学総合病院 腫瘍センター   特任助教

    2010年4月 - 2013年4月

学歴

  • 新潟大学大学院   医歯学総合研究科   生体機能調節医学専攻

    2005年4月 - 2010年3月

      詳細を見る

所属学協会

▶ 全件表示

委員歴

  • 日本胃癌学会   代議員、登録委員会  

    2014年 - 現在   

      詳細を見る

 

論文

  • A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001-2013).

    Yoshihiro Kakeji, Takashi Ishikawa, Satoshi Suzuki, Kohei Akazawa, Tomoyuki Irino, Isao Miyashiro, Hiroyuki Ono, Haruhisa Suzuki, Satoshi Tanabe, Shigenori Kadowaki, Kei Muro, Takeo Fukagawa, Souya Nunobe, Takeyuki Wada, Hitoshi Katai, Yasuhiro Kodera

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The nationwide registry of the Japanese Gastric Cancer Association collected data of surgically resected cases of gastric cancer between 2001 and 2013. These retrospective analyses aimed to delineate tumor characteristics, surgical history, and survival distribution. METHODS: Data from 254,706 patients with primary gastric cancer were included. The 5-year survival rates were calculated for various subsets of prognostic factors. RESULTS: The number of patients over 70 years old increased from 2001 to 2013. The frequency with which laparoscopic gastrectomy was opted for increased dramatically (from 3.5 to 40.8%) in 13 years. We focused on the patients registered between 2010 and 2013, for whom data collection was based on the 3rd edition of the Japanese classification and guidelines. Five-year overall survival (OS) rate among 92,305 patients with resected tumors was 70.6%. The 5-year OS rates of patients with pathological stage IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV disease were 89.6%, 83.2%, 77.6%, 68.1%, 59.3%, 45.6%, 29.9%, and 14.0%, respectively. CONCLUSION: Our detailed analysis highlights the historical changes in outcomes of surgically treated gastric malignancies in Japan, and provides robust dataset for future analysis.

    DOI: 10.1007/s10120-022-01317-6

    PubMed

    researchmap

  • [A Case of HER2-Positive Recurrent Breast Cancer and Liver Metastases of GIST Treated with Combined Anti-HER2 Therapy and Imatinib].

    Haruka Uchida, Chie Toshikawa, Kazuki Moro, Takashi Ishikawa, Yasuo Obata, Junko Tsuchida, Masayuki Nagahashi, Hiroshi Ichikawa, Takaaki Hanyu, Kazuyasu Takizawa, Yoshifumi Shimada, Jun Sakata, Hajime Umezu, Yu Koyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   48 ( 13 )   1725 - 1727   2021年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 70-year-old female with liver metastases from gastrointestinal stromal tumor(GIST)that were found 3 months after partial gastrectomy for the primary GIST underwent Auchincloss operation for left breast cancer with ipsilateral axillary lymph node metastases. The diagnosis was microinvasive ductal cancer that was pT1miN1M0, pStage ⅡA, hormone receptor negative, and HER2 positive. Given the impact of this cancer on the prognosis of liver metastases of GIST, imatinib therapy, but not adjuvant chemotherapy, was started promptly for breast cancer after surgery. Four months after the surgery, left subclavian lymph node recurrence of breast cancer was found. Since the liver metastases of GIST had been stable, imatinib was discontinued, and paclitaxel and anti-HER2 therapy were administered. After confirming tolerability, imatinib was carefully added in combination. Because the lymph nodes shrank and liver metastases of GIST were stable, both anti-HER2 therapy and imatinib were continued. There are few reports of combined chemotherapy for synchronous double cancer, and we report our experience in which careful treatment was required.

    PubMed

    researchmap

  • HER2陽性再発乳癌とGIST肝転移に対し抗HER2療法とイマチニブを併用した1例

    内田 遥, 利川 千絵, 諸 和樹, 石川 卓, 小幡 泰生, 土田 純子, 永橋 昌幸, 市川 寛, 羽入 隆晃, 滝沢 一泰, 島田 能史, 坂田 純, 梅津 哉, 小山 諭, 若井 俊文

    癌と化学療法   48 ( 13 )   1725 - 1727   2021年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    症例は70歳、女性。胃GIST術後3ヵ月目に左乳癌、腋窩リンパ節転移、GIST肝転移を認め、左乳癌に対し手術を施行した。病理組織学的結果はHER2陽性乳癌、pT1miN1M0、pStage IIAであった。予後規定因子はGIST肝転移と考え、イマチニブを開始した。乳癌術後4ヵ月目に乳癌左鎖骨下リンパ節再発を認めた。GIST肝転移の病勢は安定していたためイマチニブをいったん休薬し、パクリタキセル、抗HER2療法を開始した。忍容性を確認した後、慎重にイマチニブを併用した。リンパ節は著明に縮小し肝転移も増大を認めず、パクリタキセルを7コースで終了した。現在は抗HER2療法、イマチニブを継続中である。転移性の重複癌において両者に対する薬物療法を同時併用した報告は少なく、若干の考察を加えて報告する。(著者抄録)

    researchmap

    その他リンク: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J00296&link_issn=&doc_id=20220117600064&doc_link_id=%2Fab8gtkrc%2F2021%2F004813%2F064%2F1725b1727%26dl%3D3&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2021%2F004813%2F064%2F1725b1727%26dl%3D3&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_4.gif

  • 大動脈周囲リンパ節転移を伴う膵頭部癌に対し集学的治療により長期生存を得た1例

    大竹 紘子, 滝沢 一泰, 長櫓 宏規, 峠 弘治, 廣瀬 雄己, 石川 博補, 三浦 宏平, 市川 寛, 羽入 隆晃, 永橋 昌幸, 島田 能史, 石川 卓, 坂田 純, 小林 隆, 若井 俊文

    癌と化学療法   48 ( 13 )   2002 - 2004   2021年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    症例は64歳、男性。慢性腎臓病で当院通院中に腹部CTで膵頭部癌と診断された。腹部CTおよびMRIでは遠隔転移や大動脈周囲リンパ節(PALN)転移は認めなかった。手術の方針とし術中にPALNサンプリングを行ったところ、迅速病理診断にてリンパ節4個中2個に転移を認めた。非切除とした場合、腎機能障害のため標準的な化学療法を施行できないと考え、PALN郭清を伴う亜全胃温存膵頭十二指腸切除術を施行した。病理診断は浸潤性膵管癌であり、S-1による術後補助化学療法を減量して行った。術後1年10ヵ月で腸間膜内リンパ節再発および肺転移再発を認めた。さらに、術後2年で腹腔内再発による上腸間膜動静脈狭窄を認めた。腹腔内再発に対し放射線療法を行い、引き続きgemcitabine単独療法を行った。肝外門脈狭窄による腹水貯留や消化管出血は治療により軽快した。結果、術後5年7ヵ月の長期生存を得た。(著者抄録)

    researchmap

    その他リンク: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J00296&link_issn=&doc_id=20220117600154&doc_link_id=%2Fab8gtkrc%2F2021%2F004813%2F154%2F2002b2004%26dl%3D3&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2021%2F004813%2F154%2F2002b2004%26dl%3D3&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_4.gif

  • Accuracy of the endoscopic evaluation of esophageal involvement in esophagogastric junction cancer. 国際誌

    Takeshi Sakai, Hiroshi Ichikawa, Takaaki Hanyu, Kenji Usui, Yosuke Kano, Yusuke Muneoka, Takashi Ishikawa, Yoshifumi Shimada, Jun Sakata, Toshifumi Wakai

    Annals of medicine and surgery (2012)   68   102590 - 102590   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Esophageal involvement length (EIL) is a promising indicator of metastasis or recurrence in mediastinal lymph nodes (MLNs) in adenocarcinoma of the esophagogastric junction (EGJ). This study aimed to elucidate the accuracy of the preoperative endoscopic evaluations of EIL and its clinical significance in this disease. Materials and methods: In total, 75 patients with Siewert type II (N = 53) or III (N = 22) adenocarcinoma of the EGJ, who underwent surgical resection without preoperative therapy between 1995 and 2016 were enrolled. We retrospectively examined the accuracy of the preoperative endoscopic evaluations of EIL (preoperative EIL), compared to the pathologically evaluated EIL. Finally, we investigated the association between preoperative EIL and metastasis or recurrence in MLNs. Results: The accuracy of the preoperative EIL within a 1-cm interval was only 53.3%. Among patients with discordance between the pre- and postoperative evaluations, 68.6 % had the underestimation in the preoperative EIL. pN1-3 (OR = 5.85, 95% CI: 1.03-33.17) and undifferentiated histologic type (OR = 2.52, 95% CI: 0.89-7.14) were potential risk factors for the discordance. Regarding metastasis or recurrence in MLNs, preoperative EIL of 2-3 cm (OR = 10.41, 95% CI: 1.35-80.11) and >3 cm (OR = 8.33, 95% CI: 1.09-63.96) were independent predictors. Conclusion: Although the accuracy of the endoscopic evaluations of EIL is insufficient with many underestimations, EIL should be assessed in preoperative staging because of significant predictive power for metastasis or recurrence in MLNs.

    DOI: 10.1016/j.amsu.2021.102590

    PubMed

    researchmap

  • 胃癌患者における術後炎症が長期予後に与える影響

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 宗岡 悠介, 茂木 大輔, 島田 能史, 永橋 昌幸, 坂田 純, 若井 俊文

    日本消化器外科学会総会   76回   P003 - 3   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 肝内・肝外胆管癌の診断で外科切除された良性胆管狭窄症例の検討

    廣瀬 雄己, 坂田 純, 滝沢 一泰, 三浦 宏平, 石川 博補, 峠 弘治, 長櫓 宏規, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 小林 隆, 若井 俊文

    ENDOSCOPIC FORUM for digestive disease   37 ( 1 )   33 - 33   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 肝内・肝外胆管癌の診断で外科切除された良性胆管狭窄症例の検討

    廣瀬 雄己, 坂田 純, 滝沢 一泰, 三浦 宏平, 石川 博補, 峠 弘治, 長櫓 宏規, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 小林 隆, 若井 俊文

    ENDOSCOPIC FORUM for digestive disease   37 ( 1 )   33 - 33   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 当院における腹腔鏡・内視鏡合同手術(LECS)の現状と課題

    加納 陽介, 羽入 隆晃, 佐藤 裕樹, 水野 研一, 市川 寛, 石川 卓, 宗岡 悠介, 茂木 大輔, 須藤 翔, 小柳 英人, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 寺井 崇二, 若井 俊文

    ENDOSCOPIC FORUM for digestive disease   37 ( 1 )   36 - 36   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry.

    Satoshi Suzuki, Arata Takahashi, Takashi Ishikawa, Kohei Akazawa, Hitoshi Katai, Yoh Isobe, Isao Miyashiro, Hiroyuki Ono, Satoshi Tanabe, Takeo Fukagawa, Kei Muro, Souya Nunobe, Shigenori Kadowaki, Haruhisa Suzuki, Tomoyuki Irino, Shiyori Usune, Hiroaki Miyata, Yoshihiro Kakeji

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   24 ( 3 )   545 - 566   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The National Clinical Database (NCD) nationwide registry program of gastric cancer started in 2018. The purpose of this study was to report the treatment results of the NCD registry in the form of treatment results of the real world in Japan. METHODS: Patients' characteristics, tumor features, treatments, and outcomes were collected using a web-based data entry system. We analyzed the initial NCD database for data on surgically treated gastric cancer patients in 2011. RESULTS: A total of 30,257 patients with malignant gastric tumors were enrolled by the NCD registry program from 501 hospitals in all 47 prefectures. Of these, the status of data entry was not approved in 8.8% of the registered data, and follow-up information was missing in 1.2% of the approved cases. Excluding 1777 cases, which were not resected for primary gastric cancer, 25,306 resected cases included 44.4% of stomach surgeries recorded in the NCD. The 5 year survival rate of the resected cases was 71.3% and the operative mortality rate was 0.41%. The stage-specific 5 year survival rates were as follows: 89.6% for stage IA, 83.8% for stage IB, 77.3% for stage IIA, 69.1% for stage IIB, 58.7% for stage IIIA, 44.1% for stage IIIB, 30.1% for stage IIIC, and 13.4% for stage IV. CONCLUSIONS: The NCD gastric cancer registry program demonstrated validity for database construction. The gastric cancer registry is expected to become a nationwide registry with the dissemination of data entry system and method in the NCD.

    DOI: 10.1007/s10120-021-01178-5

    PubMed

    researchmap

  • Determinant Factors on Differences in Survival for Gastric Cancer Between the United States and Japan Using Nationwide Databases.

    Yuri Ito, Isao Miyashiro, Takashi Ishikawa, Kohei Akazawa, Keisuke Fukui, Hitoshi Katai, Souya Nunobe, Ichiro Oda, Yoh Isobe, Shunichi Tsujitani, Hiroyuki Ono, Satoshi Tanabe, Takeo Fukagawa, Satoshi Suzuki, Yoshihiro Kakeji, Mitsuru Sasako, Anton Bilchik, Manabu Fujita

    Journal of epidemiology   31 ( 4 )   241 - 248   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Although the incidence and mortality have decreased, gastric cancer (GC) is still a public health issue globally. An international study reported higher survival in Korea and Japan than other countries, including the United States. We examined the determinant factors of the high survival in Japan compared with the United States. METHODS: We analysed data on 78,648 cases from the nationwide GC registration project, the Japanese Gastric Cancer Association (JGCA), from 2004-2007 and compared them with 16,722 cases from the Surveillance, Epidemiology, and End Results Program (SEER), a United States population-based cancer registry data from 2004-2010. We estimated 5-year relative survival and applied a multivariate excess hazard model to compare the two countries, considering the effect of number of lymph nodes (LNs) examined. RESULTS: Five-year relative survival in Japan was 81.0%, compared with 45.0% in the United States. After controlling for confounding factors, we still observed significantly higher survival in Japan. Among N2 patients, a higher number of LNs examined showed better survival in both countries. Among N3 patients, the relationship between number of LNs examined and differences in survival between the two countries disappeared. CONCLUSION: Although the wide differences in GC survival between Japan and United States can be largely explained by differences in the stage at diagnosis, the number of LNs examined may also help to explain the gaps between two countries, which is related to stage migration.

    DOI: 10.2188/jea.JE20190351

    PubMed

    researchmap

  • 生理機能から見たハイリスク胃癌患者に対する胃全摘の適応 胃癌根治患者における胃全摘術と他病死に関する検討

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 小杉 伸一, 宗岡 悠介, 茂木 大輔, 小柳 英人, 廣瀬 雄己, 須藤 翔, 三浦 宏平, 田島 陽介, 中野 麻恵, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   PD - 5   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 膵全摘術後の長期生存例の検討:多施設共同研究

    石川 博補, 坂田 純, 堅田 朋大, 滝沢 一泰, 三浦 宏平, 廣瀬 雄己, 峠 弘治, 長櫓 宏規, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 若井 俊文, 野村 達也, 横山 直行, 北見 智恵, 青野 高志, 小林 隆

    日本外科学会定期学術集会抄録集   121回   PS - 3   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • Bismuth IV型肝門部領域胆管癌の手術成績と予後因子の検討

    三浦 宏平, 坂田 純, 長櫓 宏規, 三浦 要平, 安藤 拓也, 油座 築, 峠 浩治, 廣瀬 雄己, 石川 博補, 須藤 翔, 滝沢 一泰, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 若井 俊文, 小林 隆

    日本外科学会定期学術集会抄録集   121回   SF - 3   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 非乳頭部十二指腸癌においてリンパ節転移個数が術後遠隔成績に及ぼす影響 多施設共同研究

    廣瀬 雄己, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 須藤 翔, 石川 博補, 峠 弘治, 油座 築, 長櫓 宏規, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 高野 可赴, 野村 達也, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   SF - 7   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 年代別に見た大腸癌治療成績の比較

    中野 雅人, 島田 能史, 松本 瑛生, 阿部 馨, 田中 花菜, 小柳 英人, 田島 陽介, 中野 麻恵, 三浦 宏平, 市川 寛, 滝沢 一泰, 羽入 隆晃, 永橋 昌幸, 坂田 純, 小林 隆, 野上 仁, 丸山 聡, 瀧井 康公, 石川 卓, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   PS - 7   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 食道癌手術における食道胃管吻合部狭窄の検討

    茂木 大輔, 市川 寛, 番場 竹生, 加納 陽介, 羽入 隆晃, 須藤 翔, 石川 卓, 宗岡 悠介, 廣瀬 雄己, 三浦 宏平, 田島 陽介, 滝沢 一泰, 中野 雅人, 永橋 昌幸, 島田 能史, 坂田 純, 小林 隆, 小杉 伸一, 中川 悟, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   PS - 3   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 食道癌手術における胃管再建 当科の標準術式と短期成績

    市川 寛, 羽入 隆晃, 加納 陽介, 石川 卓, 茂木 大輔, 宗岡 悠介, 須藤 翔, 小柳 英人, 廣瀬 雄己, 三浦 宏平, 田島 陽介, 中野 麻恵, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 小杉 伸一, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   PS - 6   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 再発胆道癌に対する外科切除 再発形式からみた成績

    長櫓 宏規, 坂田 純, 滝沢 一泰, 三浦 宏平, 廣瀬 雄己, 峠 弘治, 油座 築, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 若井 俊文, 野村 達也, 青野 高志, 北見 智恵, 横山 直行, 皆川 昌広, 小林 隆

    日本外科学会定期学術集会抄録集   121回   SF - 5   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • アクチビン受容体2A型遺伝子変異がMSI-H胃癌に及ぼす影響

    油座 築, 永橋 昌幸, 加納 陽介, 市川 寛, 羽入 隆晃, 坂田 純, 滝沢 一泰, 三浦 宏平, 須藤 翔, 廣瀬 雄己, 峠 弘治, 長櫓 宏規, 中野 雅人, 島田 能史, 石川 卓, 中川 悟, 藪崎 裕, 佐藤 信昭, 小杉 伸一, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   SF - 2   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 再発胆道癌に対する外科切除 再発形式からみた成績

    長櫓 宏規, 坂田 純, 滝沢 一泰, 三浦 宏平, 廣瀬 雄己, 峠 弘治, 油座 築, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 若井 俊文, 野村 達也, 青野 高志, 北見 智恵, 横山 直行, 皆川 昌広, 小林 隆

    日本外科学会定期学術集会抄録集   121回   SF - 5   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 乳癌術前患者用パンフレットの有用性に関する研究

    土田 純子, 永橋 昌幸, 長谷川 遥, 遠藤 麻巳子, 諸 和樹, 山浦 久美子, 利川 千絵, 五十嵐 麻由子, 小山 諭, 市川 寛, 羽入 隆晃, 滝沢 一泰, 島田 能史, 小林 隆, 石川 卓, 金子 耕司, 神林 智寿子, 佐藤 信昭, 坂田 純, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   PS - 7   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • トリプルネガティブ乳癌において腫瘍組織のみを用いた癌遺伝子パネル検査で検出された二次的所見開示を検討すべき体細胞変異

    利川 千絵, 永橋 昌幸, 遠藤 麻巳子, 諸 和樹, 土田 純子, 庭野 稔之, 長谷川 美樹, 五十嵐 麻由子, 小山 諭, 市川 寛, 羽入 隆晃, 滝沢 一泰, 島田 能史, 石川 卓, 小林 隆, 神林 智寿子, 金子 耕司, 佐藤 信昭, 坂田 純, 若井 俊文

    日本外科学会定期学術集会抄録集   121回   PS - 2   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本外科学会  

    researchmap

  • 癌遺伝子パネルを用いた胃癌MSI解析とミスマッチ修復遺伝子発現の関連

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 宗岡 悠介, 茂木 大輔, 島田 能史, 永橋 昌幸, 坂田 純, 若井 俊文

    日本胃癌学会総会記事   93回   243 - 243   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本胃癌学会  

    researchmap

  • ASO Author Reflections: ypTNM Stage Grouping in the 8th Edition of the AJCC Cancer Staging Manual Refines the Prognostic Prediction for Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy. 国際誌

    Natsuru Sudo, Hiroshi Ichikawa, Yusuke Muneoka, Takaaki Hanyu, Yosuke Kano, Takashi Ishikawa, Yuki Hirose, Kohei Miura, Yoshifumi Shimada, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Takeo Bamba, Satoru Nakagawa, Shin-Ichi Kosugi, Toshifumi Wakai

    Annals of surgical oncology   28 ( 2 )   661 - 662   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-020-09184-0

    PubMed

    researchmap

  • Clinical Utility of ypTNM Stage Grouping in the 8th Edition of the American Joint Committee on Cancer TNM Staging System for Esophageal Squamous Cell Carcinoma. 国際誌

    Natsuru Sudo, Hiroshi Ichikawa, Yusuke Muneoka, Takaaki Hanyu, Yosuke Kano, Takashi Ishikawa, Yuki Hirose, Kohei Miura, Yoshifumi Shimada, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Takeo Bamba, Satoru Nakagawa, Shin-Ichi Kosugi, Toshifumi Wakai

    Annals of surgical oncology   28 ( 2 )   650 - 660   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system provided a specific 'ypTNM' stage grouping for patients with esophageal cancer. OBJECTIVE: This study aimed to evaluate the clinical utility of the AJCC 8th edition ypTNM stage grouping for patients with esophageal squamous cell carcinoma (ESCC). METHODS: We enrolled 152 patients with ESCC who underwent surgery after neoadjuvant cisplatin plus 5-fluorouracil (CF) therapy between June 2005 and December 2011. ypStage was evaluated according to the AJCC 7th and 8th editions. Predictive performance for disease-specific survival (DSS) and overall survival (OS) was compared between both editions. The prognostic significance of ypTNM stage grouping was evaluated using univariate and multivariate analyses. RESULTS: Revision of the AJCC 7th edition to the 8th edition was associated with a change in ypStage in 96 patients (63.2%). The AJCC 8th edition revealed a better predictive performance than the 7th edition in terms of DSS (Akaike's information criterion [AIC] 499 vs. 513; Bayesian information criterion [BIC] 505 versus 519; concordance index [C-index] 0.725 versus 0.679) and OS (AIC 662 vs. 674; BIC 669 vs. 681; C-index 0.662 vs. 0.622). On univariate and multivariate analyses, ypStage in the 8th edition was an independent prognostic factor for both DSS and OS. CONCLUSIONS: ypTNM stage grouping in the AJCC 8th edition provided a better predictive performance for DSS and OS than that in the 7th edition. ypStage in the 8th edition was the most reliable prognostic factor for ESCC patients who underwent surgery after neoadjuvant CF therapy.

    DOI: 10.1245/s10434-020-09181-3

    PubMed

    researchmap

  • Activin a Receptor Type 2A Mutation Affects the Tumor Biology of Microsatellite Instability-High Gastric Cancer. 国際誌

    Kizuki Yuza, Masayuki Nagahashi, Hiroshi Ichikawa, Takaaki Hanyu, Masato Nakajima, Yoshifumi Shimada, Takashi Ishikawa, Jun Sakata, Shiho Takeuchi, Shujiro Okuda, Yasunobu Matsuda, Manabu Abe, Kenji Sakimura, Kazuaki Takabe, Toshifumi Wakai

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract   25 ( 9 )   2231 - 2241   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Activin A receptor type 2A (ACVR2A) is one of the most frequently mutated genes in microsatellite instability-high (MSI-H) gastric cancer. However, the clinical relevance of the ACVR2A mutation in MSI-H gastric cancer patients remains unclear. The aims of this study were to explore the effect of ACVR2A mutation on the tumor behavior and to identify the clinicopathological characteristics of gastric cancer patients with ACVR2A mutations. METHODS: An in vitro study was performed to investigate the biological role of ACVR2A via CRISPR/Cas9-mediated ACVR2A knockout MKN74 human gastric cancer cells. One hundred twenty-four patients with gastric cancer were retrospectively analyzed, and relations between MSI status, ACVR2A mutations, and clinicopathological factors were evaluated. RESULTS: ACVR2A knockout cells showed less aggressive tumor biology than mock-transfected cells, displaying reduced proliferation, migration, and invasion (P < 0.05). MSI mutations were found in 10% (13/124) of gastric cancer patients, and ACVR2A mutations were found in 8.1% (10/124) of patients. All ACVR2A mutations were accompanied by MSI. The 5-year overall survival rates of ACVR2A wild-type patients and ACVR2A-mutated patients were 57% and 90%, respectively (P = 0.048). Multivariate analysis revealed that older age (P = 0.015), distant metastasis (P < 0.001), and ACVR2A wild-type status (P = 0.040) were independent prognostic factors for overall survival. CONCLUSIONS: Our study demonstrated that gastric cancer patients with ACVR2A mutation have a significantly better prognosis than those without. Dysfunction of ACVR2A in MKN74 human gastric cancer cells caused less aggressive tumor biology, indicating the importance of ACVR2A in the progression of MSI-H tumors.

    DOI: 10.1007/s11605-020-04889-9

    PubMed

    researchmap

  • 患者目線を目指したインフォームド・コンセント監査

    鳥谷部 真一, 平賀 智之, 冨樫 礼子, 伊藤 圭子, 石川 卓

    医療の質・安全学会誌   16 ( 1 )   5 - 11   2021年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)医療の質・安全学会  

    researchmap

  • [Long-Term Survival after Surgery with Postoperative Chemotherapy for Perihilar Cholangiocarcinoma with Residual Invasive Carcinoma at Ductal Resection Margins-A Case Report].

    Tomo Oiwa, Kohei Miura, Jun Sakata, Kizuki Yuza, Koji Toge, Yuki Hirose, Kazuyasu Takizawa, Hiroshi Ichikawa, Takaaki Hanyu, Masato Nakano, Masayuki Nagahashi, Yoshifumi Shimada, Takashi Ishikawa, Takashi Kobayashi, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   47 ( 13 )   1899 - 1901   2020年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 64-year-old man with liver dysfunction was given a diagnosis of perihilar cholangiocarcinoma(Bismuth type Ⅳ). The tumor was predominantly right-sided and invaded to the bifurcation of the right and left portal veins. After confirming sufficient liver functional reserve and future liver remnant, the patient underwent extended right hepatectomy, extrahepatic bile duct resection, and portal vein resection and reconstruction. Intraoperative examination of frozen sections revealed the presence of residual invasive carcinoma on both the hepatic and duodenal sides of the ductal resection margins. However, we did not perform pancreaticoduodenectomy or additional resection of the margin-positive proximal bile duct considering the curability and invasiveness of these procedures. He received postoperative chemotherapy with biweekly gemcitabine plus cisplatin for 1 year, followed by gemcitabine monotherapy for 1 year, and S-1 monotherapy has been performed since then. He remains alive and well with no evidence of disease 63 months after surgery.

    PubMed

    researchmap

  • [Amelanotic Malignant Melanoma of the Esophagogastric Junction-A Case Report].

    Ryota Magara, Yosuke Kano, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Yusuke Muneoka, Kohei Miura, Kazuyasu Takizawa, Yoshifumi Shimada, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Kaori Takamura, Hajime Umezu, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   47 ( 13 )   2083 - 2085   2020年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 73-year-old man presented with anemia, and gastroscopy showed a nonpigmented tumor in the esophagogastric junction. The result of the tumor biopsy initially suspected poorly differentiated adenocarcinoma. However, additional immunohistochemical examination revealed malignant melanoma. The final diagnosis was amelanotic malignant melanoma of the esophagogastric junction with adrenal and spinal metastasis. Although immunotherapy was performed, the patient died 132 days after diagnosis.

    PubMed

    researchmap

  • [A Case of Umbilical Metastasis from Pancreatic Cancer after Surgery].

    Kazuyasu Takizawa, Jun Sakata, Hiroki Nagaro, Kizuki Yuza, Koji Toge, Yuki Hirose, Hirosuke Ishikawa, Natsuru Sudo, Kohei Miura, Hiroshi Ichikawa, Masayuki Nagahashi, Yoshifumi Shimada, Takashi Kobayashi, Takashi Ishikawa, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   47 ( 13 )   2409 - 2411   2020年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    The patient was a 63-year-old woman with diagnosis of pancreatic cancer. Abdominal CT showed pancreatic head tumor and paraaortic lymph node metastasis. We performed chemotherapy with nab-paclitaxel plus gemcitabine. After 5 courses of chemotherapy, the tumor reduced in size. Pancreaticoduodenectomy followed by adjuvant chemotherapy with S-1 was performed. Fourteen months after surgery, umbilical metastasis(Sister Mary Joseph's nodule: SMJN)was found in the umbilicus near the abdominal incisional hernia. There was no evidence of metastasis except in the umbilicus, we performed the umbilical tumor resection and abdominal incisional hernia repair. Pathological diagnosis was pancreatic cancer metastasis. Although following chemotherapy, multiple skin metastases was found in the lower abdomen 3 months after umbilical resection. We performed skin metastases resection to relieve pain and symptoms of bleeding. But she died 29 months after the initial therapy(7 months after umbilical resection).

    PubMed

    researchmap

  • 胃癌手術後の他病死に関する検討

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会   75回   P087 - 4   2020年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy: a retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association.

    Hitoshi Katai, Takashi Ishikawa, Kohei Akazawa, Takeo Fukagawa, Yoh Isobe, Isao Miyashiro, Ichiro Oda, Shunichi Tsujitani, Hiroyuki Ono, Satoshi Tanabe, Souya Nunobe, Satoshi Suzuki, Yoshihiro Kakeji

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   23 ( 6 )   1091 - 1101   2020年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: No guidelines are available for defining the extent of lymph node (LN) dissection in patients with remnant gastric carcinoma (RGC). Hence, this retrospective study aimed to determine the optimal extent of LN dissection in patients with RGC. METHODS: We retrospectively evaluated the therapeutic outcomes of node dissection for RGC from a nationwide registry. When the metastatic rate or 5-year survival rate exceeded 10%, dissection was recommended. We calculated the dissection index by multiplying the incidence of metastasis at that nodal station by the 5-year survival rate of patients with metastasis at the station. A dissection index of > 1.0 was considered significant. RESULTS: We included 1133 patients with RGC (T2-T4 tumor) who had undergone distal gastrectomy as the primary surgery for the evaluation of the survival benefit of nodal dissection. Any regional node station was considered significant. When the primary surgery was for malignant disease, the index was high for Nos. 3 (10.2), 7 (9.5), 1 (7.1), and 9 (8.0) nodes. For nodes at the splenic hilum, the index value was 4.4, which was higher than that for the perigastric nodes (Nos. 4sa and 4sb). The index for No. 10 nodes was the highest (10.5) when tumors involved a greater curvature. CONCLUSIONS: The therapeutic strategy for RGC remains the same, regardless of the histology of the primary disease during the initial surgery. Total gastrectomy and dissection of the perigastric LNs (Nos. 1-4), suprapancreatic LNs (Nos. 7-9 and 11), and LNs at the splenic hilum (No. 10) are justified.

    DOI: 10.1007/s10120-020-01081-5

    PubMed

    researchmap

  • 胆道 悪性

    廣瀬 雄己, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 堅田 朋大, 石川 博補, 峠 弘治, 油座 築, 安藤 拓也, 三浦 要平, 長櫓 宏規, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   300 - 300   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 胆道 悪性

    油座 築, 坂田 純, 滝沢 一泰, 三浦 宏平, 堅田 朋大, 石川 博補, 廣瀬 雄己, 峠 弘治, 安藤 拓也, 三浦 要平, 長櫓 宏規, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 小林 隆, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   299 - 299   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 胆道 悪性

    長櫓 宏規, 坂田 純, 三浦 宏平, 廣瀬 雄己, 油座 築, 安藤 拓也, 堅田 朋大, 石川 博補, 峠 弘治, 三浦 要平, 滝沢 一泰, 小林 隆, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   298 - 298   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 胆道 悪性

    坂田 純, 三浦 宏平, 廣瀬 雄己, 油座 築, 安藤 拓也, 堅田 朋大, 石川 博補, 峠 弘治, 三浦 要平, 長櫓 宏規, 滝沢 一泰, 小林 隆, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   298 - 298   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • その他 栄養・合併症

    三浦 宏平, 坂田 純, 長櫓 宏規, 三浦 要平, 油座 築, 安藤 拓也, 峠 弘治, 廣瀬 雄己, 堅田 朋大, 石川 博補, 加納 陽介, 市川 寛, 滝沢 一泰, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 小林 隆, 石川 卓, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   157 - 157   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 大腸 集学的治療

    島田 能史, 小柳 英人, 荒引 みちる, 松本 瑛生, 田中 花菜, 阿部 馨, 中野 麻恵, 中野 雅人, 廣瀬 雄己, 堅田 朋大, 加納 陽介, 三浦 宏平, 市川 寛, 羽入 隆晃, 滝沢 一泰, 永橋 昌幸, 坂田 純, 石川 卓, 小林 隆, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   229 - 229   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 胃 手術(悪性)

    加納 陽介, 羽入 隆晃, 市川 寛, 宗岡 悠介, 石川 卓, 藪崎 裕, 桑原 史郎, 河内 保之, 内藤 哲也, 蛭川 浩史, 廣瀬 雄己, 須藤 翔, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   286 - 286   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 胃 化学療法など

    市川 寛, 羽入 隆晃, 加納 陽介, 石川 卓, 根本 万理子, 酒井 剛, 茂木 大輔, 宗岡 悠介, 須藤 翔, 小柳 英人, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   277 - 277   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 胃 その他

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 茂木 大輔, 酒井 剛, 根本 万理子, 宗岡 悠介, 小柳 英人, 峠 弘治, 廣瀬 雄己, 須藤 翔, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 若井 俊文

    日本消化器外科学会雑誌   53 ( Suppl.2 )   260 - 260   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • Primary lung squamous cell carcinoma and its association with gastric metastasis: A case report and literature review. 国際誌

    Mariko Nemoto, Pankaj Prasoon, Hiroshi Ichikawa, Takaaki Hanyu, Yosuke Kano, Yusuke Muneoka, Kenji Usui, Yuki Hirose, Kohei Miura, Yoshifumi Shimada, Masayuki Nagahashi, Jun Sakata, Takashi Ishikawa, Masanori Tsuchida, Toshifumi Wakai

    Thoracic cancer   11 ( 6 )   1708 - 1711   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Nearly 50% of primary lung carcinoma patients present with distant metastasis at their first visit. However, gastrointestinal tract (GIT) metastasis is an infrequent impediment. Herein, we report a case of progressive dysphagia and epigastralgia as an initial manifestation of recurrence as gastric metastasis of primary lung squamous cell carcinoma (SCC) after curative surgery. A 64-year-old man was diagnosed with primary lung SCC of the right lower lobe, and underwent thoracoscopic lower lobectomy. One year after lobectomy, computed tomography (CT) scan showed a gastric fundal mass located in the gastric cardia which measured 5 cm. Endoscopic biopsies and histopathology subsequently confirmed that tumor was SCC. The patient then underwent proximal gastrectomy with resection of the diaphragmatic crus. Following surgery, histopathological examination revealed gastric metastasis from primary lung SCC. KEY POINTS: Gastric metastasis of primary lung carcinoma is one of the rarest phenomena. Gastrointestinal symptoms should raise suspicion of the presence of advanced metastatic disease with poor prognosis.

    DOI: 10.1111/1759-7714.13410

    PubMed

    researchmap

  • Surgical outcomes of elderly patients with Stage I gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association.

    Souya Nunobe, Ichiro Oda, Takashi Ishikawa, Kohei Akazawa, Hitoshi Katai, Yoh Isobe, Isao Miyashiro, Shunichi Tsujitani, Hiroyuki Ono, Satoshi Tanabe, Takeo Fukagawa, Satoshi Suzuki, Yoshihiro Kakeji

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   23 ( 2 )   328 - 338   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The proportion of elderly patients undergoing surgery for gastric cancer is increasing. However, limited number of therapeutic outcomes in the elderly has been reported. Here we examined the surgical results based on a nationwide survey of elderly patients who underwent surgery for Stage I gastric cancer. METHODS: Data from 68,353 Stage I patients who underwent gastrectomy between 2001 and 2007 were retrospectively collected. The accumulated data were reviewed and analyzed by the Japanese Gastric Cancer Association registration committee. We first classified the patients as those aged ≤ 74 years and ≥ 75 years. We further classified those patients aged ≥ 75 years into groups by 5-year increments to examine their short- and long-term postoperative outcomes. RESULTS: Patients aged ≥ 75 years accounted for 46.5%. The 30-day mortality rate was < 0.7% for any age group, but for those aged ≥ 75 years, the 60-day and 90-day mortality rates were 0.9-2.3% and 1.2-5.1%, respectively. An examination of long-term survival indicated that, as the class of age increased, the 5-year overall survival (OS) was 47.0-93.1% and disease-specific survival (DSS) was 91.4-98.2%, respectively. Although high DSS rates of ≥ 90% were found for all age groups, OS only accounted for ≤ 82% of patients aged ≥ 75 years. CONCLUSION: Among elderly patients with Stage I gastric cancer, deaths due to other diseases were frequently observed in the long term. Thus, for elderly patients, it may be appropriate to reconsider the treatment strategy with respect to the balance between the invasiveness of the treatment and the prognosis.

    DOI: 10.1007/s10120-019-01000-3

    PubMed

    researchmap

  • Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate. 国際誌

    Hideo Takahashi, Mariko Asaoka, Li Yan, Omar M Rashid, Masanori Oshi, Takashi Ishikawa, Masayuki Nagahashi, Kazuaki Takabe

    Scientific reports   10 ( 1 )   1852 - 1852   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    While cancer cells gain aggressiveness by mutations, abundant mutations release neoantigens, attracting anti-cancer immune cells. We hypothesized that in breast cancer (BC), where mutation is less common, tumors with high mutation rates demonstrate aggressive phenotypes and attract immune cells simultaneously. High mutation rates were defined as the top 10% of the mutation rate, utilizing TCGA and METABRIC transcriptomic data. Mutation rate did not impact survival although high mutation BCs were associated with aggressive clinical features, such as more frequent in ER-negative tumors (p < 0.01), in triple-negative subtype (p = 0.03), and increased MKI-67 mRNA expression (p < 0.01) in both cohorts. Tumors with high mutation rates were associated with APOBEC3B and homologous recombination deficiency, increasing neoantigen loads (all p < 0.01). Cell proliferation and immune activity pathways were enriched in BCs with high mutation rates. Furthermore, there were higher lymphocytes and M1 macrophage infiltration in high mutation BCs. Additionally, T-cell receptor diversity, cytolytic activity score (CYT), and T-cell exhaustion marker expression were significantly elevated in BCs with high mutation rates (all p < 0.01), indicating strong immunogenicity. In conclusion, enhanced immunity due to neoantigens can be one of possible forces to counterbalance aggressiveness of a high mutation rate, resulting in similar survival rates to low mutation BCs.

    DOI: 10.1038/s41598-020-58995-4

    PubMed

    researchmap

  • Long-Term Trends in Respiratory Function After Esophagectomy for Esophageal Cancer. 国際誌

    Takahiro Otani, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Yosuke Kano, Tatsuo Kanda, Shin-Ichi Kosugi, Toshifumi Wakai

    The Journal of surgical research   245   168 - 178   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Esophagectomy for esophageal cancer is known to lead to deterioration in respiratory function (RF). The aim of this study was to assess long-term trends in RF after esophagectomy and the impact of different operative procedures. METHODS: A total of 52 patients with thoracic esophageal cancer who were scheduled for esophagectomy from 2003 to 2012 were enrolled. We prospectively evaluated patients for vital capacity (VC), forced expiratory volume in 1 s (FEV1.0), and 6-min walk distance (6MWD) before and after esophagectomy at 3, 6, 12, 24, and 60 mo. RESULTS: Patients had mostly recovered their VC and FEV1.0 after 12 mo. After that point, VC and FEV1.0 declined again, reaching levels lower than baseline at 60 mo, with a median change ratio of 0.85 and 0.86, respectively. Although the 6MWD after open esophagectomy declined, patients treated with transhiatal esophagectomy and minimally invasive esophagectomy maintained above baseline levels throughout the follow-up period. Furthermore, we identified transhiatal esophagectomy (odds ratio [OR] = 0.03, 95% confidence interval [CI] 0.002-0.43, P = 0.01) and minimally invasive esophagectomy (OR = 0.14, 95% CI 0.02-0.94, P = 0.04) as favorable factors and postoperative pulmonary complication (OR = 9.14, 95% CI 1.22-68.6, P = 0.03) as an unfavorable factor for RF after 12 mo. Operative procedures had no significant impact on RF after 60 mo. CONCLUSIONS: Our results support the notion that RF does not recover to the baseline level, and operative procedures have no significant impact on RF at late phase after esophagectomy.

    DOI: 10.1016/j.jss.2019.07.040

    PubMed

    researchmap

  • [A Case of Esophageal Cancer Achieving a Pathological Complete Response after Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy].

    Daisuke Motegi, Hiroshi Ichikawa, Yosuke Kano, Takaaki Hanyu, Takashi Ishikawa, Kenji Usui, Takeshi Sakai, Yuki Hirose, Kohei Miura, Masayuki Nagahashi, Yoshifumi Shimada, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   46 ( 13 )   2192 - 2194   2019年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 66-year-old man with middle thoracic esophageal squamous cell carcinoma with supraclavicular lymph node metastasis visited our hospital. He underwent 3 courses of preoperative chemotherapy with docetaxel, cisplatin, and 5-FU(DCF)with a clinically-determined partial response. Minimally-invasive esophagectomy with 3-fieldlymphad enectomy was subsequently performed. Histopathologic examination revealedno viable tumor cells in the resectedesophagus andsupraclavicular lymph node. DCF is a promising preoperative chemotherapy regimen for locally advanced esophageal cancer because of its higher complete response rate comparedto that for cisplatin plus 5-FU.

    PubMed

    researchmap

  • [A Case of Esophageal Primary Malignant Melanoma That Developed During the Follow-Up of Esophageal Melanocytosis].

    Daisuke Yamai, Hiroshi Ichikawa, Yosuke Kano, Takaaki Hanyu, Takashi Ishikawa, Kenji Usui, Mariko Nemoto, Yuki Hirose, Kohei Miura, Masayuki Nagahashi, Yoshifumi Shimada, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   46 ( 13 )   2012 - 2014   2019年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 78-year-old woman was endoscopically followed up for benign melanocytosis in the middle thoracic esophagus that was detected 3 years prior. She presented with chest tightness, and an endoscopic examination revealed a protruding tumor at the melanotic lesion. She was histologically diagnosedwith an esophageal primary malignant melanoma. Computedtomography showedno metastatic lesions. She underwent minimally invasive esophagectomy with 2-fieldlymphad enectomy. Immunotherapy with nivolumab is ongoing for liver metastasis, which developed1 year and6 months after esophagectomy. Careful follow-up for esophageal melanocytosis is important for early diagnosis of esophageal primary malignant melanoma.

    PubMed

    researchmap

  • Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer. 国際誌

    Shota Saito, Kyoko Nakazawa, Masayuki Nagahashi, Takashi Ishikawa, Kouhei Akazawa

    Personalized medicine   16 ( 6 )   439 - 448   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Aim: Olaparib monotherapy improves progression-free survival in patients with metastatic breast cancer and BRCA1/2 mutations. We evaluated the cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use. Methods: A Markov cohort model was generated to compare the 5-year cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use. Results: The incremental cost-effectiveness ratio of BRCA1/2 mutation profiling plus olaparib monotherapy was JPY14,677,259/quality-adjusted life year (QALY) (US$131,047/QALY), compared with standard chemotherapy alone. Conclusion:BRCA1/2 mutation profiling to target olaparib use is not a cost-effective strategy for metastatic breast cancer. The strategy provides minimal incremental benefit at a high incremental cost per QALY. Hence, further cost reductions in the cost of both BRCA1/2 mutation profiling and olaparib are required.

    DOI: 10.2217/pme-2018-0141

    PubMed

    researchmap

  • 胃癌周術期合併症が予後に与える影響

    羽入 隆晃, 市川 寛, 石川 卓, 加納 陽介, 小杉 伸一, 酒井 剛, 根本 万理子, 臼井 賢司, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 中野 麻恵, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌   52 ( Suppl.2 )   120 - 120   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 日本人ゲノム安定型胃癌の特徴

    酒井 剛, 市川 寛, 永橋 昌幸, 羽入 隆晃, 石川 卓, 臼井 賢司, 根本 万理子, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 田島 陽介, 滝沢 一泰, 中野 雅人, 島田 能史, 坂田 純, 小林 隆, 藪崎 裕, 中川 悟, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌   52 ( Suppl.2 )   108 - 108   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 肝外胆管切除を伴う肝切除症例における予後予測因子の検討

    安藤 拓也, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 堅田 朋大, 廣瀬 雄己, 峠 弘治, 油座 築, 諸 和樹, 加納 陽介, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌   52 ( Suppl.2 )   218 - 218   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 高齢者術後再発膵癌に対するGemcitabine+nab-Paclitaxel併用療法の検討

    滝沢 一泰, 坂田 純, 安藤 拓也, 油座 築, 峠 弘治, 廣瀬 雄己, 齋藤 敬太, 堅田 朋大, 三浦 宏平, 小林 隆, 諸 和樹, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌   52 ( Suppl.2 )   157 - 157   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • 内視鏡的切除後pT1b胃癌における簇出はリンパ節転移と関連するか?

    岡村 拓磨, 島田 能史, 羽入 隆晃, 亀山 仁史, 中野 雅人, 中野 麻恵, 石川 卓, 市川 寛, 加納 陽介, 廣瀬 雄己, 三浦 宏平, 坂田 純, 小林 隆, 若井 俊文

    日本臨床外科学会雑誌   80 ( 増刊 )   614 - 614   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本臨床外科学会  

    researchmap

  • Palliative interventions for patients with incurable locally advanced or metastatic thoracic esophageal carcinoma.

    Tomoyuki Kakuta, Shin-Ichi Kosugi, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Tatsuo Kanda, Toshifumi Wakai

    Esophagus : official journal of the Japan Esophageal Society   16 ( 3 )   278 - 284   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The aim of this study was to assess the clinical outcomes of palliative interventions for patients with incurable locally advanced or metastatic esophageal carcinoma. METHODS: A total of 131 patients with thoracic esophageal carcinoma who underwent palliative interventions were enrolled. Insertion of a self-expandable metallic stent (SEMS), tube enterostomy for enteral nutrition (EN), and palliative esophagectomy (PE) were performed in 38, 65, and 28 patients, respectively. The clinicopathological characteristics and clinical outcomes of each group were retrospectively reviewed. RESULTS: Patients in the EN group frequently received chemoradiotherapy (P < 0.01). SEMS insertion, but not PE or EN, improved the mean dysphagia score after the intervention (P < 0.01). For the SEMS, EN, and PE groups, the occurrence of intervention-related complications was 31.6, 10.8, and 96.4%, respectively, the median survival time was 88, 208, and 226 days (P < 0.01), and the mean ratio of duration of home care to survival time was 28.9, 38.5, and 39.6% (P = 0.95). CONCLUSIONS: SEMS insertion effectively relieved obstructive symptoms, but had no survival benefit. Tube enterostomy showed a low complication rate and has the potential to improve survival in combination with additional treatment, with no palliation of obstructive symptoms.

    DOI: 10.1007/s10388-019-00665-0

    PubMed

    researchmap

  • Pyloroantrectomy and Pedunculated Short Gastric-Tube Interposition in Esophageal Carcinoma Patients Associated With Early Gastric Adenocarcinoma

    Yu Sato, Tatsuo Kanda, Shin-ichi Kosugi, Takashi Ishikawa, Tetsuya Tada, Toshifumi Wakai

    International Surgery   104 ( 3-4 )   143 - 148   2019年3月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:International College of Surgeons  

    Gastric carcinoma is one of the most common secondary malignancies in esophageal cancer patients. We herein report our surgical procedure for esophageal reconstruction in esophageal cancer patients associated with synchronous or metachronous early gastric adenocarcinoma. Gastric adenocarcinoma was removed by pyloroantrectomy with preservation of the right gastroepiploic artery and vein, and a pedunculated short gastric tube was used as an esophageal substitute in a Roux-en-Y fashion. Surgical data of 6 esophageal cancer patients who underwent this type of surgery between 1993 and 2012 were analyzed. Three patients had synchronous early gastric carcinoma and the remaining 3 patients had metachronous early gastric adenocarcinoma. The gastric tube was easily pulled up to the neck and no problems occurred during this procedure. Postoperative complications, including leakage of esophagogastrostomy, acute respiratory failure, and diffuse peritonitis, were observed in 3 patients. No patients suffered from necrosis of the gastric tube. Although 3 patients died of other diseases, gastric cancer recurrence has not been observed to date. Despite the need for precaution to ensure technical safety, pyloroantrectomy and esophageal reconstruction using a pedunculated short gastric-tube are oncologically feasible as a potential curative surgery for esophageal cancer patients with early gastric adenocarcinoma.

    DOI: 10.9738/intsurg-d-16-00011.1

    researchmap

  • Hyperbilirubinemia predicts the infectious complications after esophagectomy for esophageal cancer. 国際誌

    Yusuke Muneoka, Hiroshi Ichikawa, Shin-Ichi Kosugi, Takaaki Hanyu, Takashi Ishikawa, Yosuke Kano, Yoshifumi Shimada, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Kohei Akazawa, Toshifumi Wakai

    Annals of medicine and surgery (2012)   39   16 - 21   2019年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Surgical stress and inflammation can cause hyperbilirubinemia, which sometimes occurs after esophagectomy for esophageal cancer (EC). The aim of this study was to elucidate the clinical significance of postoperative hyperbilirubinemia in the management of EC patients. Materials and methods: We retrospectively reviewed records of 81 EC patients who underwent esophagectomy from 2009 to 2014. We compared the clinicopathological and perioperative factors, including the presence of hyperbilirubinemia (total bilirubin ≥1.5 mg/dL), between patients with postoperative infectious complications (PIC group) and those without (Non-PIC group). Results: PIC developed in 52 patients (64.2%). There were significant differences in incidence of postoperative hyperbilirubinemia between the PIC group and the non-PIC group (34.6% vs. 3.4%, P = 0.002), as well as the approach of esophagectomy (P = 0.045), the surgical duration (469 vs. 389 min, P < 0.001), the amount of blood loss (420 vs. 300 mL, P = 0.018), the frequency of intraoperative blood transfusions (32.7% vs. 6.9%, P = 0.012) and the peak postoperative C-reactive protein level (17.3 vs. 8.6 mg/dL, P = 0.007). Multivariate analysis revealed hyperbilirubinemia was independently associated with the occurrence of PICs (odds ratio: 38.6, P = 0.010). The median time to the diagnosis of hyperbilirubinemia was significantly shorter than that of PICs (3.0 vs. 4.5 days, P = 0.025). Conclusions: Postoperative hyperbilirubinemia was associated with the occurrence of PICs and frequently occurred before any PICs become apparent. More attention should be paid to the serum bilirubin level in the management after esophagectomy for EC.

    DOI: 10.1016/j.amsu.2019.02.004

    PubMed

    researchmap

  • Phospho-Sphingosine Kinase 1 Expression in Lymphatic Spread of Esophageal Squamous Cell Carcinoma. 国際誌

    Mariko Nemoto, Hiroshi Ichikawa, Masayuki Nagahashi, Takaaki Hanyu, Takashi Ishikawa, Yosuke Kano, Yusuke Muneoka, Toshifumi Wakai

    The Journal of surgical research   234   123 - 131   2019年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Lymphatic spread is the main mode of progression of esophageal squamous cell carcinoma (ESCC). Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid mediator, which produced by sphingosine kinase 1 (SphK1) activated by phosphorylation. The SphK1-S1P axis has a crucial role in lymphangiogenesis. However, the significance of phospho-SphK1 (pSphK1) in the progression of ESCC has not been fully investigated. MATERIALS AND METHODS: We evaluated pSphK1 expression in 92 surgically resected tumor tissues of ESCC by the immunohistochemistry. Fifty-nine (64%) patients with moderate or strong expression and 33 (36%) with negative or weak expression were classified in the pSphK1-high and pSphK1-low groups, respectively. RESULTS: Higher pathological N category (pN) was more frequently observed in the pSphK1-high group (P < 0.01). The median number of lymph node metastasis (pSphK1-high: 2 versus pSphK1-low: 0; P < 0.01), the proportion of patients with lymphatic invasion (69% versus 18%; P < 0.01) and that with intramural metastasis (27% versus 3%; P < 0.01) were significantly higher in the pSphK1-high group. The presence of lymphatic invasion (odds ratio [OR] 5.63; P < 0.01) and pN1-3 (OR 3.26; P = 0.04) were independently associated with high pSphK1 expression. The 5-y overall survival rate of the pSphK1-high group was significantly lower than that of the pSphK1-low group (50.8% versus 67.3%; P = 0.01). High pSphK1 expression was not identified as a significant independent prognostic factor. CONCLUSIONS: We provide the first evidence of the association between high expression of pSphK1 and both lymphatic spread and patient outcomes in ESCC.

    DOI: 10.1016/j.jss.2018.09.012

    PubMed

    researchmap

  • [Chemoresistance in Microsatellite Instability-High Gastric Cancer-A Case Report].

    Takahiro Otani, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Takeshi Sakai, Mariko Nemoto, Yusuke Muneoka, Kenji Usui, Natsuru Sudo, Yosuke Kano, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   45 ( 13 )   1895 - 1897   2018年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 74-year-old woman with cT4aN2M0, cStage ⅢB gastric cancer underwent neoadjuvant chemotherapy comprising 2 courses of S-1 plus cisplatin, and the clinical response was determined as non-CR/non-PD according to RECIST ver 1.1. Although distal gastrectomy with D2 lymphadenectomy was planned, the tumor was considered as unresectable with peritoneal metastases during laparotomy. After the subsequent chemotherapy with 1 course of capecitabine plus cisplatin, tumor bleeding, and obstruction due to rapid tumor progression occurred. We performed palliative distal gastrectomy; however, the patient died 17 days after gastrectomy. A comprehensive genomic analysis using cancer-gene panel identified the tumor as a microsatellite instability-high(MSI-H). Recently post hoc analysis of the large-scale clinical trials showed no clinical benefit of perioperative chemotherapy in MSI-H gastric cancer. MSI status has a potential to optimize the perioperative treatment strategy in gastric cancer.

    PubMed

    researchmap

  • 巨大食道胃接合部癌における治療戦略

    羽入 隆晃, 市川 寛, 石川 卓, 須藤 翔, 大渓 隆弘, 根本 万理子, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌   51 ( Suppl.2 )   140 - 140   2018年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • Expression of phosphorylated sphingosine kinase 1 is associated with diffuse type and lymphatic invasion in human gastric cancer. 国際誌

    Takaaki Hanyu, Masayuki Nagahashi, Hiroshi Ichikawa, Takashi Ishikawa, Takashi Kobayashi, Toshifumi Wakai

    Surgery   163 ( 6 )   1301 - 1306   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Sphingosine-1-phosphate, a pleiotropic bioactive lipid mediator, is an important player in cancer progression. Previous studies suggested that sphingosine-1-phosphate produced by sphingosine kinase 1, which is activated by phosphorylation, plays important roles in the progression of disease and metastasis. The association between phospho-sphingosine-1-phosphate produced by sphingosine kinase 1 and clinical parameters in human gastric cancer have not been fully investigated to date. METHODS: We created phospho-sphingosine-1-phosphate produced by sphingosine kinase expression profiles by immunohistochemistry for 136 patients who underwent operative intervention for gastric cancer in 2007-2009. Phospho-sphingosine-1-phosphate produced by sphingosine kinase expression and compared clinicopathologic factors by univariate and multivariate analyses. RESULTS: The univariate analysis revealed that phospho-sphingosine-1-phosphate produced by sphingosine kinase expression was correlated significantly with depth of tumor invasion, lymph node metastasis, distant metastasis, histologic type, and lymphatic invasion. The multivariate analysis revealed that the diffuse type (odds ratio 2.210; 95% confidence interval, 1.045-4.671, P=.038) and the presence of lymphatic invasion (odds ratio 3.697; 95% confidence interval, 1.161-8.483, P=.002) were associated independently with phospho-sphingosine-1-phosphate produced by sphingosine kinase expression in patients with gastric cancer. The 5-year rate of disease-specific survival was 79.3% in patients with phospho-sphingosine-1-phosphate produced by sphingosine kinasephospho-sphingosine-1-phosphate produced by sphingosine kinase-positive expression and 98.3% in those with phospho-sphingosine-1-phosphate produced by sphingosine kinase-negative expression (P=.002). In multivariate analysis, however, high phospho-sphingosine-1-phosphate produced by sphingosine kinase expression was not an independent prognostic factor for disease-specific survival (hazard ratio 5.540; 95% confidence interval, 0.717-42.81, P=.100). CONCLUSION: We provide the first evidence that diffuse histologic type and lymphatic invasion were independently associated with high phospho-sphingosine-1-phosphate produced by sphingosine kinase expression in gastric cancer patients, indicating a role of sphingosine-1-phosphate in disease progression among patients with gastric cancer. (Surgery 2017;160:XXX-XXX.).

    DOI: 10.1016/j.surg.2017.11.024

    PubMed

    researchmap

  • Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. 国際誌

    Shota Saito, Motoi Azumi, Yusuke Muneoka, Katsuhiko Nishino, Takashi Ishikawa, Yuichi Sato, Shuji Terai, Kouhei Akazawa

    The European journal of health economics : HEPAC : health economics in prevention and care   19 ( 4 )   545 - 555   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: A combination of assays for the presence of serum anti-Helicobacter pylori IgG antibody (HPA) and serum pepsinogen (PG) concentrations can be used to screen for gastric cancer risk. In Japan, this "ABC method" is considered an effective means of stratifying gastric cancer risk. This study aimed to ascertain its cost-effectiveness for assessing gastric cancer risk. METHODS: A Markov model was constructed to compare the cost-effectiveness of two strategies for gastric cancer-risk screening over a 30-year period: the ABC method, which uses a combination of assessing the presence of HPA and measuring serum PG concentrations and scheduling endoscopies accordingly, and annual endoscopic screening. Clinical and epidemiological data on variables in the model were obtained from published reports. Analyses were made from the perspective of the Japanese health care payer. RESULTS: According to base-case analysis, the ABC method cost less than annual endoscopic screening (64,489 vs. 64,074 USD) and saved more lives (18.16 vs. 18.30 quality-adjusted life years). One-way analyses confirmed the robustness of the cost-effectiveness results. The probability that the ABC method is cost-effective in Japanese individuals aged 50 years was 0.997. CONCLUSIONS: A combination of HPA and serum PG assays, plus scheduling endoscopy accordingly, is a cost-effective method of screening for gastric cancer risk in Japan.

    DOI: 10.1007/s10198-017-0901-y

    PubMed

    researchmap

  • 家族性胃癌におけるBRCA1/2胚細胞性変異(Pathogenic germline BRCA1/2 mutations and familial predisposition to gastric cancer) 国際誌

    市川 寛, 永橋 昌幸, 島田 能史, 羽入 隆晃, 石川 卓, 加納 陽介, 宗岡 悠介, 滝沢 一泰, 坂田 純, 小林 隆, 亀山 仁史, 中川 悟, 北川 雄光, 吉田 和弘, 沖 英次, 若井 俊文

    日本胃癌学会総会記事   90回   530 - 530   2018年3月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本胃癌学会  

    DOI: 10.1200/PO.18.00097

    PubMed

    researchmap

  • Carcinoma in the Remnant Stomach During Long-Term Follow-up After Distal Gastrectomy for Gastric Cancer: Analysis of Cumulative Incidence and Associated Risk Factors. 国際誌

    Takaaki Hanyu, Atsuhiro Wakai, Takashi Ishikawa, Hiroshi Ichikawa, Hitoshi Kameyama, Toshifumi Wakai

    World journal of surgery   42 ( 3 )   782 - 787   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The number of patients with remnant gastric cancer following resection of gastric cancer may increase. The aims of this study were to investigate the development of remnant gastric cancer after distal gastrectomy for gastric cancer and to examine its cumulative incidence, clinicopathological characteristics, and risk factors. METHODS: We examined 437 patients with relapse-free survival for 5 years or more after distal gastrectomy with Billroth I reconstruction for gastric cancer performed between 1985 and 2005. RESULTS: A total of 17 patients suffered from remnant gastric cancer. The cumulative incidence was 3.7% at 10 years and 5.4% at 20 years. The median time until development of remnant gastric cancer was 79 months (range 30-209 months). The presence of synchronous multiple gastric cancers was a significant independent risk factor for remnant gastric cancer (hazard ratio 4.036; 95% confidence interval 1.478-11.02; P = 0.006). Of the 17 patients, the 13 whose remnant gastric cancer was detected via regular endoscopy showed better prognoses than the patients detected by other means (P < 0.001). CONCLUSION: The cumulative incidence of remnant gastric cancer was 5.4% at 20 years. In particular, patients who had multiple gastric cancers at initial gastrectomy were at higher risk for remnant gastric cancer. Therefore, long-term endoscopic surveillance is important.

    DOI: 10.1007/s00268-017-4227-9

    PubMed

    researchmap

  • Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007).

    Hitoshi Katai, Takashi Ishikawa, Kohei Akazawa, Yoh Isobe, Isao Miyashiro, Ichiro Oda, Shunichi Tsujitani, Hiroyuki Ono, Satoshi Tanabe, Takeo Fukagawa, Souya Nunobe, Yoshihiro Kakeji, Atsushi Nashimoto

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   21 ( 1 )   144 - 154   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The aim of this retrospective study was to investigate the tumor characteristics, surgical details, and survival distribution of surgically resected cases of gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association. METHODS: Data from 118,367 patients with primary gastric carcinoma who underwent resection between 2001 and 2007 were included in the survival analyses. The 5-year survival rates were calculated for various subsets of prognostic factors. RESULTS: The median age of the patients was 67 years. The proportions of patients with pathological stage (Japanese Gastric Cancer Association) IA, IB, II, IIIA, IIIB, and IV disease were 44.0%, 14.7%, 11.7%, 9.5%, 5.0%, and 12.4% respectively. The death rate within 30 days of operation was 0.5%. The 5-year overall survival rate in the 118,367 patients who were treated by resection was 71.1%. The 5-year overall survival rates of patients with pathological stage IA, IB, II, IIIA, IIIB, and IV disease were 91.5%, 83.6%, 70.6%, 53.6%, 34.8%, and 16.4% respectively. The 5-year disease-specific survival rates in the patients with pT1 (mucosa) disease after D1+ dissection of lymph node station no. 7 (D1 + α), D1+ dissection of lymph node station nos. 7, 8, and 9 (D1+ β), and D2 lymphadenectomy were 99.4%, 99.6%, and 99.1% respectively. The 5-year disease-specific survival rates in the patients with pT1 (submucosa) disease after D1 + α, D1 + β, and D2 lymphadenectomy were 97.3%, 98.1%, and 96.9% respectively. CONCLUSION: Detailed analyses of the data from more than 100,000 patients show the recent trends of the outcomes of gastric cancer treatment in Japan and provide baseline information for use by medical communities around world.

    DOI: 10.1007/s10120-017-0716-7

    PubMed

    researchmap

  • Neoadjuvant therapy for gastrointestinal stromal tumor. 国際誌

    Takashi Ishikawa, Tatsuo Kanda, Hitoshi Kameyama, Toshifumi Wakai

    Translational gastroenterology and hepatology   3   3 - 3   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Molecular-targeting therapy using tyrosine kinase inhibitor imatinib mesylate is effective for metastasis/recurrent gastrointestinal stromal tumors (GISTs). Likewise, imatinib would be effective in the neoadjuvant therapy for high-risk GIST. Neoadjuvant therapy may have the potential to increase the complete resection rate and to avoid the surgical rupture by decreasing the tumor size. Thereby, it is expected that improvement of recurrence rate and survival rate can be obtained by neoadjuvant therapy. Neoadjuvant therapy is also expected to be favored from the viewpoint of organ/function preservation by tumor shrinkage. The existing results of clinical trials established the feasibility of neoadjuvant imatinib therapy. However, proof of the survival effectiveness of neoadjuvant imatinib therapy has not been sufficiently demonstrated. The aim of this article is to introduce previous evidence and strategies regarding neoadjuvant therapy for GIST.

    DOI: 10.21037/tgh.2018.01.01

    PubMed

    researchmap

  • Management of rectal gastrointestinal stromal tumor. 国際誌

    Hitoshi Kameyama, Tatsuo Kanda, Yosuke Tajima, Yoshifumi Shimada, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Toshifumi Wakai

    Translational gastroenterology and hepatology   3   8 - 8   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. However, rectal GIST is rare, the incident rate of it is approximately 5% of all GISTs. Rectal GIST symptoms generally include bleeding and/or pain and occasionally, urinary symptoms. Immunohistochemical evaluation finds that most rectal GIST tumors are CD117 (KIT) positive, and are sometimes CD34, platelet-derived growth factor receptor alpha (PDGFRA), smooth muscle actin, S-100, or vimentin positive. The National Institutes of Health (NIH) classifies rectal GIST as very-low risk, low risk, intermediate risk, or high risk, and the frequencies have been estimated as 0-23.8% for very-low risk, 0-45% for low risk, 0-34% for intermediate risk, and 21-100% for high risk tumors. The first-line treatment for localized GIST is curative resection, but is difficult in rectal GIST because of anatomical characteristics such as the deep, narrow pelvis and proximity to the sphincter muscle or other organs. Several studies noted the efficacy of the minimally invasive surgery, such as trans-anal, trans-sacral, trans-vaginal resection, or laparoscopic resection. The appropriate surgical procedure should be selected depending on the case. Imatinib mesylate (IM) is indicated as first-line treatment of metastatic or unresectable GIST, and clinical outcomes are correlated with KIT mutation genotype. However, the KIT mutation genotypes in rectal GIST are not well known. In this review, as in other GISTs, a large proportion (59-100%) of rectal GISTs carry exon 11 mutations. Although curative resection is indicated for localized rectal GIST, a high rate of local recurrence is a problem. Multimodal therapy including perioperative IM may improve postoperative outcomes, contributing to anus-preserving surgery. Moreover, KIT mutation analysis before IM treatment is important. This review summarizes current treatment strategies for rectal GIST.

    DOI: 10.21037/tgh.2018.01.08

    PubMed

    researchmap

  • Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan. 国際誌

    Shota Saito, Yusuke Muneoka, Takashi Ishikawa, Kouhei Akazawa

    Clinical therapeutics   39 ( 12 )   2380 - 2388   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: The combination of paclitaxel + ramucirumab is a standard second-line treatment in patients with advanced gastric cancer. This therapy has been associated with increased median overall survival and progression-free survival compared with those with paclitaxel monotherapy. We evaluated the cost-effectiveness of paclitaxel + ramucirumab combination therapy in patients with advanced gastric cancer, from the perspective of health care payers in Japan. METHODS: We constructed a Markov model to compare, over a time horizon of 3 years, the costs and effectiveness of the combination of paclitaxel + ramucirumab and paclitaxel alone as second-line therapies for advanced gastric cancer in Japan. Health outcomes were measured in life-years (LYs) and quality-adjusted (QA) LYs gained. Costs were calculated using year-2016 Japanese yen (\1 = US $17.79) according to the social insurance reimbursement schedule and drug tariff of the fee-for-service system in Japan. Model robustness was addressed through 1-way and probabilistic sensitivity analyses. The costs and QALYs were discounted at a rate of 2% per year. The willingness-to-pay threshold was set at the World Health Organization's criterion of \12 million, because no consensus exists regarding the threshold for acceptable cost per QALY ratios in Japan's health policy. FINDINGS: Paclitaxel + ramucirumab combination therapy was estimated to provide an additional 0.09 QALYs (0.10 LYs) at a cost of \3,870,077, resulting in an incremental cost-effectiveness ratio of \43,010,248/QALY. The incremental cost-effectiveness ratio for the combination therapy was >\12 million/QALY in all of the 1-way and probabilistic sensitivity analyses. IMPLICATIONS: Adding ramucirumab to a regimen of paclitaxel in the second-line treatment of advanced gastric cancer is expected to provide a minimal incremental benefit at a high incremental cost per QALY. Based on our findings, adjustments in the price of ramucirumab, as well as improves in other clinical parameters such as survival time and adverse event in advanced gastric cancer therapy, are needed.

    DOI: 10.1016/j.clinthera.2017.10.017

    PubMed

    researchmap

  • Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. 国際誌

    Yoshifumi Shimada, Hitoshi Kameyama, Masayuki Nagahashi, Hiroshi Ichikawa, Yusuke Muneoka, Ryoma Yagi, Yosuke Tajima, Takuma Okamura, Masato Nakano, Jun Sakata, Takashi Kobayashi, Hitoshi Nogami, Satoshi Maruyama, Yasumasa Takii, Tetsu Hayashida, Hiromasa Takaishi, Yuko Kitagawa, Eiji Oki, Tsuyoshi Konishi, Fumio Ishida, Shin-Ei Kudo, Jennifer E Ring, Alexei Protopopov, Stephen Lyle, Yiwei Ling, Shujiro Okuda, Takashi Ishikawa, Kohei Akazawa, Kazuaki Takabe, Toshifumi Wakai

    Oncotarget   8 ( 55 )   93567 - 93579   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Objectives: Anti-epidermal growth factor receptor (EGFR) therapy has been found to be more effective against left-sided colorectal cancer (LCRC) than right-sided colorectal cancer (RCRC). We hypothesized that RCRC is more likely to harbor genetic alterations associated with resistance to anti-EGFR therapy and tested this using comprehensive genomic sequencing. Materials and methods: A total of 201 patients with either primary RCRC or LCRC were analyzed. We investigated tumors for genetic alterations using a 415-gene panel, which included alterations associated with resistance to anti-EGFR therapy: TK receptors (ERBB2, MET, EGFR, FGFR1, and PDGFRA), RAS pathway (KRAS, NRAS, HRAS, BRAF, and MAPK2K1), and PI3K pathway (PTEN and PIK3CA). Patients whose tumors had no alterations in these 12 genes, theoretically considered to respond to anti-EGFR therapy, were defined as "all wild-type", while remaining patients were defined as "mutant-type". Results: Fifty-six patients (28%) and 145 patients (72%) had RCRC and LCRC, respectively. Regarding genetic alterations associated with anti-EGFR therapy, only 6 of 56 patients (11%) with RCRC were "all wild-type" compared with 41 of 145 patients (28%) with LCRC (P = 0.009). Among the 49 patients who received anti-EGFR therapy, RCRC showed significantly worse progression-free survival (PFS) than LCRC (P = 0.022), and "mutant-type" RCRC showed significantly worse PFS compared with "all wild-type" LCRC (P = 0.004). Conclusions: RCRC is more likely to harbor genetic alterations associated with resistance to anti-EGFR therapy compared with LCRC. Furthermore, our data shows primary tumor sidedness is a surrogate for the non-random distribution of genetic alterations in CRC.

    DOI: 10.18632/oncotarget.20510

    PubMed

    researchmap

  • [A Case of Gastric Cancer with Splenic Artery Aneurysm, Intraoperative ICG Fluorography Is Useful in Evaluating the Blood Flow of Stomach and Spleen].

    Kenji Usui, Kaoru Sakamoto, Kentaro Akabane, Kazuki Hayasaka, Toru Mizuki, Yutaka Yagi, Yasuhiro Shirahata, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Hitoshi Kameyama, Satoshi Suzuki, Kiyohiro Saito, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   44 ( 12 )   1497 - 1499   2017年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    An 81-year-oldwoman with advancedgastric cancer was referredto our hospital. Preoperative contrast-enhancedCT revealeda roundcalcification of the splenic hilum with 15mm in diameter as a splenic artery aneurysm. She underwent transcatheter arterial embolization(TAE)for the splenic artery aneurysm. Celiac artery angiography showedcollateral arterial network of the spleen from left gastric artery. Surgery for the gastric cancer was performed1 4 days after TAE. We cut the right gastric andbilateral epigastric arteries. After the left gastric artery clamping, we performedintraoperative indocyanine green(ICG)fluorography. ICG fluorography confirmedthat the bloodflow of the upper thirdof the stomach andspleen were maintained. We safely performed distal gastrectomy, and the postoperative course was uneventful.

    PubMed

    researchmap

  • Actionable gene-based classification toward precision medicine in gastric cancer. 国際誌

    Hiroshi Ichikawa, Masayuki Nagahashi, Yoshifumi Shimada, Takaaki Hanyu, Takashi Ishikawa, Hitoshi Kameyama, Takashi Kobayashi, Jun Sakata, Hiroshi Yabusaki, Satoru Nakagawa, Nobuaki Sato, Yuki Hirata, Yuko Kitagawa, Toshiyuki Tanahashi, Kazuhiro Yoshida, Ryota Nakanishi, Eiji Oki, Dana Vuzman, Stephen Lyle, Kazuaki Takabe, Yiwei Ling, Shujiro Okuda, Kohei Akazawa, Toshifumi Wakai

    Genome medicine   9 ( 1 )   93 - 93   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Intertumoral heterogeneity represents a significant hurdle to identifying optimized targeted therapies in gastric cancer (GC). To realize precision medicine for GC patients, an actionable gene alteration-based molecular classification that directly associates GCs with targeted therapies is needed. METHODS: A total of 207 Japanese patients with GC were included in this study. Formalin-fixed, paraffin-embedded (FFPE) tumor tissues were obtained from surgical or biopsy specimens and were subjected to DNA extraction. We generated comprehensive genomic profiling data using a 435-gene panel including 69 actionable genes paired with US Food and Drug Administration-approved targeted therapies, and the evaluation of Epstein-Barr virus (EBV) infection and microsatellite instability (MSI) status. RESULTS: Comprehensive genomic sequencing detected at least one alteration of 435 cancer-related genes in 194 GCs (93.7%) and of 69 actionable genes in 141 GCs (68.1%). We classified the 207 GCs into four The Cancer Genome Atlas (TCGA) subtypes using the genomic profiling data; EBV (N = 9), MSI (N = 17), chromosomal instability (N = 119), and genomically stable subtype (N = 62). Actionable gene alterations were not specific and were widely observed throughout all TCGA subtypes. To discover a novel classification which more precisely selects candidates for targeted therapies, 207 GCs were classified using hypermutated phenotype and the mutation profile of 69 actionable genes. We identified a hypermutated group (N = 32), while the others (N = 175) were sub-divided into six clusters including five with actionable gene alterations: ERBB2 (N = 25), CDKN2A, and CDKN2B (N = 10), KRAS (N = 10), BRCA2 (N = 9), and ATM cluster (N = 12). The clinical utility of this classification was demonstrated by a case of unresectable GC with a remarkable response to anti-HER2 therapy in the ERBB2 cluster. CONCLUSIONS: This actionable gene-based classification creates a framework for further studies for realizing precision medicine in GC.

    DOI: 10.1186/s13073-017-0484-3

    PubMed

    researchmap

  • 早期胃癌に対するESD非治癒切除症例に関する検討

    羽入 隆晃, 市川 寛, 橋本 哲, 石川 卓, 宗岡 悠介, 大渓 隆弘, 根本 万理子, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌   50 ( Suppl.2 )   271 - 271   2017年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • Benign esophageal schwannoma: a brief overview and our experience with this rare tumor. 国際誌

    Kazuki Moro, Masayuki Nagahashi, Kotaro Hirashima, Shin-Ichi Kosugi, Takaaki Hanyu, Hiroshi Ichikawa, Takashi Ishikawa, Gen Watanabe, Emmanuel Gabriel, Tsutomu Kawaguchi, Kazuaki Takabe, Toshifumi Wakai

    Surgical case reports   3 ( 1 )   97 - 97   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Benign esophageal tumors are uncommon, comprising approximately 2% of esophageal tumors. Esophageal schwannomas constitute an even rarer entity, with few cases reported in the literature. CASE PRESENTATION: We present a 66-year-old male who was referred for dysphagia. A computed tomography scan showed a well-demarcated, enhancing, and homogenous esophageal tumor measuring 50 mm. The tumor was hypermetabolic on positron emission tomography, and an endoscopic ultrasound-guided fine needle aspiration demonstrated the presence of benign spindle cells. We performed an uncomplicated, simple, tumor enucleation through a cervical approach. Histology revealed spindle-shaped cells in a fasciculated, disarrayed pattern. Immunohistochemistry demonstrated positive staining for S-100 protein and negative staining for KIT, CD34, desmin, and α-smooth muscle actin. These findings were consistent with a benign esophageal schwannoma. CONCLUSIONS: We report our experience with esophageal schwannoma, a rare but benign diagnosis of the esophagus.

    DOI: 10.1186/s40792-017-0369-0

    PubMed

    researchmap

  • Appropriate extent of lymphadenectomy for squamous cell carcinoma of the esophagogastric junction. 国際誌

    Shin-Ichi Kosugi, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Toshifumi Wakai

    International journal of surgery (London, England)   44   339 - 343   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: To investigate the appropriate extent of lymphadenectomy for squamous cell carcinoma (SCC) of the esophagogastric junction (ECJ). METHODS: We retrospectively reviewed the cases of 52 patients with SCC of the ECJ who underwent extended mediastinal lymphadenectomy. We assessed potential risk factors for lymph node metastasis (LNM) in the upper/middle mediastinum by conducting univariate and multivariate analyses, and a receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value. Survival rates were calculated using the Kaplan-Meier method, and the therapeutic value index of each nodal basin dissection was calculated by multiplying the frequency of metastasis at the basin and the 5-year overall survival rate of patients with metastasis at that basin. RESULTS: Twenty patients (38%) had mediastinal LNM; 13 (25%) had metastasis in the upper/middle mediastinum, and 13 (25%) had metastasis in the lower mediastinum. Tumor length (P = 0.03) and pathological nodal status (P = 0.01) were independent risk factors for upper/middle mediastinal LNM. The optimal ROC cutoff value of tumor length was 54 mm. The 5-year overall survival rate of the patients with LNM in the upper/middle mediastinum was 46%. The therapeutic value index of upper/middle mediastinal lymphadenectomy was 11.6, which was inferior to that of perigastric lymphadenectomy at 17.3, but superior to that of lower mediastinal lymphadenectomy at 5.8. CONCLUSION: An upper/middle mediastinal lymphadenectomy may be required for patients with tumors that are ≥54 mm long, and in those with suspected LNM.

    DOI: 10.1016/j.ijsu.2017.07.041

    PubMed

    researchmap

  • Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. 国際誌

    Yukinori Kurokawa, Han-Kwang Yang, Haruhiko Cho, Min-Hee Ryu, Toru Masuzawa, Sook Ryun Park, Sohei Matsumoto, Hyuk-Joon Lee, Hiroshi Honda, Oh Kyoung Kwon, Takashi Ishikawa, Kyung Hee Lee, Kazuhito Nabeshima, Seong-Ho Kong, Toshio Shimokawa, Jeong-Hwan Yook, Yuichiro Doki, Seock-Ah Im, Seiichi Hirota, Seokyung Hahn, Toshirou Nishida, Yoon-Koo Kang

    British journal of cancer   117 ( 1 )   25 - 32   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. METHODS: We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate. RESULTS: A total of 56 patients were enroled in this study. In the full analysis set of 53 patients, neoadjuvant imatinib for ≥6 months was completed in 46 patients. Grade 3-4 neutropenia and rash occurred in 8% and 9%, respectively, but there were no treatment-related deaths. The response rate by RECIST was 62% (95% CI, 48-75%). The R0 resection rate was 91% (48/53) (95% CI, 79-97%). Preservation of at least half of the stomach was achieved in 42 of 48 patients with R0 resection. At the median follow-up time of 32 months, 2-year overall and progression-free survival rates were 98% and 89%, respectively. CONCLUSIONS: Neoadjuvant imatinib treatment for 6-9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.

    DOI: 10.1038/bjc.2017.144

    PubMed

    researchmap

  • Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST. 国際誌

    Tatsuo Kanda, Toru Masuzawa, Toshihiro Hirai, Osamu Ikawa, Akinori Takagane, Yasuhiro Hata, Hitoshi Ojima, Harutsugu Sodeyama, Izumi Mochizuki, Takashi Ishikawa, Tatsuo Kagimura, Toshirou Nishida

    Japanese journal of clinical oncology   47 ( 4 )   369 - 372   2017年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We conducted a multicenter prospective study to clarify the efficacy and safety of surgery and imatinib for liver oligometastasis of gastrointestinal stromal tumors. Eligible gastrointestinal stromal tumor patients were enrolled in the surgery trial or the imatinib trial. Primary endpoints were recurrence-free survival and progression-free survival, respectively. The trials were prematurely terminated due to amendment of guidelines for adjuvant imatinib therapy and low patient accrual. In the surgery trial, all the six patients showed hepatic recurrence: median recurrence-free survival was 145 days (range: 62-1366 days). Of the five patients receiving salvage imatinib therapy, two showed progressive disease although no death was observed. Of the five patients enrolled in the imatinib trial, one died of pneumonia after progressive disease, and four had not shown progressive disease as of last visit. The results suggest that liver oligometastasis of gastrointestinal stromal tumor may not be controllable by surgery alone and require concomitant imatinib therapy.

    DOI: 10.1093/jjco/hyw203

    PubMed

    researchmap

  • Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy. 国際誌

    Takahito Sugase, Tsuyoshi Takahashi, Takashi Ishikawa, Hiroshi Ichikawa, Tatsuo Kanda, Seiichi Hirota, Kiyokazu Nakajima, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Yukinori Kurokawa, Makoto Yamasaki, Shuji Takiguchi, Toshifumi Wakai, Masaki Mori, Yuichiro Doki

    Surgical case reports   2 ( 1 )   137 - 137   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Nilotinib inhibits the tyrosine kinase activities of ABL1/BCR-ABL1, KIT, and platelet-derived growth factor receptors (PDGFRs). The results of a phase III clinical trial indicated that nilotinib could not be recommended for broad use as first-line therapy for gastrointestinal stromal tumor (GIST). However, some clinical studies have reported the effectiveness of nilotinib. We report here the cases of two patients who underwent surgical resections of nilotinib-resistant lesions after long-term nilotinib administration. CASE PRESENTATION: Two Japanese female patients, aged 66 and 70 years, experienced peritoneal recurrence of intestinal GIST several years after surgery. Both were registered in the ENESTg1 trial and received nilotinib therapy. Although they continued nilotinib administration with a partial response according to the protocol, nilotinib-resistant lesions, which were diagnosed as focally progressive disease, developed and complete surgical resection was performed. Pathological examination revealed that the tumors were composed of viable KIT-positive spindle cells, and the recurrent tumors were diagnosed as nilotinib-resistant GIST. In gene mutation analysis, a secondary KIT gene mutation was detected in one case. Both patients have survived more than 5 years after the first surgery. CONCLUSIONS: Of patients who were registered in this trial, we have encountered two patients with long-term effects after nilotinib administration. Moreover, secondary mutations in the KIT gene, similar to those involved in resistance to imatinib, might be involved in resistance to nilotinib.

    PubMed

    researchmap

  • Surgical and long-term outcomes following oesophagectomy in oesophageal cancer patients with comorbidity. 国際誌

    Hiroshi Ichikawa, Shin-Ichi Kosugi, Tatsuo Kanda, Kazuhito Yajima, Takashi Ishikawa, Takaaki Hanyu, Yusuke Muneoka, Takahiro Otani, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Toshifumi Wakai

    International journal of surgery (London, England)   36 ( Pt A )   212 - 218   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: The elucidation of the clinical impact of comorbidities is important to optimize the treatment and follow-up strategy in oesophageal cancer. We aimed to clarify the surgical and long-term outcomes following oesophagectomy in oesophageal cancer patients with comorbidity. METHODS: A total of 658 consecutive patients who underwent oesophagectomy for oesophageal cancer between 1985 and 2008 at our institution were enrolled. Based on the criteria of comorbidity as we defined it, we retrospectively reviewed and compared the surgical outcomes and survival between the comorbid (n = 251) and non-comorbid group (n = 407). RESULTS: Postoperative morbidity and mortality were not significantly different between the two groups. The 5-year overall survival rate of the comorbid group was significantly lower (39.3% vs. 45.2%, adjusted HR = 1.31, 95% CI: 1.07-1.62) but the 5-year disease-specific survival rate was not significantly different between the comorbid and non-comorbid groups (53.9% vs. 53.1%, adjusted HR = 1.11, 95% CI: 0.86-1.42). The 5-year incidence rate of death from other diseases in the comorbid group was significantly higher than that in the non-comorbid group (26.7% vs. 14.8%, P < 0.01). The leading cause of death from other diseases was pneumonia. CONCLUSIONS: Oesophagectomy in oesophageal cancer patients with comorbidity can be safely performed. However, the overall survival after oesophagectomy in these patients was unfavorable because of the high incidence of death from other diseases, especially pneumonia.

    DOI: 10.1016/j.ijsu.2016.10.041

    PubMed

    researchmap

  • Low fat-containing elemental formula is effective for postoperative recovery and potentially useful for preventing chyle leak during postoperative early enteral nutrition after esophagectomy. 国際誌

    Kazuki Moro, Yu Koyama, Shin-Ichi Kosugi, Takashi Ishikawa, Hiroshi Ichikawa, Takaaki Hanyu, Kohei Miura, Masayuki Nagahashi, Masato Nakajima, Kumiko Tatsuda, Junko Tsuchida, Chie Toshikawa, Mayuko Ikarashi, Yoshifumi Shimada, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Toshifumi Wakai

    Clinical nutrition (Edinburgh, Scotland)   35 ( 6 )   1423 - 1428   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Transthoracic esophagectomy using 3-field lymphadenectomy (TTE-3FL) for esophageal cancer is one of the most aggressive gastrointestinal surgeries. Early enteral nutrition (EN) for TTE-3FL patients is useful and valid for early recovery; however, EN using a fat-containing formula risks inducing chyle leak. In the present study, we retrospectively examined esophageal cancer patients treated byTTE-3FL and administered postoperative EN to elucidate the validity of lowering the fat levels in elemental formulas to prevent postoperative chyle leak and improve postoperative recovery. METHODS: A total of 74 patients who received TTE-3FL for esophageal cancer were retrospectively examined. Patients were classified into two groups according to the type of postoperative EN: Group LF patients received a low-fat elemental formula, and Group F patients received a standard fat-containing polymeric formula. The following clinical factors were compared between the groups: EN start day, maximum EN calories administered, duration of respirator use, length of ICU stay, incidence of postoperative infectious complications, use of parenteral nutrition (PN), and incidence of postoperative chyle leak. RESULTS: Patients in Group LF were started on EN significantly earlier after surgery and they consumed significantly higher maximum EN calories compared to Group F patients (P < 0.01). Duration of respirator use and length of ICU stay were also significantly shorter, and TPN was used significantly less in Group LF compared to Group F (P < 0.05). Postoperative chyle leak was observed in six patients in total (8.1%); five patients in Group F and one patient in Group LF, although there was no significant difference in frequency of chyle leak per patient between Group LF and Group F. CONCLUSIONS: Early EN using low-fat elemental formula after esophagectomy with three-field lymphadenectomy was safe and valid for postoperative recovery and potentially useful in preventing chyle leak.

    DOI: 10.1016/j.clnu.2016.03.018

    PubMed

    researchmap

  • [A Case of Simultaneous Multiple Gastric Cancers Showing Differences of Response after Neoadjuvant Chemotherapy with Docetaxel, CDDP, and S-1].

    Takeshi Sakai, Hiroshi Ichikawa, Takashi Ishikawa, Shinichi Kosugi, Takaaki Hanyu, Kenji Usui, Yusuke Muneoka, Takahiro Otani, Mariko Hishiki, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   43 ( 12 )   2377 - 2379   2016年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 63-year-old man with epigastralgia was referred to our hospital and diagnosed with simultaneous multiple gastric cancers. One lesion was type 2 advanced and the other was type 0- II c early gastric cancer. CT examination revealed 4 regional lymph node metastases. Neoadjuvant chemotherapy(NAC)with docetaxel/CDDP/S-1was administered. After 2 courses of NAC, total gastrectomy with D2(-No. 10), lymphadenectomy was performed. The pathological response to NAC was judged to be Grade 3 for advanced gastric cancer and Grade 0 for early gastric cancer. The patient is alive with no evidence of disease during the 10 months after the operation.

    PubMed

    researchmap

  • Nomogram for 5-year relapse-free survival of a patient with advanced gastric cancer after surgery. 国際誌

    Yusuke Muneoka, Kohei Akazawa, Takashi Ishikawa, Hiroshi Ichikawa, Atsushi Nashimoto, Hiroshi Yabusaki, Norio Tanaka, Shin-Ichi Kosugi, Toshifumi Wakai

    International journal of surgery (London, England)   35   153 - 159   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Prognoses vary substantially among patients with advanced gastric cancer following curative surgery. The aim of the current study was to develop and verify the validity of a novel nomogram that predicts the probability of 5-year relapse-free survival (RFS) in patients who underwent curative resection for stage II/III gastric cancer. MATERIALS AND METHODS: A nomogram to predict 5-year RFS following surgical resection of gastric cancer was constructed based on the data of patients who underwent surgery for primary gastric carcinoma at three institutions in Japan in January 2001-December 2006. Multivariate analysis using a Cox proportional hazards regression model was performed, and the nomogram's predictive accuracy (discrimination) and the agreement between observed outcomes and predictions (calibration) were evaluated by internal validation. RESULTS: Multivariate analyses revealed that age at operation, depth of tumor, tumor location, lymph node classification, and presence of combined resection were significant prognostic factors for RFS. In the internal validation, discrimination of the developed nomogram for 5-year RFS was superior to that of the American Joint Committee on Cancer TNM classification (concordance indices of 0.80 versus 0.67; P < 0.001). Moreover, calibration appeared to be accurate. Based on these results, we have created free software to more easily predict 5-year RFS. CONCLUSION: We developed and validated a nomogram to predict 5-year RFS after curative surgery for stage II/III gastric cancer. This tool will be useful for the assessing a patient's individual recurrence risk when considering additional therapy in clinical practice.

    DOI: 10.1016/j.ijsu.2016.09.080

    PubMed

    researchmap

  • [A Case of Advanced Gastric Cancer Resected for Rebleeding after Palliative Radiotherapy for Hemostasis].

    Yusuke Muneoka, Hiroshi Ichikawa, Takashi Ishikawa, Takaaki Hanyu, Yu Sato, Yosuke Kano, Kenji Usui, Takahiro Otani, Mariko Hishiki, Kohei Miura, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Shinichi Kosugi, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   43 ( 12 )   1936 - 1938   2016年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    We report a case of advanced gastric cancer(AGC)that was resected for rebleeding after palliative radiotherapy for hemostasis. A 74-year-old man with Stage IV gastric cancer received chemotherapy and achieved stable disease. After 23 months, he experienced continuous bleeding from the tumor due to regrowth. Palliative radiotherapy was conducted to control the bleeding, and the tumor successfully achieved hemostasis. However, 6 weeks later, the patient experienced rebleeding and developed hemostatic shock. We then performed a successful emergency gastrectomy. Bleeding negatively affects quality of life in patients with AGC and is potentially lethal. Although palliative radiotherapy for bleeding of gastric cancer is a safe and useful treatment within a short time frame in cases of rebleeding, emergency gastrectomy may be necessary. Therefore, when we select this treatment, the possibility of subsequent surgical treatment must be considered.

    PubMed

    researchmap

  • [A Case of Advanced Gastric Cancer with Portosystemic Shunt Successfully Treated with Percutaneous Transvenous Coil Embolization].

    Kenji Usui, Takaaki Hanyu, Hiroshi Ichikawa, Takashi Ishikawa, Yusuke Muneoka, Yu Sato, Yosuke Kano, Takahiro Otani, Mariko Hishiki, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Shinichi Kosugi, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   43 ( 12 )   1917 - 1919   2016年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 57-year-old man with advanced gastric cancer and multiple liver metastases was referred to our hospital. He underwent a palliative gastrectomy to treat hemorrhage, and S-1 and cisplatin therapy was administered. After 7 courses of chemotherapy, a new liver metastatic lesion and a tumor thrombus in the right portal vein appeared. Moreover, the serum level of ammonia was elevated(296 mg/dL)following a consciousness disorder. Enhanced CT revealed an inferior mesenteric vein to left renal vein shunt, which led to the diagnosis of portal systemic encephalopathy due to portosystemic shunt. Percutaneous transvenous coil embolization was performed. The serum ammonia level decreased, and the encephalopathy disappeared. As a result, he was able to continue chemotherapy.

    PubMed

    researchmap

  • Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.

    Tatsuo Kanda, Takashi Ishikawa, Shin-Ichi Kosugi, Kyo Ueki, Tetsuya Naito, Toshifumi Wakai, Seiichi Hirota

    International journal of clinical oncology   21 ( 2 )   295 - 301   2016年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Patients undergoing imatinib therapy for gastrointestinal stromal tumors (GISTs) show drug resistance during treatment in the late stages. The aims of this study were to determine survival after the appearance of imatinib secondary resistance (ISR) and to identify the prognostic factors. METHODS: Eligible were patients with unresectable and metastatic GISTs who were diagnosed with ISR and/or underwent treatment for ISR in our institution between 2001 and 2012. A total of 48 patients were enrolled and overall survival was retrospectively analyzed. The Cox proportional hazards model was used to identify the independent prognostic factors. Median follow-up time was 58 months. RESULTS: As of the cutoff date, 41 of the 48 patients with ISR had died, of which 39 died of GISTs. The overall 1-, 3-, and 5-year survival rates of the 48 patients were 64.6, 32.8, and 20.4 %, respectively, and median survival time was 22 months. The favorable independent prognostic factors identified were long progression-free survival in first-line imatinib therapy (P = 0.04), small diameter of progressive disease (PD) (P = 0.02), and surgical resection of PD (P = 0.01). CONCLUSION: Surgical resection of PD in selected cases could improve prognosis in ISR patients undergoing GIST treatment.

    DOI: 10.1007/s10147-015-0903-7

    PubMed

    researchmap

  • [A Case of Minimally Invasive Apocrine Carcinoma Derived from Ductal Adenoma].

    Kazuki Moro, Yu Koyama, Masayuki Nagahashi, Miki Hasegawa, Chie Toshikawa, Junko Tsuchida, Takaaki Hanyu, Takashi Ishikawa, Yoshifumi Shimada, Jun Sakata, Hitoshi Kameyama, Takashi Kobayashi, Masahiro Minagawa, Shinichi Kosugi, Takashi Kato, Gen Watanabe, Yoichi Ajioka, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   43 ( 2 )   235 - 7   2016年2月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 63-year-old woman was found to have a mass in her right breast and visited our hospital to undergo a detailed examination. A histopathological examination by using ultrasound-guided core needle biopsy revealed ductal carcinoma in situ. A partial mastectomy with sentinel lymph node biopsy was performed for the cancer of the right breast. The postoperative histopathological examination indicated apocrine carcinoma with a predominantly intraductal component without lymph node metastasis. The discrimination between ductal adenoma and apocrine carcinoma sometimes becomes a problem in making decisions about treatment. We need to take care when making a diagnosis.

    PubMed

    researchmap

  • Risk Factors and Clinical Outcomes of Recurrent Laryngeal Nerve Paralysis After Esophagectomy for Thoracic Esophageal Carcinoma. 国際誌

    Yu Sato, Shin-ichi Kosugi, Naotaka Aizawa, Takashi Ishikawa, Yosuke Kano, Hiroshi Ichikawa, Takaaki Hanyu, Kotaro Hirashima, Takeo Bamba, Toshifumi Wakai

    World journal of surgery   40 ( 1 )   129 - 36   2016年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The objectives of this study were to assess the incidence of recurrent laryngeal nerve paralysis (RLNP) using laryngoscopy after esophagectomy for thoracic esophageal carcinoma and to clarify the risk factors influencing postoperative RLNP. METHODS: A total of 299 patients who underwent laryngoscopic examination after esophagectomy were retrospectively reviewed. Patients who were found to have postoperative RLNP were followed up every 1–3 months, with a median follow-up period of 3 months. Recovery from paralysis was also evaluated on the basis of each affected nerve. Multivariate analyses using logistic regression were used to identify independent risk factors for RLNP. Cumulative recovery rate was calculated using Kaplan–Meier method. RESULTS: A total of 178 (59.5%) patients were diagnosed with RLNP by first laryngoscopy [bilateral in 59 (33.1%) patients, right in 15 (8.4%), and left in 104 (58.4%)]. In 206 patients who underwent transthoracic and thoracoscopic esophagectomy, independent risk factors for RLNP were lymph node dissection along the right RLN (odds ratio [OR] 3.01, 95% confidence interval [CI] 1.06–8.54, P = 0.04) and cervical anastomosis (OR 5.94, 95% CI 1.78–19.80, P < 0.01). Cumulative recovery rate from RLNP was 61.7% at 12 months after esophagectomy with 91 nerves eventually recovering from paralysis. Median recovery time was 6 months. CONCLUSIONS: RLNP developed in 60 % of patients after esophagectomy and may be associated with lymphadenectomy around the right RLN and cervical esophageal mobilization. Although 62% of affected nerves recovered within 12 months, great attention should be given when performing these procedures.

    PubMed

    researchmap

  • Prognostic significance of NQO1 expression in esophageal squamous cell carcinoma after preoperative chemotherapy with cisplatin and 5-fluorouracil followed by curative esophagectomy 査読

    Hiroshi Ichikawa, Shin-ichi Kosugi, Yuki Hirose, Yasunobu Matsuda, Takashi Ishikawa, Takaaki Hanyu, Kenji Usui, Yusuke Muneoka, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Hitoshi Kameyama, Toshifumi Wakai

    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY   9 ( 7 )   7393 - 7401   2016年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:E-CENTURY PUBLISHING CORP  

    NAD(P) H:quinone oxidoreductase-1 (NQO1) confers resistance to anticancer agents, particularly to oxidative stress inducers such as cisplatin or 5-fluorouracil in malignant tumors. Here we evaluated the association between NQO1 expression in esophageal squamous cell carcinoma (ESCC) cells and the patients' responses to preoperative chemotherapy with cisplatin and 5-fluorouracil (CF), and we elucidated the prognostic significance of NQO1 expression in ESCC patients. We retrospectively analyzed the cases of 40 patients who underwent preoperative CF therapy followed by curative esophagectomy with lymphadenectomy. Immunohistochemistry of the surgically resected specimens was conducted using the primary monoclonal antibody against NQO1. Eighteen of the 40 patients (45%) had tumors that showed high NQO1 expression (NQO1-high group). The poorer histological response to preoperative CF therapy was dominant in the NQO1-high group compared to the NQO1-low group (72% and 45%, respectively) but the difference was not significant (P=0.09). The 3-year recurrence-free survival rate after esophagectomy in the NQO1-high group was significantly lower compared to the NQO1-low group (39% vs. 76%; P&lt;0.01). A Cox proportional hazards model revealed that high NQO1 expression was an independent unfavorable prognostic factor (HR=3.53; P=0.02) as was pN3 (HR=14.7; P&lt;0.01). The immunohistochemical evaluation of NQO1 expression has potential to predict the treatment response and prognosis in patients who undergo preoperative CF therapy followed by esophagectomy for ESCC.

    Web of Science

    researchmap

  • Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer. 国際誌

    Yosuke Kano, Shin-ichi Kosugi, Takashi Ishikawa, Takahiro Otani, Yusuke Muneoka, Yu Sato, Takaaki Hanyu, Kotaro Hirashima, Takeo Bamba, Toshifumi Wakai

    Surgery   158 ( 6 )   1581 - 9   2015年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: We sought to determine the prognostic significance of intraoperative peritoneal lavage cytology (CY) at 3 different abdominal cavities and establish the optimal treatment for gastric cancer patients with positive peritoneal cytology (CY1). METHODS: A total of 1,039 patients with primary gastric adenocarcinoma who underwent CY at 3 cavities (Douglas' pouch, left subphrenic cavity, and right subhepatic cavity) were enrolled; 116 (11%) patients had at least one positive cavity. We retrospectively analyzed the clinicopathologic characteristics and survival of these 116 patients with CY1. RESULTS: Seventeen (15%) of the patients had negative cytology at Douglas' pouch but positive cytology at one or both of the other cavities. The 116 patients' overall 2-year survival rate was 22.9%, with the median survival time of 11 months. The overall 2-year survival rates for the patients with positive cytology at 1, 2, and 3 cavities were 41.9%, 35.8%, and 15%, with median survival times of 17, 18, and 9 months, respectively (P < .01). A multivariate analysis revealed that macroscopic type 4 tumor, R2 resection, lymph node metastasis, and postoperative chemotherapy were independent prognostic factors. Among the CY1 patients with type 4 tumors, there was no substantial difference in survival between the patients who underwent R1 or R2 resection, although the statistical power of this subgroup analysis was low. CONCLUSION: CY at 3 cavities might be a useful method to decrease the false-negative rate. Palliative gastrectomy for CY1 patients with type 4 tumors is still controversial.

    DOI: 10.1016/j.surg.2015.04.004

    PubMed

    researchmap

  • [Locally Advanced Breast Cancer Treated with Halsted's Operation Because of Drug-Induced Lung Injury Caused by Neoadjuvant Chemotherapy--A Case Report].

    Kazuki Moro, Masayuki Nagahashi, Junko Tsuchida, Kumiko Tatsuda, Chie Toshikawa, Miki Hasegawa, Takashi Ishikawa, Yoshifumi Shimada, Jun Sakata, Hitoshi Kameyama, Takashi Kobayashi, Masahiro Minagawa, Shin-ichi Kosugi, Yu Koyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   42 ( 12 )   1803 - 5   2015年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 64-year-old woman discovered a mass in her left breast and visited our hospital. A thorough examination resulted in a diagnosis of left, locally advanced breast cancer (cT4bN3, M0, cStage Ⅲc) with muscle invasion and Level Ⅲ lymph node metastases. Because of drug-induced lung disease following 4 courses of adriamycin and cyclophosphamide, the chemotherapy had to be stopped. Halsted's operation and postoperative radiotherapy (50 Gy) were performed. The patient was alive with no evidence of recurrence 9 months after surgery. Although multidisciplinary therapy is recommended in locally advanced breast cancer, chemotherapy sometimes cannot be performed due to factors such as age and physical status. Halsted's operation could be considered as a treatment of choice in patients with locally advanced breast cancer. It is important to choose the treatment strategy based on the condition of the patient.

    PubMed

    researchmap

  • [Mesorectal Lymph Node Metastasis Arising from Rectal Invasion by an Ovarian Cancer--A Case Report].

    Toru Mizuki, Yoshifumi Shimada, Yutaka Yagi, Yosuke Tajima, Mae Nakano, Masato Nakano, Kumiko Tatsuda, Takashi Ishikawa, Jun Sakata, Hitoshi Kameyama, Takashi Kobayashi, Shin-ichi Kosugi, Yu Koyama, Toshifumi Wakai, Takayuki Enomoto

    Gan to kagaku ryoho. Cancer & chemotherapy   42 ( 12 )   2300 - 2   2015年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 58-year-old woman presenting with abdominal distension was diagnosed with a tumor in the right ovary. A chest-abdominal-pelvic computed tomography scan revealed multiple lung metastases, multiple liver metastases, and peritoneal dissemination. Invasion of the rectum by peritoneal dissemination of the Douglas' pouch was suspected. She was diagnosed with Stage Ⅳ right ovarian cancer and was treated with preoperative chemotherapy. After chemotherapy, debulking surgery of the abdominal cavity (total hysterectomy, bilateral salpingo-oophorectomy, partial omentectomy, and Hartmann's procedure) was performed. Because there was swelling observed in multiple mesorectal lymph nodes, lymph node dissection was performed based on methods used for rectal cancer surgery. Postoperative histopathological examination revealed multiple mesorectal lymph node metastases arising from ovarian cancer. We suggest that mesorectal lymph node dissection be considered a part of debulking surgery for ovarian cancers that have invaded the rectum.

    PubMed

    researchmap

  • 家族性大腸腺腫症術後に発症した回腸嚢内腺腫、回腸嚢内腺癌の検討

    中野 雅人, 亀山 仁史, 島田 能史, 阿部 馨, 山田 沙季, 庭野 稔之, 岩城 孝和, 廣瀬 雄己, 八木 亮磨, 田島 陽介, 岡村 拓磨, 中野 麻恵, 永橋 昌幸, 石川 卓, 坂田 純, 小林 隆, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本消化器外科学会雑誌   48 ( Suppl.2 )   360 - 360   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • ニロチニブ耐性GISTに対して手術を施行した2例

    菅生 貴仁, 高橋 剛, 石川 卓, 市川 寛, 廣田 誠一, 中島 清一, 宮崎 安弘, 牧野 知紀, 黒川 幸典, 山崎 誠, 瀧口 修司, 若井 俊文, 森 正樹, 土岐 祐一郎

    日本癌治療学会誌   50 ( 3 )   2490 - 2490   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • [A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma].

    Takuya Ando, Jun Sakata, Tomohiro Maruyama, Yuki Hirose, Yasuyuki Okabe, Kazuyasu Takizawa, Masayuki Nagahashi, Yoshifumi Shimada, Takashi Ishikawa, Hitoshi Kameyama, Takashi Kobayashi, Masahiro Minagawa, Shinichi Kosugi, Yu Koyama, Aya Ohtsubo, Satoshi Watanabe, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   42 ( 7 )   847 - 9   2015年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Pneumatosis cystoides intestinalis (PCI) is a relatively rare condition, characterized by subserosal or submucosal air within the bowel wall. Herein, we report a rare case of PCI secondary to treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). A 71-year-old man, who had received gefitinib therapy for 2 years and 5 months for lung adenocarcinoma with metastases to the bones and brain, presented with abdominal pain, diarrhea, and vomiting. Computed tomography of the abdomen revealed intramural air in the small bowel, free air in the abdomen, and moderate ascites. A diagnosis of PCI was made, and the patient was managed conservatively by discontinuing gefitinib treatment, because his vital signs were stable and there was no sign of peritonitis. The patient's symptoms gradually improved, and follow-up CT after 1 week revealed that the initial findings had almost completely resolved. Clinicians should note that treatment with gefitinib might cause PCI.

    PubMed

    researchmap

  • Incidence and Risk Factors for Anastomotic Stricture after Esophagectomy with Gastric Tube Reconstruction. 国際誌

    Takaaki Hanyu, Shin-Ichi Kosugi, Takashi Ishikawa, Hiroshi Ichikawa, Toshifumi Wakai

    Hepato-gastroenterology   62 ( 140 )   892 - 7   2015年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIMS: The aim of this study was to investigate the incidence and risk factors for anastomotic stricture after esophagectomy with gastric tube reconstruction. METHODOLOGY: A total of 150 consecutive patients with esophageal cancer who underwent esophagectomy with gastric tube reconstruction were analyzed in this study. Anastomotic stricture was de fined as disturbance of the passage of a standard endo scope, with no evidence of locoregional cancer recurrence. Cumulative incidence was calculated using the Kaplan-Meier method. A total of 38 clinicopathological variables were assessed to elucidate the risk factors by univariate and multivariate analyses. RESULTS: Anastomotic stricture developed in 61 of 150 patients 41%). The cumulative incidences were 34.2% at 6 months, and 37.9% at 12 months. Fifty-seven patients (93%) developed anastomotic stricture within 12 months after esophagectomy. A low preoperative partial pressure of arterial oxygen (odds ratio, 2.23; 95% confidence interval, 1.10-4.55; p = 0.027) and the presence of postoperative complications of Grade 3 or higher (3.05; 1.04-9.00; p = 0.043) were identified as the independent risk factors. CONCLUSIONS: The incidence of anastomotic stricture after esophagectomy was high. A modification of anastomotic procedure may be necessary for patients with a low preoperative partial pressure of arterial oxygen to prevent the development of stricture.

    PubMed

    researchmap

  • Severe cellulitis and abdominal wall emphysema following laparoscopic colonic surgery: A case report.

    Ryo Tanaka, Hitoshi Kameyama, Tadasu Chida, Tatsuo Kanda, Yosuke Kano, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Shin-Ichi Kosugi, Toshifumi Wakai

    Asian journal of endoscopic surgery   8 ( 2 )   193 - 6   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Abdominal wall emphysema is a common complication of laparoscopic surgery. This condition is usually harmless; however, if an infection occurs, it can develop into a serious condition such as necrotizing fasciitis. We report a case of a 51-year-old woman suffering from severe cellulitis that spread from an area of abdominal wall emphysema after laparoscopic surgery for sigmoid colon cancer. Recognizing this complication, early diagnosis, and prompt treatment are cornerstones for successful management of this potentially fatal disease.

    DOI: 10.1111/ases.12159

    PubMed

    researchmap

  • [Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].

    Hidehito Oyanagi, Hiroshi Ichikawa, Shinichi Kosugi, Takeo Banba, Takaaki Hanyu, Kotaro Hirashima, Takashi Ishikawa, Hitoshi Kameyama, Takashi Kobayashi, Masahiro Minagawa, Yu Koyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   42 ( 4 )   497 - 501   2015年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    We report three cases of esophageal carcinoma all of which achieved a pathological complete response after neoadjuvant chemotherapy (NAC) with cisplatin and 5-fluorouracil (CF). All three patients were men with clinical stage II squamous cell carcinoma of the middle thoracic esophagus. We administered 2 courses of CF treatment as NAC and then performed radical esophagectomy. Pathologic examination revealed no viable tumor cells in the resected esophagus. The patients are currently alive with no evidence of disease.

    PubMed

    researchmap

  • Prognostic analysis of submucosa-invasive gastric cancer with lymph node metastasis. 国際誌

    Takaaki Hanyu, Atsushi Matsuki, Shin-ichi Kosugi, Takashi Ishikawa, Atsushi Nashimoto, Hiroshi Yabusaki, Masaki Aizawa, Hiroshi Ichikawa, Yoshifumi Shimada, Yuki Hirose, Toshifumi Wakai

    Surgery   157 ( 4 )   716 - 22   2015年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The aims of this study were to identify prognostic factors of patients with submucosa-invasive (T1b) gastric cancer and to verify the validity of adjuvant chemotherapy for this disease. METHODS: We retrospectively examined the cases of 1,236 consecutive patients in our prospectively maintained database with T1b gastric cancer who underwent gastrectomy in 1995-2012. We used 11 clinicopathologic characteristics to identify prognostic factors by univariate and multivariate analyses. We compared the survival of the 160 node-positive T1b gastric cancer patients with that of 133 patients in the same database who had node-positive muscularis propria-invasive (T2) gastric cancer and had undergone gastrectomy without adjuvant chemotherapy during the same period, as a reference cohort. RESULTS: The 5-year overall survival rate was 91.4% for all 1,236 patients. Advanced age (hazard ratio [HR] 4.51; 95% confidence interval [CI] 3.26-6.24; P < .01), male sex (HR 2.26; 95% CI 1.56-3.26; P < .01), and the presence of lymph node metastasis (HR 1.89; 95% CI 1.33-2.70; P < .01) were independent prognostic factors. The 5-year overall survival rates were 92.5% in node-negative patients, 84.5% in patients with 1 or 2 metastatic nodes, and 80.1% in patients with 3 or more metastatic nodes (P < .01). The 5-year overall survival rates of the node-positive T1b and T2 gastric cancer patients were 83.6% and 81.2%, respectively (P = .73). CONCLUSION: The prognosis of node-positive T1b gastric cancer patients after curative gastrectomy was unsatisfactory. Adjuvant chemotherapy should be considered for these patients, especially those with 3 or more metastatic nodes.

    DOI: 10.1016/j.surg.2014.10.009

    PubMed

    researchmap

  • 食道胃接合部癌に対する下縦隔郭清のコツとピットフォール 開腹手術の立場から 経裂孔アプローチによる系統的下縦隔リンパ節郭清手技

    矢島 和人, 小杉 伸一, 岩崎 善毅, 羽入 隆晃, 番場 竹生, 石川 卓, 若井 俊文, ゆ 賢, 大日向 玲紀, 石山 哲, 高橋 慶一, 神田 達夫

    日本胃癌学会総会記事   87回   206 - 206   2015年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本胃癌学会  

    researchmap

  • Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis. 国際誌

    Hiroshi Ichikawa, Akihiko Yoshida, Tatsuo Kanda, Shin-ichi Kosugi, Takashi Ishikawa, Takaaki Hanyu, Takahiro Taguchi, Marimu Sakumoto, Hitoshi Katai, Akira Kawai, Toshifumi Wakai, Tadashi Kondo

    Cancer science   106 ( 1 )   115 - 24   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Prognostic markers are urgently needed to optimize the postoperative treatment strategies for gastrointestinal stromal tumors (GIST). GIST of the small intestine (I-GIST) show more aggressive behavior than those of the stomach (S-GIST), and the molecular background of the malignancy in I-GIST may include potential prognostic biomarkers. We conducted integrated proteomic and transcriptomic analysis to identify genes showing differential expressions according to the tumor site. We generated protein expression profiles for four cases each of surgically resected I-GIST and S-GIST using label-free proteomic analysis. For proteins showing differential expressions, global mRNA expression was compared between 9 I-GIST and 23 S-GIST. Among the 2555 genes analyzed, we found that promyelocytic leukemia (PML), a tumor suppressor gene, was significantly downregulated in I-GIST at both the protein and mRNA levels (P < 0.01; fold difference ≥2.0). Immunohistochemistry of 254 additional cases from multiple clinical facilities showed that PML-negative cases were significantly frequent in the I-GIST group (P < 0.001). The 5-year recurrence-free survival rate was significantly lower in the PML-negative than in the PML-positive cases (60.1% vs 91.7%; P < 0.001). Multivariate analysis revealed that downregulation of PML was an independent unfavorable prognostic factor (hazard ratio = 2.739; P = 0.001). Our study indicated that prognostication based on PML expression may have potential for optimizing the treatment strategy for GIST patients. Further validation studies of PML for clinical application, and investigation for the mechanistic significance of PML to clarify the molecular backgrounds of malignancy in GIST are warranted.

    DOI: 10.1111/cas.12565

    PubMed

    researchmap

  • Internal hernia after laparoscopic-assisted proximal gastrectomy with jejunal interposition for gastric cancer: a case report. 国際誌

    Kotaro Hirashima, Takashi Ishikawa, Shin-Ichi Kosugi, Yosuke Kano, Yu Sato, Hiroshi Ichikawa, Takaaki Hanyu, Takeo Bamba, Toshifumi Wakai

    Surgical case reports   1 ( 1 )   49 - 49   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Internal hernia after gastrectomy is a rare complication. It can progress rapidly to vascular disturbance, necrosis, and perforation, therefore early diagnosis and surgical treatment is essential. We present a case of internal hernia following laparoscopic-assisted proximal gastrectomy with jejunal interposition reconstruction in a 68-year-old man, who presented with acute abdominal pain and vomiting. Computed tomography showed a whirl sign, ascites, and a closed-loop formation of the small intestine. We diagnosed an internal hernia and performed emergency surgery. Laparotomy revealed chyle-like ascites and extensive small intestine with poor color. We recognized that about 20 cm of jejunum from the ligament of Treitz was strangulated behind the pedicle of the jejunum lifted during laparoscopic-assisted proximal gastrectomy. We relieved the strangulation, whereupon the color of the strangulated intestine was restored. Therefore, we did not perform intestinal resection and reconstruction. Finally, we fixed the jejunal pedicle and mesentery of the transverse colon. We report this case as there are few reported cases of internal hernia after laparoscopic-assisted proximal gastrectomy.

    DOI: 10.1186/s40792-015-0051-3

    PubMed

    researchmap

  • Conservative treatment of idiopathic spontaneous pneumoperitoneum in a bedridden patient: a case report. 国際誌

    Ryo Tanaka, Hitoshi Kameyama, Masayuki Nagahashi, Tatsuo Kanda, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Takashi Kobayashi, Jun Sakata, Shin-Ichi Kosugi, Toshifumi Wakai

    Surgical case reports   1 ( 1 )   69 - 69   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Idiopathic spontaneous pneumoperitoneum is a rare condition that is characterized by intraperitoneal gas for which no clear etiology has been identified. We report here a case of idiopathic spontaneous pneumoperitoneum, which was successfully managed by conservative treatment. A 77-year-old woman who was bedridden with speech disability as a sequela of brain hemorrhage presented at our hospital with a 1-day history of abdominal distention. On physical examination, she had stable vital signs and slight epigastric tenderness on deep palpation without any other signs of peritonitis. A chest radiograph and computed tomography showed that a large amount of free gas extended into the upper abdominal cavity. Esophagogastroduodenoscopy revealed no perforation of the upper gastrointestinal tract. The patient was diagnosed with idiopathic spontaneous pneumoperitoneum, and conservative treatment was selected. The abdominal distension rapidly disappeared, and the patient resumed oral intake on the 5th hospital day without deterioration of symptoms. Knowledge of this rare disease and accurate diagnosis with findings of clinical imaging might contribute towards refraining from unnecessary laparotomy.

    DOI: 10.1186/s40792-015-0073-x

    PubMed

    researchmap

  • Intrathoracic esophagojejunostomy using OrVil™ for gastric adenocarcinoma involving the esophagus. 国際誌

    Kazuhito Yajima, Tatsuo Kanda, Shin-Ichi Kosugi, Yosuke Kano, Takashi Ishikawa, Hiroshi Ichikawa, Takaaki Hanyu, Toshifumi Wakai

    World journal of gastrointestinal surgery   6 ( 12 )   235 - 40   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: To demonstrate a new surgical technique of lower mediastinal lymphadenectomy and intrathoracic anastomosis of esophagojejunostomy using OrVil™. METHODS: After a total median phrenotomy, the supradiaphragmatic and lower thoracic paraesophageal lymph nodes were transhiatally dissected. The esophagus was cut off using a liner stapler and OrVil™was inserted. Finally, end-to-side esophagojejunostomy was created by using a circular stapler. From July 2009, we adopted this surgical technique for five patients with gastric cancer involving the lower esophagus. RESULTS: The median operation time was 314 min (range; 210-367 min), and median blood loss was 210 mL (range; 100-838 mL). The median numbers of dissected lower mediastinal nodes were 3 (range; 1-10). None of the patients had postoperative complications including anastomotic leakage and stenosis. The median hospital stay was 16 d (range: 15-20 d). The median length of esophageal involvement was 14 mm (range: 6-48 mm) and that of the resected esophagus was 40 mm (range: 35-55 mm); all resected specimens had tumor-free margins. CONCLUSION: This surgical technique is easy and safe intrathoracic anastomosis for the patients with gastric adenocarcinoma involving the lower esophagus.

    DOI: 10.4240/wjgs.v6.i12.235

    PubMed

    researchmap

  • [A case of descending colon cancer with multiple liver metastases effectively treated with capecitabine/oxaliplatin (CapeOX) and bevacizumab].

    Mae Nakano, Hitoshi Kameyama, Yoshifumi Shimada, Yoshifumi Hashimoto, Mana Hosoi, Masato Nakano, Hitoshi Nogami, Takaaki Hanyu, Kazuyasu Takizawa, Takashi Ishikawa, Jun Sakata, Takashi Kobayashi, Masahiro Minagawa, Shinichi Kosugi, Yu Koyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 12 )   1785 - 7   2014年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 57-year-old woman was referred to our hospital because of descending colon cancer with multiple liver metastases. Abdominal magneticresonanc e imaging (MRI) revealed 13 liver metastases across the lobes. We started combination che- motherapy with capecitabine/oxaliplatin (CapeOX) and bevacizumab. After 9 courses of the treatment, the number and size of the liver metastases were remarkably reduced on MRI. Left colectomy and partial hepatectomy were performed. Histopathological examination revealed no residual cancer cells in the colon but revealed a few cancer cells in 4 of 7 resected liver specimens. At 11 postoperative months, 1 liver metastasis reappeared, for which we performed laparoscopy-assisted partial hepatectomy. At 21 months after the second operation, the patient was well without any signs of recurrence. Thus, the combination chemotherapy with CapeOX and bevacizumab allowed for the successful resection of the tumor and metastasis in our patient who initially had unresectable colon cancer and multiple liver metastases.

    PubMed

    researchmap

  • [A case of long-term survival in a patient with rectal cancer with virchow lymph node metastasis, liver metastases, and lung metastases].

    Hidehito Oyanagi, Hitoshi Kameyama, Hitoshi Nogami, Yoshifumi Shimada, Mae Nakano, Masato Nakano, Takashi Ishikawa, Jun Sakata, Takashi Kobayashi, Masahiro Minagawa, Shinichi Kosugi, Yu Koyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 12 )   1674 - 6   2014年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 69-year-old man with advanced rectal cancer and liver metastases was treated with 2 courses of chemotherapy with irinotecan and S-1 followed by low anterior resection and partial hepatectomy. Chemotherapy with S-1 was then administered for 22 months. However, lung metastases developed, for which partial pneumonectomy was performed. Seven months later, computed tomography (CT) revealed swelling of the left supraclavicular lymph node. Despite chemotherapy with 5- fluorouracil, Leucovorin, and oxaliplatin (mFOLFOX6); 5-fluorouracil, Leucovorin and irinotecan (FOLFIRI); and capecitabine plus bevacizumab, the lung metastases recurred and Virchow lymph node swelling was noted again. Accordingly, palliative therapy was administered. The patient died 3 years 1 month after Virchow lymph node resection. Herein, we describe a case of advanced rectal cancer, in which lung and Virchow lymph node metastases developed after liver metastasis. Surgical excision of the metastases resulted in long-term survival of 6 years following the first operation.

    PubMed

    researchmap

  • [A case of an elderly patient who underwent single-incision laparoscopic surgery for small intestine cancer].

    Yoshifumi Hashimoto, Hitoshi Kameyama, Yuki Hirose, Ryoma Yagi, Mae Nakano, You Sato, Tomoki Kido, Hiroshi Ichikawa, Takaaki Hanyu, Masato Nakano, Takashi Ishikawa, Yoshifumi Shimada, Takashi Kobayashi, Jun Sakata, Masahiro Minagawa, Shinichi Kosugi, Yu Koyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 12 )   2442 - 3   2014年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    An 81-year-old man presented with chief complaints of abdominal pain and vomiting. Intestinal obstruction was found at the time of admission to a local hospital in October 2011. Conservative treatment provided symptomatic relief; however, he was readmitted with similar symptoms in December 2011. Small-intestinal wall thickening was detected by abdominal and pelvic computed tomography, and he was referred to our hospital. Small-bowel endoscopy revealed an elevated subcircumferential tumor in the jejunum. Biopsy revealed well to moderately differentiated adenocarcinoma diagnosed as jejunal cancer, which caused narrowing of the jejunum. Single-incision laparoscopy-assisted small-bowel resection was performed. The intraoperative findings were a tumor with inflammatory changes in the jejunum and enlarged surrounding lymph nodes. We performed regional lymph node dissection. Histopathological analysis showed moderately differentiated small-intestinal tubular adenocarcinoma and 2 of 5 lymph nodes positive for metastatic cancer cells. After an uneventful postoperative course, he was discharged on day 7. He preferred not to undergo postoperative adjuvant chemotherapy and quickly recovered his activities of daily living postoperatively. He stayed home until he developed abdominal distention resulting from peritoneal recurrence 1 year and 6 months postoperatively and died 1 month later.

    PubMed

    researchmap

  • [A case of early gastric cancer completely responding to adjuvant chemotherapy for advanced colon cancer].

    Ryo Tanaka, Hitoshi Kameyama, Mae Nakano, Hiroshi Ichikawa, Takaaki Hanyu, Masato Nakano, Takashi Ishikawa, Yoshifumi Shimada, Jun Sakata, Takashi Kobayashi, Shinichi Kosugi, Masahiro Minagawa, Yu Koyama, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 12 )   2364 - 6   2014年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 70-year-old man was referred to our hospital with ascending colon cancer (cT3N1M0, Stage IIIa), which was found during examinations following a positive fecal occult blood test. The patient was also diagnosed with early gastric cancer (cT1a, N0, M0, Stage IA)during a preoperative gastroscopy examination. A laparoscopically assisted right colectomy and D3 lymphadenectomy was performed for the ascending colon cancer. The postoperative pathological diagnosis was Stage IIIb (pT3N2), he was administered in combination with capecitabine plus oxaliplatin (CapeOX) as adjuvant chemotherapy before the treatment for the colon cancer. After 6 months of adjuvant chemotherapy, we were unable to detect any gastric lesions at the same location using gastroscopy, and so diagnosed a clinical complete response. A follow-up gastroscopy 6 months later showed the same findings. The patient has had no recurrence of gastric cancer for 18 months after the initial operation. He will continue to be followed up closely using gastroscopy. In this case, CapeOX as adjuvant chemotherapy for advanced colon cancer was also effective for early gastric cancer.

    PubMed

    researchmap

  • Prognostic Significance of Initial Recurrence Site in Hematogenous Recurrence of Esophageal Squamous Cell Carcinoma 査読

    Hiroshi Ichikawa, Shin-ichi Kosugi, Tatsuo Kanda, Takashi Ishikawa, Kazuhito Yajima, Kohei Akazawa, Tsutomu Suzuki, Toshifumi Wakai

    HEPATO-GASTROENTEROLOGY   61 ( 136 )   2241 - 2246   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: Hematogenous recurrences of esophageal squamous cell carcinoma (ESCC) have dismal prognoses, but prognostic heterogeneity exists in this disease. The objectives of this study were to clarify the prognosis in this disease with regard to the initial recurrence site and to define the prognostic factors. Methodology: We retrospectively reviewed the cases of 67 consecutive patients with hematogenous recurrence in major organs after esophagectomy for ESCC of the thoracic esophagus and the esophagogastric junction. We analyzed clinicopathological characteristics, survival probability and potential prognostic factors. Results: Lung, liver, bone, and multiple-organ metastases occurred in 24, 19, 14, and 10 patients, respectively. Twenty-seven patients simultaneously had locoregional recurrence (combined recurrence). Among all 67 patients, the median disease-free interval (DFI) was 9.7 months, and the median survival time after the initial recurrence was 4.9 months. The patients with initial lung metastasis had most favorable prognosis with the median survival time of 9.8 months. A multivariate analysis identified that initial recurrence site, DFI, combined recurrence, and anticancer therapy were independent prognostic factors. Conclusions: The initial recurrence site contributes to the prognostic heterogeneity of patients with hematogenous recurrence of ESCC. The prognostic factors identified in this study are useful to optimize the management of these patients.

    DOI: 10.5754/hge13171

    Web of Science

    PubMed

    researchmap

  • 胃癌ESD後追加外科切除症例の検討

    田中 亮, 小杉 伸一, 市川 寛, 羽入 隆晃, 石川 卓, 橋本 哲, 竹内 学, 小林 正明, 坂田 純, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本消化器外科学会雑誌   47 ( Suppl.2 )   148 - 148   2014年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    researchmap

  • Conservative treatment of esophageal perforation related to a peptic ulcer with pyloric stenosis.

    Ryo Tanaka, Shin-Ichi Kosugi, Daisuke Sato, Hiroshi Hirukawa, Tetsuya Tada, Hiroshi Ichikawa, Takaaki Hanyu, Takashi Ishikawa, Takashi Kobayashi, Toshifumi Wakai

    Clinical journal of gastroenterology   7 ( 4 )   295 - 8   2014年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We report a case of esophageal perforation (Boerhaave syndrome) caused by vomiting related to a duodenal ulcer with pyloric stenosis. A 45-year-old male presented with left chest pain and dyspnea after forceful vomiting. Chest radiography and computed tomography (CT) revealed a massive left pleural effusion and left tension pneumothorax. Abdominal CT revealed pyloric stenosis with a remarkably dilated stomach. Tube thoracostomy and nasogastric suction were immediately performed and we selected conservative treatment based on the following factors-a stable general condition without sepsis, early diagnosis, and good drainage. Esophagogastroduodenoscopy on hospital day 9 demonstrated a healing ulcer in the lower esophagus and pyloric stenosis. We performed distal gastrectomy as elective surgery for pyloric stenosis due to a duodenal ulcer on hospital day 30. In summary, an esophageal perforation with contamination spreading to the thoracic cavity was successfully treated with conservative treatment.

    DOI: 10.1007/s12328-014-0493-3

    PubMed

    researchmap

  • [Current status of adjuvant chemotherapy in patients with p-Stage II and p-Stage III gastric cancer].

    Yu Sato, Kazuhito Yajima, Shin-ichi Kosugi, Yusuke Muneoka, Hiroshi Ichikawa, Takaaki Hanyu, Kaoru Sakamoto, Takashi Ishikawa, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 8 )   961 - 4   2014年8月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    The results of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer(ACTS-GC)demonstrated that postoperative chemotherapy using S-1 is a standard treatment in Japan for patients with p-Stage II and p-Stage III gastric cancer. We retrospectively reviewed the effect of adjuvant chemotherapy received by 47 patients with p-Stage II and p-Stage III gastric cancer between January 2007 and June 2012. Our hospital is a local university hospital with a high intensive care unit. S-1 monotherapy was administered to 32 patients(adjuvant S-1 group, 68.1%); 22 patients(68.8%)among them completed one year of therapy without any modification to the administration schedule. A total of 8 patients(25.0%)experienced grade 3 adverse events, and 9 patients required a dose reduction, a modification of the administration schedule, or termination of the therapy. S-1 was not administrated to 15 patients(no adjuvant S-1 group, 31.9%); among these patients, 12(80.0%) were not administered S-1 because of their advanced age and comorbidity. The 3-year overall survival rate was 89.3% in the adjuvant S-1 group and 77.1% in the no adjuvant S-1 group. The completion rate of S-1 and survival rate were high for patients in the adjuvant S-1 group, which was similar to the results of the ACTS-GC. However, 25 of 47 patients(53.2%) with p-Stage II and p-Stage III gastric cancer did not improve after sufficient adjuvant therapy; therefore, it is important to develop new treatment strategies for these patients.

    PubMed

    researchmap

  • Stage IV大腸癌CurB症例の検討

    野上 仁, 中野 雅人, 島田 能史, 石川 卓, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会   69回 ( 12 )   P - 5   2014年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器外科学会  

    PubMed

    researchmap

  • Prognostic factors and causes of death in patients cured of esophageal cancer. 国際誌

    Tomoyuki Kakuta, Shin-Ichi Kosugi, Tatsuo Kanda, Takashi Ishikawa, Takaaki Hanyu, Tsutomu Suzuki, Toshifumi Wakai

    Annals of surgical oncology   21 ( 5 )   1749 - 55   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The number of patients cured of esophageal cancer after esophagectomy is gradually increasing owing to advances in surgical techniques, perioperative management, and adjuvant therapies. This study assessed the clinical course and sought to identify the prognostic factors of these patients. METHODS: A series of 220 consecutive patients who underwent esophagectomy and survived for more than 5 years with no relapse were enrolled. Survival analysis was performed using 25 variables including patient characteristics and operative and perioperative factors. Potential prognostic factors were identified by univariate and multivariate analyses, and the development of other primary cancers and the causes of death were retrospectively reviewed. RESULTS: The overall 10-, 15-, and 20-year survival rates were 71.6, 50.1, and 32.2 %, respectively, with a median survival time of 180 months (range, 61-315 months). The negative independent prognostic factors identified were age at surgery [hazard ratio (HR), 1.05; P < .01], being male (HR, 2.62; P = .02), pulmonary comorbidities (HR, 2.03; P = .02), synchronous presence of other cancers (HR, 2.35; P < .01), colonic/jejunal interposition (HR, 1.76; P = .03), perioperative blood transfusion (HR, 1.92; P = .02), development of pulmonary complications (HR, 1.71; P = .02), and adjuvant radiotherapy (HR, 2.13; P = .01). Pulmonary diseases and other primary cancers were found to be the most common causes of death. CONCLUSIONS: Careful follow-up including the surveillance of other primary cancers is required for long-term survivors of esophageal cancer after esophagectomy.

    DOI: 10.1245/s10434-014-3499-7

    PubMed

    researchmap

  • Is early enteral nutrition initiated within 24 hours better for the postoperative course in esophageal cancer surgery? 国際誌

    Naoko Manba, Yu Koyama, Shin-Ichi Kosugi, Takashi Ishikawa, Hiroshi Ichikawa, Masahiro Minagawa, Takashi Kobayashi, Toshifumi Wakai

    Journal of clinical medicine research   6 ( 1 )   53 - 8   2014年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Early enteral nutrition within 24 h after surgery has become a recommended procedure. In the present study, we retrospectively examined whether initiating EN within 24 h after esophagectomy improves the postoperative course. METHODS: Among 103 patients who underwent thoracic esophagectomy for esophageal cancer, we enrolled the cases in which EN was initiated within 72 h after surgery. The patients were divided into two groups: EN started within 24 h (Group D1) and EN started at 24 - 72 h (Group D2-3). Clinical factors including days for first fecal passage, dose of postoperative albumin infusion, difference in serum albumin between pre- and postoperation, incidence of postoperative infection, and use of total parenteral nutrition were compared. Statistical analyses were performed by the Mann-Whitney U test and Chi square test, with significance defined as P < 0.05. RESULTS: There was no significant difference between the groups in clinical factors. While pneumonia was significantly more frequent in Group D1 than in Group D2-3 (P = 0.0308), the frequency of infectious complications was comparable between the groups. CONCLUSION: Initiating EN within 24 h showed no advantage for the postoperative course in esophageal cancer, and thus EN should be scheduled within 24 - 72 h, based on the patient condition.

    DOI: 10.4021/jocmr1665w

    PubMed

    researchmap

  • [Urgent gastrectomy in a patient who developed perforated gastric cancer during preoperative chemotherapy with S-1 plus cisplatin].

    Yasuyuki Okabe, Kazuhito Yajima, Takashi Ishikawa, Shin-ichi Kosugi, Kaoru Sakamoto, Yu Sato, Tatsuo Kanda, Toshifumi Wakai

    Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 1 )   95 - 8   2014年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 66 -year-old man presenting with a chief complaint of upper abdominal pain was diagnosed as having an advanced adenocarcinoma, type 2, of the lower third of the stomach after endoscopy was performed. An abdominal computed tomography( CT)scan revealed 4 lymph node metastases at the infrapyloric nodes(station No. 6)and the nodes around the proximal splenic artery(station No. 11p)and the abdominal aorta(station No. 16a2). The clinical stage was determined to be T3(SS)N2M1(LYM), Stage IV. Gastrectomy with D2 plus para-aortic node dissection was scheduled after 2 courses of S-1 plus cisplatin(CDDP)with curative intent. On day 14 after starting S-1 therapy, the patient complained of severe abdominal pain and peritoneal irritation of acute onset. Because the abdominal CT scan showed a large amount of intra-abdominal free air, we performed an urgent laparotomy with a tentative diagnosis of perforation of the gastric cancer. On laparotomy, we found a perforated malignant ulcer, 5 cm in maximum diameter, in the lesser curvature of the stomach; therefore, distal gastrectomy with D1 plus lymphadenectomy and reconstruction using the Roux-en-Y method were performed. At the end of the surgery, a macroscopic residual tumor remained in the para-aortic lymph node. The postoperative course was uneventful, and the patient was discharged on day 23 after surgery. In the present case, despite the performance of urgent gastrectomy while the patient was receiving strong chemotherapy, perioperative management was successful, with no serious postoperative complication or adverse events as a result of the chemotherapy.

    PubMed

    researchmap

  • Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature. 国際誌

    Takashi Ito, Masahiro Yamamura, Toshihiro Hirai, Takashi Ishikawa, Tatsuo Kanda, Takuya Nakai, Mizuka Ohkouchi, Yuka Hashikura, Koji Isozaki, Seiichi Hirota

    International journal of clinical and experimental pathology   7 ( 11 )   8024 - 31   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the human gut. Most sporadic GISTs have somatic gain-of-function mutations of the c-kit gene. The mutations are frequently found at exon 11, sometimes at exon 9 and rarely at exon 13 or 17. Recently, exon 8 c-kit gene mutations were reported in very minor proportion of sporadic GISTs. We also found 3 GISTs with exon 8 c-kit gene mutations in approximately 1,000 sporadic GISTs examined. In the present report, we showed the clinicopathological data of those GISTs. One case had a deletion of codon 419 of aspartate, and 2 cases had a substitution of 3 amino acids of codon 417 to codon 419 to tyrosine. The former was the same mutation recently reported in 2 GIST cases, but the latter has not been reported in any GISTs. All three cases occurred at extragastric sites and two of three showed distant metastasis. Since the remaining case was regarded as high risk for recurrence, imatinib adjuvant treatment has been done without evidence of metastasis. Our results confirmed the idea that exon 8 mutations are minor but actually existing abnormalities in sporadic GISTs, and suggested that such GISTs have a feature of extragastric development and a metastasis-prone nature. Since the exon 8 mutations appeared to be really sensitive to imatinib as shown in the present case study, accurate genotyping including exon 8 of the c-kit gene is necessary in GISTs to predict response to imatinib in both the unresectable/metastatic and adjuvant settings.

    PubMed

    researchmap

  • Treatment for perforated gastric ulcer: a multi-institutional retrospective review. 国際誌

    Ryo Tanaka, Shin-ichi Kosugi, Kaoru Sakamoto, Kazuhito Yajima, Takashi Ishikawa, Tatsuo Kanda, Toshifumi Wakai

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract   17 ( 12 )   2074 - 81   2013年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The optimal treatment for patients with perforated gastric ulcer (PGU) remains controversial. This study therefore investigated the treatment status for this disease in clinical practice. METHODS: We retrospectively reviewed 183 patients with PGU from 1998 to 2007 across 15 institutions, and analyzed patient characteristics and short- and long-term outcomes according to treatments received. RESULTS: Of the 183 patients, 57 who were treated conservatively had less abdominal tenderness, lower levels of serum C-reactive protein, and shorter time to presentation than the 126 patients who underwent emergency surgery. There was no significant difference in baseline characteristics between the 41 successful patients and 16 failed patients in the conservative treatment group; however, the latter had a longer average hospital stay. Eighty-three of the emergency surgery patients who underwent gastrectomy had longer surgical times, greater blood loss, and shorter time to resumption of diet than the 57 patients undergoing stomach-preserving surgery; however, there was no significant difference in postoperative complications and hospital stay between these groups. Of 91 patients who received stomach-preserving treatment, only three had treatment failure in the long-term follow-up period. CONCLUSION: Strictly selected patients should be initially considered for conservative treatment. The short-term outcomes of stomach-preserving surgery are comparable to gastrectomy; however, further evaluation of the long-term outcomes of stomach-preserving treatment is required.

    DOI: 10.1007/s11605-013-2362-7

    PubMed

    researchmap

  • Cervical lymph node dissection for clinically submucosal carcinoma of the thoracic esophagus. 国際誌

    Shin-ichi Kosugi, Yoshihiko Kawaguchi, Tatsuo Kanda, Takashi Ishikawa, Kaoru Sakamoto, Hidenori Akaike, Hideki Fujii, Toshifumi Wakai

    Annals of surgical oncology   20 ( 12 )   4016 - 21   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The purposes of this study were to clarify the risk factors for supraclavicular lymph node (SCLN) metastasis and the survival benefit from cervical lymph node (LN) dissections in patients with clinically submucosal (cT1b) carcinoma of the thoracic esophagus. METHODS: A total of 86 patients with this disease who underwent esophagectomy with 3-field lymph node dissection were retrospectively reviewed. Multivariate logistic regression and Cox proportional hazard model were used to identify the independent risk factors for SCLN metastasis and prognostic factors, respectively. An index calculated by multiplying the frequency of metastasis at nodal basin and the 5-year overall survival rate of patients with metastasis at that basin were used to assess the therapeutic outcomes. RESULTS: A total of 40 patients (47%) were found to have pathological LN metastasis. Also, 13 patients (15%) had cervical LN metastasis: 6 and 7 with carcinoma of the upper and mid-thoracic esophagus, respectively. SCLN metastasis was found in 6 patients (7%); however, there was no independent risk factor for SCLN metastasis. The 5-year overall survival rate was 72.5%. Cervical LN metastasis was an independent prognostic factor (p = .04; odds ratio 2.55; 95% confidence interval 1.03-6.31); however, there was no significant difference in survival between patients with SCLN metastasis and those without (p = .06). The calculated index of estimated benefit from cervical LN dissections was 6.9, following upper mediastinal LN of 15.6 and perigastric LN of 8.3. CONCLUSIONS: We could not identify risk factors to predict SCLN metastasis. Cervical LN dissection should not be omitted in patients with cT1b carcinoma, especially of the upper and mid-thoracic esophagus.

    DOI: 10.1245/s10434-013-3141-0

    PubMed

    researchmap

  • Is early enteral nutrition better for postoperative course in esophageal cancer patients? 国際誌

    Kazuaki Kobayashi, Yu Koyama, Shin-ichi Kosugi, Takashi Ishikawa, Kaoru Sakamoto, Hiroshi Ichikawa, Toshifumi Wakai

    Nutrients   5 ( 9 )   3461 - 9   2013年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We retrospectively examined esophageal cancer patients who received enteral nutrition (EN) to clarify the validity of early EN compared with delayed EN. A total of 103 patients who underwent transthoracic esophagectomy with three-field lymphadenectomy for esophageal cancer were entered. Patients were divided into two groups; Group E received EN within postoperative day 3, and Group L received EN after postoperative day 3. The clinical factors such as days for first fecal passage, the dose of postoperative albumin infusion, differences of serum albumin value between pre- and postoperation, duration of systematic inflammatory response syndrome (SIRS), incidence of postoperative infectious complication, and use of total parenteral nutrition (TPN) were compared between the groups. The statistical analyses were performed using Mann-Whitney U test and Chi square test. The statistical significance was defined as p < 0.05. Group E showed fewer days for the first fecal passage (p < 0.01), lesser dose of postoperative albumin infusion (p < 0.01), less use of TPN (p < 0.01), and shorter duration of SIRS (p < 0.01). However, there was no significant difference in postoperative complications between the two groups. Early EN started within 3 days after esophagectomy. It is safe and valid for reduction of albumin infusion and TPN, for promoting early recovery of intestinal movement, and for early recovery from systemic inflammation.

    DOI: 10.3390/nu5093461

    PubMed

    researchmap

  • Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation? 国際誌

    Tatsuo Kanda, Takashi Ishikawa, Tsuyoshi Takahashi, Toshirou Nishida

    Expert opinion on pharmacotherapy   14 ( 13 )   1859 - 67   2013年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Imatinib, a selective tyrosine kinase inhibitor (TKI), is currently the standard treatment for unresectable and metastatic gastrointestinal stromal tumors (GISTs). However, the disease control time by imatinib is limited due to intolerance or resistance. Nilotinib , a second-generation TKI, is expected to show enhanced clinical efficacy against advanced GIST. AREAS COVERED: PubMed and ClincalTrial.gov were searched to identify clinical trials of nilotinib for GIST. The key words used were GIST and nilotinib and/or AMN107. This review summarizes the clinical trials of nilotinib for advanced GIST and outlines current understanding of the clinical usefulness of nilotinib in GIST therapy. EXPERT OPINION: Clinical trials of nilotinib for advanced GIST were readily advanced from a Phase I study to Phase III studies. Unfortunately, the clinical utility of nilotinib was not demonstrated by the randomized control trials either in patients with imatinib-resistant GIST or in patients who used nilotinib as the first-line treatment. On the basis of the trial results, nilotinib is not recommended for GIST therapy generally. Nevertheless, a comparable number of patients showed significant response with different side-effect profiles from imatinib. Thus, this new TKI may still merit attention as an important alternative to imatinib in advanced GIST patients who are intolerant to imatinib.

    DOI: 10.1517/14656566.2013.816676

    PubMed

    researchmap

  • Risk factors influencing the pleural drainage volume after transthoracic oesophagectomy. 国際誌

    Shin-ichi Kosugi, Tatsuo Kanda, Kazuhito Yajima, Takashi Ishikawa, Kaoru Sakamoto

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery   43 ( 6 )   1116 - 20   2013年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: The objective of this study was to clarify the factors influencing pleural drainage volume after transthoracic oesophagectomy and to determine criteria for the selection of patients who would benefit from the early removal of chest drains. METHODS: Clinicopathological characteristics of 155 patients who underwent transthoracic oesophagectomy were prospectively collected, and the daily drainage volume of each patient was retrospectively reviewed. Potential risk factors were compared between the high-output group (n = 39) and low-output group (n = 116), which were dichotomized using the 75th percentile of total pleural drainage volume of the total study population. Multivariate logistic regression analyses were used to identify independent risk factors. RESULTS: The median duration of drainage was 10 days, with a median total drainage volume of 2258 ml. Of 27 potential risk factors influencing the drainage volume, creatinine clearance (P = 0.04), operative approach (P = 0.03) and thoracic duct removal (P = 0.01) were significantly associated with the total pleural drainage volume. The removal of the thoracic duct (P = 0.02; odds ratio, 4.02; 95% confidence interval 1.20-13.41) and lower creatinine clearance (P = 0.04; odds ratio, 1.02; 95% confidence interval 1.00-1.04) was independent risk factors for increased pleural drainage volume after transthoracic oesophagectomy. CONCLUSIONS: The early removal of chest drains may be possible in patients without these risk factors.

    DOI: 10.1093/ejcts/ezs556

    PubMed

    researchmap

  • Two-step laparoscopic surgery for a patient with synchronous double cancer of the colon and stomach accompanied by severe chronic obstructive pulmonary disease. 国際誌

    Kazuhito Yajima, Shin-Ichi Kosugi, Yosuke Kano, Takaaki Hanyu, Hiroshi Ichikawa, Takashi Ishikawa, Hitoshi Nogami, Toshifumi Wakai

    Case reports in surgery   2013   246515 - 246515   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Laparoscopic treatment strategies for synchronous intra-abdominal malignancies have not yet been standardized. We report a successful case of two-step laparoscopic surgery for synchronous double cancer of the colon and stomach accompanied by severe chronic obstructive pulmonary disease (COPD). A 66-year-old man with COPD was diagnosed as having advanced colon cancer and early gastric cancer. On admission, he could not go upstairs (Grade III according to the Hugh-Jones classification) and his forced expiratory volume in 1 second was 600 mL (35.9%). The patient initially underwent laparoscopy-assisted sigmoidectomy with D3 lymphadenectomy, followed by laparoscopy-assisted distal gastrectomy with D1 lymphadenectomy 68 days later. The patient's each postoperative course was uneventful with no pulmonary complications, and the patient was discharged 9 and 11 days after the first and second operations, respectively. The present case demonstrates that two-step laparoscopic surgery may be a safe and feasible surgical procedure for high-risk patients with synchronous intra-abdominal malignancies.

    DOI: 10.1155/2013/246515

    PubMed

    researchmap

  • Serum Intestinal Fatty Acid Binding Protein in Patients with Small Bowel Obstruction

    Kaoru Sakamoto, Tatsuo Kanda, Takeo Bamba, Hiroyuki Funaoka, Shin-ichi Kosugi, Kazuhito Yajima, Takashi Ishikawa

    Surgical Science   04 ( 06 )   302 - 307   2013年

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Scientific Research Publishing, Inc.  

    DOI: 10.4236/ss.2013.46059

    researchmap

    その他リンク: http://www.scirp.org/journal/doi.aspx?DOI=10.4236/ss.2013.46059

  • WallFlex™ Duodenal Stent Placement in a Gastric Cancer Patient with Malignant Stenosis of a Roux-en-Y Gastrojejunostomy following Distal Gastrectomy. 国際誌

    Tomoyuki Kakuta, Kazuhito Yajima, Seiji Kayama, Yoshihiro Tsuno, Keita Saito, Takashi Ishikawa, Shin-Ichi Kosugi, Tatsuo Kanda

    Case reports in oncology   5 ( 3 )   554 - 60   2012年9月

     詳細を見る

    記述言語:英語  

    A 69-year-old Japanese woman with a history of distal gastrectomy with a Roux-en-Y reconstruction for advanced gastric cancer was admitted to our hospital complaining of severe dysphagia. On admission, the patient was only able to take liquids, and a firm, fist-sized tumor was palpable in her left upper abdomen. An endoscopic examination disclosed stenosis of the jejunal limb of the gastrojejunostomy. Abdominal computed tomography revealed that a recurrent tumor, 5.0 cm in diameter, was compressing the jejunal limb of the gastrojejunostomy. A knitted nitinol self-expandable metallic stent (WallFlex™ duodenal stent) was placed endoscopically at the stenotic jejunum from the gastrojejunostomy. The time required for stenting and total endoscopic manipulation was 12 and 35 minutes, respectively. No stent-related complications were observed. The patient could resume oral ingestion 1 day after endoscopic stenting and was discharged on the fifth day after treatment. She survived for 201 days after stenting. She continued oral ingestion for 194 days and stayed at home for 165 days. The WallFlex duodenal stent allows safe endoscopic stenting, even in cases of malignant stenosis of a gastrojejunostomy following distal gastrectomy. This stenting device will extend the indications for endoscopic palliation of gastric cancer patients with gastric outlet stenosis.

    DOI: 10.1159/000341851

    PubMed

    researchmap

  • Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study.

    Tatsuo Kanda, Kazuhito Yajima, Shin-Ichi Kosugi, Takashi Ishikawa, Yoichi Ajioka, Katsuyoshi Hatakeyama

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   15 ( 3 )   235 - 44   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Current advances in chemotherapy provide opportunities for stage IV gastric cancer patients with distant metastasis to undergo potentially curable resection. There are, however, few data on gastrectomy as a secondary surgery aimed at rendering such patients cancer-free. METHODS: We investigated stage IV gastric cancer patients who underwent surgery with curative intent after S-1-based chemotherapy between 2000 and 2008. Twenty-eight patients from 12 hospitals were enrolled in this study. Factors indicating that the tumors were incurable included clinical stage T4 in 9 patients, para-aortic node metastasis in 15, peritoneal metastasis in 7, and liver metastasis in 4. RESULTS: Of the 28 laparotomy patients, 26 underwent complete resection with no residual tumor, obtaining a complete resection rate of 92.9%. There were no in-hospital deaths or reoperations. In four patients, the primary tumor showed pathological complete response. The 1-, 3-, and 5-year overall survival rates after secondary gastrectomy were 82.1, 45.9, and 34.4%, respectively, with a median survival time of 29 months. Univariate analysis revealed histological tumor length, clinical depth of tumor invasion, number of metastatic nodes, pathological depth of tumor invasion, and pathological response to be the factors influencing patient survival after secondary surgery. On multivariate analysis, histological tumor length (5.0 cm or larger) was the only significant prognostic factor (relative risk 3.23, P = 0.028). CONCLUSIONS: Secondary gastrectomy following S-1-based chemotherapy was a safe and effective treatment for stage IV gastric cancer. Primary tumor size is an indicator for the appropriate selection of patients for this treatment.

    DOI: 10.1007/s10120-011-0100-y

    PubMed

    researchmap

  • Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy. 国際誌

    Tatsuo Kanda, Takashi Ishikawa, Seiichi Hirota, Kazuhito Yajima, Shin-ichi Kosugi, Manabu Ohashi, Satoshi Suzuki, Yasuoki Mashima, Yoichi Ajioka, Katsuyoshi Hatakeyama

    Japanese journal of clinical oncology   42 ( 7 )   578 - 85   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Limited data are available concerning long-term results of imatinib therapy in patients with advanced gastrointestinal stromal tumors. We aimed to clarify the long-term outcomes of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors. METHODS: A prospective, observational study of imatinib therapy for unresectable and metastatic gastrointestinal stromal tumors was conducted in our institution. Imatinib was initiated at a dose of 400 mg daily and continued until disease progression. Safety, efficacy and long-term tolerability and survival were evaluated in an intent-to-treat population. The median follow-up period in this study was 68 months. RESULTS: Seventy patients were enrolled between December 2001 and December 2009. Treatment-related Grade 3/4 adverse events occurred in 49 patients (70.0%). Although 14 patients required adverse effect management with hospitalization, only 5 patients (7.1%) withdrew from the treatment owing to imatinib intolerance. The tumor response and clinical benefit rates were 61.4 and 85.7%, respectively. Thirty-seven patients (52.9%) maintained the treatment at 400 mg daily imatinib, whereas 33 patients (47.1%) had their dose reduced to 300 mg daily or less. The overall survival rate at 5 years was 60.9% and the median survival time was 70 months. The median progression-free survival time of all the 70 enrolled patients was 30 months. Seven patients (10.0%) suffered from second malignancies, including three patients with genitourinary carcinomas. CONCLUSIONS: Despite the need for dose reduction, the long-term results of imatinib therapy for advanced gastrointestinal stromal tumors were good in Japanese patients. Physicians should pay attention to the occurrence of second malignancies during imatinib therapy for gastrointestinal stromal tumor patients.

    DOI: 10.1093/jjco/hys056

    PubMed

    researchmap

  • Clinicopathological characteristics and prognosis of patients with esophageal carcinoma invading adjacent structures found during esophagectomy. 国際誌

    Shin-ichi Kosugi, Hiroshi Ichikawa, Tatsuo Kanda, Kazuhito Yajima, Takashi Ishikawa, Katsuyoshi Hatakeyama

    Journal of surgical oncology   105 ( 8 )   767 - 72   2012年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: A treatment strategy for patients with esophageal carcinoma invading adjacent structures found during esophagectomy (surgical T4; sT4) has not been established and the role of esophagectomy remains controversial. The aims of this study were to assess the clinicopathological characteristics and to clarify the prognostic factors of patients who underwent esophagectomy for sT4 tumors. METHODS: A consecutive series of 76 patients who were found to have sT4 tumors was reviewed retrospectively. T4 tumors were divided into two groups according to the invaded structures. Cox's multivariate proportional hazard model was used to identify prognostic factors. RESULTS: Complete tumor clearance with combined resection was performed in 12 patients (16%). Overall 1-, 3-, and 5-year survival rates were 40.8%, 9.2%, and 7.9%, respectively. There was no significant relationship between survival and invaded structure type or residual tumor status. Postoperative therapy was selected as an independent prognostic factor. CONCLUSIONS: The complete resection rate was low and the prognosis of patients with sT4 tumors was poor. Subclassification according to the invaded structures was not a prognostic factor in this study. Postoperative therapy may improve survival in sT4 patients and should be considered irrespective of residual tumor status after esophagectomy.

    DOI: 10.1002/jso.22092

    PubMed

    researchmap

  • Reexpansion Pulmonary Edema following Laparoscopy-Assisted Distal Gastrectomy for a Patient with Early Gastric Cancer: A Case Report. 国際誌

    Kazuhito Yajima, Tatsuo Kanda, Ryo Tanaka, Yu Sato, Takashi Ishikawa, Shin-Ichi Kosugi, Tadayuki Honda, Katsuyoshi Hatakeyama

    Case reports in surgery   2012   863163 - 863163   2012年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We report here a case of reexpansion pulmonary edema following laparoscopy-assisted distal gastrectomy (LADG) for early gastric cancer. A 57-year-old Japanese woman with no preoperative comorbidity was diagnosed with early gastric cancer. The patient underwent LADG using the pneumoperitoneum method. During surgery, the patient was unintentionally subjected to single-lung ventilation for approximately 247 minutes due to intratracheal tube dislocation. One hour after surgery, she developed severe dyspnea and produced a large amount of pink frothy sputum. Chest radiography results showed diffuse ground-glass attenuation and alveolar consolidation in both lungs without cardiomegaly. A diagnosis of pulmonary edema was made, and the patient was immediately intubated and received ventilatory support with high positive end-expiratory pressure. The patient gradually recovered and was weaned from the ventilatory support on the third postoperative day. This case shows that single-lung ventilation may be a risk factor for reexpansion pulmonary edema during laparoscopic surgery with pneumoperitoneum.

    DOI: 10.1155/2012/863163

    PubMed

    researchmap

  • Risk factors that influence early death due to cancer recurrence after extended radical esophagectomy with three-field lymph node dissection. 国際誌

    Shin-Ichi Kosugi, Tatsuo Kanda, Kazuhito Yajima, Takashi Ishikawa, Katsuyoshi Hatakeyama

    Annals of surgical oncology   18 ( 10 )   2961 - 7   2011年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Extended radical esophagectomy with three-field lymph node dissection (3-FLD) has offered significant survival benefit, but some patients still suffer from early recurrence and die within 1 year after surgery. The purpose of this study was to identify the risk factors that influence early death due to cancer recurrence after extended radical esophagectomy with 3-FLD. METHODS: A consecutive series of 276 patients who underwent extended radical esophagectomy with 3-FLD was retrospectively reviewed. Excluding patients who underwent incomplete resection or died of other diseases within 1 year, we compared the clinicopathological characteristics between 203 patients who survived more than 1 year (1-year survival group) and 27 who died of cancer recurrence within 1 year (early-death group) by univariate and multivariate analysis. RESULTS: Sixty-six patients (32.5%) had recurrent disease in the 1-year survival group. Hematogenous recurrences were more frequent in the early-death group than in the 1-year survival group (41% vs. 26%, respectively, p = 0.0481). There was a significant difference in nodal status, number of metastatic nodes, pathological stage, vessel invasion, and intramural metastasis, and there was borderline significance in the difference of depth of invasion and histological type between the two groups by univariate analysis. Multivariate analysis demonstrated that intramural metastasis was an independent risk factor. CONCLUSIONS: Patients with intramural metastasis have a significant risk of early death even after extended radical esophagectomy with 3-FLD; however, it remains unknown whether surgical intervention can play a significant role for these patients.

    DOI: 10.1245/s10434-011-1712-5

    PubMed

    researchmap

  • Secondary resistance to imatinib mesylate 70 months after initiation of therapy in a patient with a metastatic gastric gastrointestinal stromal tumor.

    Kumiko Tatsuda, Tatsuo Kanda, Takashi Ishikawa, Seiichi Hirota, Ken Nishikura, Kazuhito Yajima, Shin-Ichi Kosugi, Katsuyoshi Hatakeyama

    Clinical journal of gastroenterology   4 ( 4 )   218 - 222   2011年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    It is unknown how long the risk of developing secondary resistance to imatinib persists in patients with gastrointestinal stromal tumors (GISTs). Here we report a case of a patient with a metastatic gastric GIST who developed secondary resistance to imatinib 70 months after initiation of imatinib therapy. A 62-year-old woman with a gastric GIST underwent total gastrectomy with pancreaticosplenectomy. Immunohistochemistry revealed a KIT-positive GIST. The mitotic index of the tumor was 13/50 high-power fields, indicating a high-risk malignancy. After surgery, the patient developed a solitary liver metastasis and underwent right hepatic lobectomy. Four months later, a metastatic tumor was found at the left adrenal gland, and imatinib therapy was initiated in December 2004. Imatinib therapy led to marked tumor shrinkage and complete clinical remission in the patient. However, in October 2010, computed tomography scans revealed a peritoneal metastasis in the ileocecal area. The tumor progression was clinically determined to be due to the development of secondary resistance to imatinib, and the patient's treatment was switched to sunitinib. This case illustrates secondary resistance to imatinib can develop even after a sustained and marked treatment response. Long-term therapy and close monitoring are recommended for the management of patients with metastatic GISTs.

    DOI: 10.1007/s12328-011-0234-9

    PubMed

    researchmap

  • [Treatment strategy for marginally resectable GIST].

    Tatsuo Kanda, Takashi Ishikawa, Toshiro Ozaki, Kazuhito Yajima, Shinichi Kosugi, Katsuyoshi Hatakeyama

    Gan to kagaku ryoho. Cancer & chemotherapy   38 ( 8 )   1266 - 70   2011年8月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Gastrointestinalstromaltumors (GIST)are occasionally found as large abdominal tumors at presentation. However, the best treatment approach for such large and marginally resectable GISTs remains unclear. The survival of patients with clinically malignant GISTs or GISTs with incomplete resection was as short as 1-2 years. Imatinib, a KIT kinase inhibitor, shows promise as a preoperative treatment for marginally resectable GIST, because it exhibits potent antitumor activity for unresectable and metastatic GISTs. Data obtained from imatinib therapy for advanced GISTs indicate that preoperative treatment with 400 mg of imatinib daily for 6-12 months is recommended, although no standard regimen has been established so far. Positron emission tomography is useful for the early assessment of the efficacy of preoperative imatinib treatment, a critical step for the management of patients with marginally resectable GIST. Two case studies have shown the safety and strong antitumor activity of preoperative imatinib treatment and concluded that treatment contributed to reducing surgical morbidity. However, a multicenter phase II trial conducted in the United States has shown that complete resection was not sufficiently achieved in patients who underwent preoperative imatinib treatment: complete resection rates were 77% for primary cases and 58% for metastatic cases, whereas the treatment was not associated with severe postoperative complications. The clinical guidelines for GIST in Japan regard preoperative imatinib treatment for marginally resectable GIST as an experimental treatment. More clinical evidence is required before making preoperative imatinib treatment the standard treatment for marginally resectable GIST.

    PubMed

    researchmap

  • [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].

    Takashi Ishikawa, Tatsuo Kanda, Shinichi Kosugi, Kazuhito Yajima, Katsuyoshi Hatakeyama

    Gan to kagaku ryoho. Cancer & chemotherapy   38 ( 6 )   916 - 21   2011年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Gastrointestinal stromal tumor(GIST)is one ofthe representative diseases for which molecularly targeted therapy is very effective. Imatinib mesylate, a tyrosine kinase inhibitor of KIT and platelet-derived growth factor receptor(PDGFR), has dramatically improved the prognosis ofpatients with advanced, recurrent, and/or metastatic GISTs. Although the rate of response to imatinib therapy is high, the emergence ofimatinib -resistant tumors and the second-line therapy following imatinib therapy have become new clinical problems. Sunitinib malate, a multi-targeted tyrosine kinase inhibitor that shows activity against KIT and other receptor tyrosine kinases, including PDGFR and vascular endothelial growth factor receptor, is the only treatment for imatinib-resistant GISTs that is covered by national health insurance in Japan as ofthis writing. Several clinical trials that evaluated sunitinib as potential second-line therapy in Western countries and Japan found a clinical benefit rate of2 4 to 39% and a median time to progression of7 months. However, it is necessary to adequately manage the adverse events of sunitinib therapy in order to receive the full benefits of the therapy, because various severe adverse events, particularly thrombocytopenia and hand-foot syndrome in Japanese GIST patients, frequently lead to poor tolerability. Further investigation is required to find an appropriate regimen for Japanese GIST patients.

    PubMed

    researchmap

  • Pedunculated gastric tube interposition in an esophageal cancer patient with prepyloric adenocarcinoma. 国際誌

    Tatsuo Kanda, Yu Sato, Kazuhito Yajima, Shin-Ichi Kosugi, Atsushi Matsuki, Takashi Ishikawa, Takeo Bamba, Hajime Umezu, Tsutomu Suzuki, Katsuyoshi Hatakeyama

    World journal of gastrointestinal oncology   3 ( 5 )   75 - 8   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gastric carcinoma is one of the malignancies that are most frequently associated with esophageal carcinoma. We describe herein our device for advanced esophageal cancer associated with early gastric cancer in the antrum. A 57-year-old man presenting with dysphagia and upper abdominal pain was admitted to our hospital. Preoperative examinations revealed locally advanced squamous cell carcinoma (SCC) of the middle thoracic esophagus (T3N0M0 Stage IIA) and mucosal signet-ring cell carcinoma of the gastric antrum (T1N0M0 Stage IA). Although the gastric tumor appeared to be an intramucosal carcinoma, its margin was obscure, so endoscopic en-bloc resection was considered inadequate. We chose surgical resection of the gastric tumor as well as the esophageal SCC after neoadjuvant chemotherapy with 5-fluorouracil and cisplatin for advanced esophageal cancer. Following transthoracic esophagectomy with three-field lymph node dissection, the gastric carcinoma was removed by gastric antrectomy, which preserved the right gastroepiploic vessels, and a pedunculated short gastric tube was used as the esophageal substitute. Twenty-eight months after the surgery, the patient is well with no evidence of cancer recurrence. Because it minimizes surgical stress and organ sacrifice, gastric tube interposition is a potentially useful technique for esophageal cancer associated with localized early gastric cancer.

    DOI: 10.4251/wjgo.v3.i5.75

    PubMed

    researchmap

  • [An update on surgical treatment for gastrointestinal stromal tumor].

    Takashi Ishikawa, Tatsuo Kanda, Shin-Ichi Kosugi, Kazuhito Yajima, Katsuyoshi Hatakeyama

    Gan to kagaku ryoho. Cancer & chemotherapy   38 ( 5 )   722 - 7   2011年5月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Complete surgical resection is the treatment of choice for primary gastrointestinal stromal tumor (GIST), even with current advances in molecular targeting therapy with imatinib and sunitinib. In recent years, function-preserving and minimally invasive surgeries have also been performed as treatment strategies for submucosal tumors, including GISTs that are clinically diagnosed as low-risk. It is crucial, however, not to compromise radicality when indicating these procedures. On the other hand, a multidisciplinary treatment, including surgical resection, is necessary even for the treatment of advanced or metastatic/ recurrent GISTs in which the treatment of choice is imatinib therapy. Furthermore, surgical treatment is expected to be effective for resectable liver metastases, secondary resistance to imatinib, or residual tumors responding to imatinib. In this regard, surgical resection as a multidisciplinary treatment is considered to have gained recognition as an important option. However, sufficient evidence is lacking, and thus, the results of ongoing clinical trials are highly anticipated. For the surgical treatment of GIST, it is important to select patients carefully based on objective data to obtain maximum therapeutic effects.

    PubMed

    researchmap

  • Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis. 国際誌

    Takuya Watanabe, Jun Sakata, Takashi Ishikawa, Yoshio Shirai, Takeyasu Suda, Haruka Hirono, Katsuhiko Hasegawa, Kenji Soga, Koichi Shibasaki, Yukifumi Saito, Hajime Umezu

    World journal of hepatology   1 ( 1 )   103 - 9   2009年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    As a result of having undergone computed tomography (CT), a 75-year-old woman with type-C liver cirrhosiswas shown to have two tumors on the ventral and dorsal sides of subsegment 3 (S3). The tumor on the ventral side was diagnosed as a classic hepatocellular carcinoma (HCC), while that on the dorsal side was considered atypical for a HCC. Although the indocyanine green (ICG) findings indicated poor hepatic reserve, the prothrombin time (PT) was relatively good. An operation was performed in February 2007; however, this resulted in exploratory laparotomy. Dynamic CT performed 12 mo after the operation revealed that the tumor on the dorsal side of S3 had apparently increased. The marginal portion of the tumor was shown to be in the early and parenchymal phases, while the internal portion was found to have grown only slightly in the delayed phase. We diagnosed this tumor as a cholangiocellular carcinoma (CCC). S3 subsegmentectomy was performed in April 2008. The tumor on the ventral side was pathologically diagnosed as a moderately differentiated HCC, and that on the dorsal side was diagnosed as a CCC. We can therefore report a rare case of synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type-C liver cirrhosis. We also add a literature review for all the reported cases published in Japan and around the world, and summarize the features of double cancer exhibiting both HCC and CCC.

    DOI: 10.4254/wjh.v1.i1.103

    PubMed

    researchmap

  • In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice. 国際誌

    Takashi Ishikawa, Norihiro Nakai, Ning-Ning Liu, Kazuhiro Shiba, Koji Isozaki, Ikuo Matsuda, Takashi Ito, Jiro Fujimoto, Katsuyoshi Hatakeyama, Tatsuo Kanda, Seiichi Hirota

    Laboratory investigation; a journal of technical methods and pathology   89 ( 10 )   1161 - 8   2009年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Two families with a germline Asp820Tyr mutation at exon 17 of the c-kit gene and multiple gastrointestinal stromal tumors (GISTs) have been reported. Recently, we generated a knock-in mouse model of the family, and mice with KIT-Asp818Tyr corresponding to human KIT-Asp820Tyr showed a cecal GIST-like tumor. In this report, we examined the in vivo effect of imatinib on tumor progression in knock-in mice. Imatinib of 100 microg/g body weight was administered to heterozygous (KIT-Asp818Tyr/+) mice orally for 7, 14 and 28 days, and cecal tumors were dissected. Both macroscopic size and the measured volume of cecal tumors were not significantly reduced after a 7-, 14- and 28-day administration of imatinib when compared with those before imatinib administration. Cell proliferation was assessed by Ki-67 immunohistochemistry and the labeling index significantly decreased after imatinib administration, but the value of the index after imatinib was only about half compared with that before imatinib. Western blotting and real-time PCR revealed that KIT expression was almost equivalent, but KIT phosphorylation was significantly but not completely inhibited in tumor tissues after 7, 14 and 28 days of imatinib administration when compared with that before imatinib administration. Phosphorylation of Akt and Stat1 was accordingly inhibited after imatinib administration. Thus, imatinib seemed to inhibit in vivo tumor proliferation but not decrease tumor volume on this mouse model, probably because of an insufficient inhibition of phosphorylation of KIT and its downstream signaling molecules. These results suggested that progression of multiple GISTs in patients with germline Asp820Tyr might be partially controlled by imatinib and that model mice provide an opportunity to examine the effect of various other targeted drugs on in vivo tumor progression.

    DOI: 10.1038/labinvest.2009.78

    PubMed

    researchmap

  • Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. 国際誌

    Toshirou Nishida, Tatsuo Kanda, Akiko Nishitani, Tsuyoshi Takahashi, Kiyokazu Nakajima, Takashi Ishikawa, Seiichi Hirota

    Cancer science   99 ( 4 )   799 - 804   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Although imatinib showed high activity for advanced gastrointestinal stromal tumor (GIST) and improved the prognosis of GIST patients, resistance to the drug appears with prolonged use. Mechanisms of acquired resistance are still under investigation. In the present study, we carried out histologic and genetic analysis of 45 secondary resistant lesions obtained from 25 Japanese GIST patients treated with imatinib. All resistant lesions showed viable tumor cells expressing KIT protein, whereas imatinib-sensitive lesions did not. All pre-imatinib samples have KIT mutations either in exon 9 (n = 3) or exon 11 (n = 22), identified in the KIT gene of corresponding resistant tumors. In addition to primary mutations, 33 out of 45 tumors (73%) showed secondary KIT mutations in the kinase domain of the KIT gene. Secondary mutations are missense mutations and are mostly located in the kinase domains of the same allele to the primary mutations (cis-position). Resistant lesions showed monoclonal development of tumor cells. Taken together, additional cis-positioned mutations in the kinase domains are a major cause of secondary resistance to imatinib in Japanese GIST patients.

    DOI: 10.1111/j.1349-7006.2008.00727.x

    PubMed

    researchmap

  • [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].

    Takeo Bamba, Tatsuo Kanda, Manabu Ohashi, Takaaki Hanyu, Kaoru Sakamoto, Takashi Ishikawa, Kazuhito Yajima, Shigeto Makino, Tadashi Tanabe, Shin-ichi Kosugi, Katsuyoshi Hatakeyama

    Gan to kagaku ryoho. Cancer & chemotherapy   32 ( 11 )   1695 - 7   2005年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    We examined safety and efficacy of hypotonic CDDP intraperitoneal administration followed by systemic chemotherapy using MTX/5-FU and UFT. Between 1998 and 2004, seven patients who had histologically proven gastric adenocarcinoma with peritoneal metastases underwent palliative gastrectomy at Niigata University Medical Hospital. For residual peritoneal tumors, 100 mg/body of CDDP diluted with distilled water was intraperitoneally administered to the patients before closure of abdominal wall and was drained 30 to 60 minutes after administration. During the postoperative period, a patient suffered from intraperitoneal abscess and another patient had a renal dysfunction with an increasing level of serum Cr (2.1 mg/dl). As adverse effects of the following systemic chemotherapy, three patients had grade 3 anemia and one had grade 3 leukopenia. The median time to progression was 109 days and the median survival time was 248 days. Although intraperitoneal CDDP administration is safe to be carried out intraoperatively, the effect on survival is not better than new anticancer drugs, such as TS-1 and paclitaxel.

    PubMed

    researchmap

  • An esophageal cancer case unresectable due to tuberculous fibrosing mediastinitis: report of a case

    Tatsuo Kanda, Tsutomu Suzuki, Shin-ichi Kosugi, Masato Nakano, Takashi Ishikawa, Satoru Nakagawa, Katsuyoshi Hatakeyama

    Esophagus   1 ( 3 )   2004年9月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1007/s10388-004-0020-6

    researchmap

    その他リンク: http://link.springer.com/article/10.1007/s10388-004-0020-6/fulltext.html

▶ 全件表示

書籍等出版物

  • 血管新生阻害薬のベストマネジメント : 癌治療と副作用対策

    西田, 俊朗, 大津, 敦, 土井, 俊彦

    金原出版  2011年11月  ( ISBN:9784307101554

     詳細を見る

    総ページ数:xii, 195, iiip   記述言語:日本語

    CiNii Books

    researchmap

MISC

▶ 全件表示

講演・口頭発表等

  • 胃癌手術後の他病死に関する検討

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2020年12月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2020年12月

    記述言語:日本語  

    researchmap

  • [胃]高度進行胃癌に対するConversion surgery Stage IV胃癌に対するConversion surgeryの成績 多施設共同研究

    加納 陽介, 羽入 隆晃, 市川 寛, 石川 卓, 藪崎 裕, 桑原 史郎, 河内 保之, 内藤 哲也, 蛭川 浩史, 若井 俊文

    日本消化器外科学会総会  2020年12月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2020年12月

    記述言語:日本語  

    researchmap

  • Genomically stableサブタイプ胃癌の遺伝子異常と臨床病理学的特徴の検討

    永橋 昌幸, 市川 寛, 島田 能史, 羽入 隆晃, 石川 卓, 滝沢 一泰, 小林 隆, 坂田 純, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2020年12月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2020年12月

    記述言語:日本語  

    researchmap

  • 消化管疾患に対する低侵襲治療の現状と今後の展開-内科、外科の立場から- 当院における腹腔鏡・内視鏡合同手術(LECS)の現状と課題

    加納 陽介, 羽入 隆晃, 佐藤 裕樹, 水野 研一, 市川 寛, 石川 卓, 宗岡 悠介, 茂木 大輔, 須藤 翔, 小柳 英人, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 寺井 崇二, 若井 俊文

    日本消化器病学会甲信越支部例会抄録集  2020年11月  日本消化器病学会-甲信越支部

     詳細を見る

    開催年月日: 2020年11月

    記述言語:日本語  

    researchmap

  • 胃管瘻抜去後の難治性皮膚瘻をOver-The-Scope Clip(OTSC)で閉鎖した食道癌術後患者の一例

    茂木 大輔, 市川 寛, 川田 雄三, 水野 研一, 加納 陽介, 羽入 隆晃, 須藤 翔, 石川 卓, 廣瀬 雄己, 三浦 宏平, 滝沢 一泰, 小柳 英人, 中野 雅人, 永橋 昌幸, 島田 能史, 坂田 純, 小林 隆, 若井 俊文

    日本消化器病学会甲信越支部例会抄録集  2020年11月  日本消化器病学会-甲信越支部

     詳細を見る

    開催年月日: 2020年11月

    記述言語:日本語  

    researchmap

  • 心疾患を有する高リスクの肝細胞癌に対して大動脈バルーンパンピング下に拡大後区域切除術を施行した1例

    長櫓 宏規, 坂田 純, 三浦 宏平, 油座 築, 峠 弘治, 廣瀬 雄己, 石川 博補, 滝沢 一泰, 小林 隆, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 若井 俊文

    日本消化器病学会甲信越支部例会抄録集  2020年11月  日本消化器病学会-甲信越支部

     詳細を見る

    開催年月日: 2020年11月

    記述言語:日本語  

    researchmap

  • 良悪性鑑別困難な胆膵疾患の診断と治療の最前線-内科、外科の立場から- 肝内・肝外胆管癌の診断で外科切除された良性胆管狭窄症例の検討

    廣瀬 雄己, 坂田 純, 滝沢 一泰, 三浦 宏平, 石川 博補, 峠 弘治, 長櫓 宏規, 加納 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 小林 隆, 若井 俊文

    日本消化器病学会甲信越支部例会抄録集  2020年11月  日本消化器病学会-甲信越支部

     詳細を見る

    開催年月日: 2020年11月

    記述言語:日本語  

    researchmap

  • 術後13年目に眼窩転移を来たし急速に進行した再発乳癌の1例

    長谷川 遥, 利川 千絵, 諸 和樹, 土田 純子, 五十嵐 麻由子, 永橋 昌幸, 市川 寛, 羽生 隆晃, 島田 能史, 坂田 純, 石川 卓, 小林 隆, 梅津 哉, 小山 論, 若井 俊文

    日本臨床外科学会雑誌  2020年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2020年10月

    記述言語:日本語  

    researchmap

  • 経過中に肺血栓塞栓症を併発した上腸間膜静脈閉塞症の1例

    大竹 紘子, 滝沢 一泰, 田中 花菜, 峠 弘治, 石川 博補, 三浦 宏平, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 坂田 純, 石川 卓, 小林 隆, 若井 俊文

    日本臨床外科学会雑誌  2020年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2020年10月

    記述言語:日本語  

    researchmap

  • 左閉鎖リンパ節再々発に対し放射線療法を行いcCRが得られたMSI-H直腸癌の1例

    小柳 英人, 島田 能史, 中野 雅人, 荒引 みちる, 松本 瑛生, 田中 花菜, 中野 麻恵, 峠 弘治, 石川 博輔, 須藤 翔, 加納 陽介, 三浦 宏平, 市川 寛, 羽入 隆晃, 滝沢 一泰, 永橋 昌幸, 坂田 純, 石川 卓, 小林 隆, 若井 俊文

    日本大腸肛門病学会雑誌  2020年9月  (一社)日本大腸肛門病学会

     詳細を見る

    開催年月日: 2020年9月

    記述言語:日本語  

    researchmap

  • 非アルコール性脂肪性肝疾患関連肝細胞癌におけるATM発現が肝切除後の予後に与える影響

    廣瀬 雄己, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 堅田 朋大, 峠 弘治, 油座 築, 安藤 拓也, 三浦 要平, 加納 陽介, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • 慢性炎症による癌の増殖・転移を促進する脂質メディエーター分子機構

    永橋 昌幸, 土田 純子, 油座 築, 諸 和樹, 根本 万里子, 廣瀬 雄己, 利川 千絵, 五十嵐 麻由子, 三浦 宏平, 田島 陽介, 市川 寛, 羽入 隆晃, 滝沢 一泰, 中島 真人, 島田 能史, 小林 隆, 坂田 純, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • 上部胃癌に対する噴門側胃切除術の栄養学的意義と再建手技の検討

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 根本 万理子, 酒井 剛, 宗岡 悠介, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 滝沢 一泰, 田島 陽介, 中野 麻恵, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • 食道癌根治切除後血清総ビリルビン値の腫瘍学的予後への影響

    市川 寛, 羽入 隆晃, 加納 陽介, 石川 卓, 根本 万理子, 酒井 剛, 宗岡 悠介, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • トリプルネガティブ乳癌におけるBRCA体細胞変異の同定について

    利川 千絵, 永橋 昌幸, 遠藤 麻巳子, 諸 和樹, 土田 純子, 庭野 稔之, 山浦 久美子, 長谷川 美樹, 五十嵐 麻由子, 中島 真人, 小山 諭, 市川 寛, 羽入 隆晃, 島田 能史, 滝沢 一泰, 小林 隆, 坂田 純, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • Actute care surgeryの現状と未来 外科医が担うACS

    滝沢 一泰, 坂田 純, 油座 築, 三浦 要平, 峠 弘治, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 小林 隆, 加納 陽介, 田島 陽介, 市川 寛, 中野 麻恵, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • 当院におけるリンパ節転移陽性胃癌に対する術前補助化学療法の成績

    加納 陽介, 羽入 隆晃, 市川 寛, 石川 卓, 根本 万理子, 酒井 剛, 宗岡 悠介, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • 食道胃接合部腺癌における術前内視鏡検査による食道浸潤長評価の臨床的意義

    酒井 剛, 市川 寛, 羽入 隆晃, 石川 卓, 加納 陽介, 宗岡 悠介, 臼井 賢司, 根本 万理子, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • 日本人外科医として世界に発信できるトランスレーショナルリサーチ

    永橋 昌幸, 土田 純子, 諸 和樹, 油座 築, 廣瀬 雄己, 三浦 宏平, 田島 陽介, 利川 千絵, 五十嵐 麻由子, 中島 真人, 市川 寛, 羽入 隆晃, 滝沢 一泰, 島田 能史, 小林 隆, 坂田 純, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • ミラノ基準内再発肝細胞癌に対する再肝切除症例の予後因子解析

    三浦 宏平, 三浦 要平, 安藤 拓也, 油座 築, 廣瀬 雄己, 堅田 朋大, 加納 陽介, 田島 陽介, 中野 麻恵, 市川 寛, 羽入 隆晃, 永橋 昌幸, 中野 雅人, 島田 能史, 坂田 純, 石川 卓, 亀山 仁史, 小林 隆, 若井 俊文

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • がんゲノム医療は外科手術を変えるか 固形癌の外科治療戦略におけるゲノム解析の臨床的意義

    若井 俊文, 島田 能史, 永橋 昌幸, 市川 寛, 荒引 みちる, 田中 花菜, 小柳 英人, 中野 麻恵, 油座 築, 廣瀬 雄己, 三浦 宏平, 加納 陽介, 中野 雅人, 滝沢 一泰, 羽入 隆晃, 坂田 純, 石川 卓, 亀山 仁史, 小林 隆

    日本外科学会定期学術集会抄録集  2020年8月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2020年8月

    記述言語:日本語  

    researchmap

  • 当科における進行胃癌に対する術前補助化学療法の検討(Analyses of neoadjuvant chemotherapy for advanced gastric cancer)

    羽入 隆晃, 市川 寛, 加納 陽介, 石川 卓, 根本 万理子, 酒井 剛, 宗岡 悠介, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2020年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2020年3月

    記述言語:英語  

    researchmap

  • Siewert type II/III食道胃接合部腺癌における遺伝子異常の違い(Genetic differences between Siewert type II and III adenocarcinoma of the esophagogastric junction)

    市川 寛, 羽入 隆晃, 加納 陽介, 石川 卓, 根本 万理子, 酒井 剛, 茂木 大輔, 中川 悟, 藪崎 裕, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2020年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2020年3月

    記述言語:英語  

    researchmap

  • 高齢者胃癌に対する治療戦略 高齢者胃癌の治療成績の時代的変化(Treatment strategy for elderly gastric cancer patients Trends in surgical and survival outcomes of elderly patients in gastric cancer)

    加納 陽介, 羽入 隆晃, 市川 寛, 石川 卓, 根本 万理子, 酒井 剛, 宗岡 悠介, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2020年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2020年3月

    記述言語:英語  

    researchmap

  • 当科における腹腔鏡下幽門側胃切除Billroth I法delta吻合を安全に行うための工夫

    加納 陽介, 市川 寛, 羽入 隆晃, 石川 卓, 酒井 剛, 永橋 昌幸, 島田 能史, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本内視鏡外科学会雑誌  2019年12月  (一社)日本内視鏡外科学会

     詳細を見る

    開催年月日: 2019年12月

    記述言語:日本語  

    researchmap

  • 胃癌周術期合併症が予後に与える影響

    羽入 隆晃, 市川 寛, 石川 卓, 加納 陽介, 小杉 伸一, 酒井 剛, 根本 万理子, 臼井 賢司, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 中野 麻恵, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌  2019年11月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2019年11月

    記述言語:日本語  

    researchmap

  • 高齢者術後再発膵癌に対するGemcitabine+nab-Paclitaxel併用療法の検討

    滝沢 一泰, 坂田 純, 安藤 拓也, 油座 築, 峠 弘治, 廣瀬 雄己, 齋藤 敬太, 堅田 朋大, 三浦 宏平, 小林 隆, 諸 和樹, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌  2019年11月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2019年11月

    記述言語:日本語  

    researchmap

  • 肝外胆管切除を伴う肝切除症例における予後予測因子の検討

    安藤 拓也, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 堅田 朋大, 廣瀬 雄己, 峠 弘治, 油座 築, 諸 和樹, 加納 陽介, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌  2019年11月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2019年11月

    記述言語:日本語  

    researchmap

  • 日本人ゲノム安定型胃癌の特徴

    酒井 剛, 市川 寛, 永橋 昌幸, 羽入 隆晃, 石川 卓, 臼井 賢司, 根本 万理子, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 田島 陽介, 滝沢 一泰, 中野 雅人, 島田 能史, 坂田 純, 小林 隆, 藪崎 裕, 中川 悟, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌  2019年11月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2019年11月

    記述言語:日本語  

    researchmap

  • 上部消化管癌における腫瘍局在とエビデンスレベルに基づく遺伝子異常

    市川 寛, 島田 能史, 永橋 昌幸, 羽入 隆晃, 加納 陽介, 宗岡 悠介, 石川 卓, 廣瀬 雄己, 三浦 宏平, 坂田 純, 小林 隆, 中川 悟, 藪崎 裕, 亀山 仁史, 若井 俊文

    日本癌治療学会学術集会抄録集  2019年10月  (一社)日本癌治療学会

     詳細を見る

    開催年月日: 2019年10月

    記述言語:英語  

    researchmap

  • 胆嚢摘出術時の胆管損傷に対する胆道再建術後の晩期合併症として多発肝内結石を生じた1例

    小幡 泰生, 廣瀬 雄己, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 堅田 朋大, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2019年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2019年10月

    記述言語:日本語  

    researchmap

  • 下大静脈血栓症および肺血栓塞栓症を伴う巨大肝嚢胞の1切除例

    齋藤 征爾, 堅田 朋大, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 廣瀬 雄己, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2019年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2019年10月

    記述言語:日本語  

    researchmap

  • 内腔突出型頸部食道平滑筋腫の一切除例

    大岩 智, 市川 寛, 加納 陽介, 羽入 隆晃, 石川 卓, 酒井 剛, 永橋 昌幸, 島田 能史, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2019年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2019年10月

    記述言語:日本語  

    researchmap

  • ケイキサレートの関与が疑われた大腸狭窄の1例

    阿部 馨, 亀山 仁史, 山田 沙季, 田中 花奈, 小柳 英人, 堀田 真之介, 田島 陽介, 中野 麻恵, 中野 雅人, 島田 能史, 廣瀬 雄己, 三浦 宏平, 市川 寛, 羽入 隆晃, 滝沢 一泰, 永橋 昌幸, 石川 卓, 坂田 純, 小林 隆, 若井 俊文

    日本大腸肛門病学会雑誌  2019年9月  (一社)日本大腸肛門病学会

     詳細を見る

    開催年月日: 2019年9月

    記述言語:日本語  

    researchmap

  • 消化器外科領域に応用可能な分子レベルの技術開発 次世代シークエンサーを用いた遺伝子検査とゲノム解析データベース構築(Molecular Technology Development for Gastroenterological Diseases Next-generation sequencing-based gene test and construction of a genomic analysis database)

    永橋 昌幸, 若井 俊文, 島田 能史, 市川 寛, 羽入 隆晃, 滝沢 一泰, 石川 卓, 坂田 純, 小林 隆, 亀山 仁史, 竹内 志穂, 奥田 修二郎

    日本癌学会総会記事  2019年9月  (一社)日本癌学会

     詳細を見る

    開催年月日: 2019年9月

    記述言語:英語  

    researchmap

  • 早期胃癌根治術後患者における骨格筋量及び体重の長期的経時変化

    臼井 賢司, 市川 寛, 羽入 隆晃, 石川 卓, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2019年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2019年7月

    記述言語:日本語  

    researchmap

  • 消化器外科領域における術前フレイル・QOL評価の重要性

    亀山 仁史, 島田 能史, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 石川 卓, 坂田 純, 小林 隆, 若井 俊文

    日本消化器外科学会総会  2019年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2019年7月

    記述言語:日本語  

    researchmap

  • 腫瘍随伴症候群を伴って発見された胃癌症例の検討

    羽入 隆晃, 市川 寛, 石川 卓, 臼井 賢司, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2019年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2019年7月

    記述言語:日本語  

    researchmap

  • 食道癌ゲノム解析による術前化学療法最適化の可能性

    市川 寛, 番場 竹生, 中川 悟, 羽入 隆晃, 石川 卓, 加納 陽介, 宗岡 悠介, 酒井 剛, 亀山 仁史, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2019年6月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2019年6月

    記述言語:日本語  

    researchmap

  • 食道癌術後の逆流性食道炎に対してvonoprazanが有効であった3症例

    茂木 大輔, 市川 寛, 羽入 隆晃, 石川 卓, 臼井 賢司, 根本 万理子, 酒井 剛, 亀山 仁史, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2019年6月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2019年6月

    記述言語:日本語  

    researchmap

  • 直腸癌術後腸閉塞による嘔吐を契機に特発性食道破裂を発症した1例

    酒井 剛, 市川 寛, 山井 大介, 茂木 大輔, 根本 万理子, 臼井 賢司, 羽入 隆晃, 石川 卓, 亀山 仁史, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2019年6月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2019年6月

    記述言語:日本語  

    researchmap

  • 大腸癌診療におけるprecision medicine 大腸癌における次世代シークエンサーを使用した遺伝子パネルの臨床応用の可能性

    島田 能史, 永橋 昌幸, 市川 寛, 阿部 馨, 油座 築, 田中 花菜, 小柳 英人, 廣瀬 雄己, 田島 陽介, 中野 雅人, 羽入 隆晃, 坂田 純, 小林 隆, 亀山 仁史, 野上 仁, 丸山 聡, 瀧井 康公, 石川 卓, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 膵癌に対するUICC TNM病期分類第8版の検証

    安藤 拓也, 滝沢 一泰, 油座 築, 峠 弘治, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 坂田 純, 小林 隆, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 石川 卓, 永橋 昌幸, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 外科医の特性を活かしたトランスレーショナル研究の試み

    諸 和樹, 永橋 昌幸, 遠藤 麻巳子, 土田 純子, 庭野 稔之, 山浦 久美子, 利川 千絵, 長谷川 美樹, 五十嵐 麻由子, 廣瀬 雄己, 市川 寛, 羽入 隆晃, 島田 能史, 小林 隆, 坂田 純, 石川 卓, 亀山 仁史, 川口 耕, 小山 諭, 高部 和明, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 外科侵襲と予後 消化器外科入院患者における自宅退院を困難とする因子の検討

    亀山 仁史, 田中 花菜, 島田 能史, 阿部 馨, 油座 築, 小柳 英人, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 田島 陽介, 中野 麻恵, 市川 寛, 羽入 隆晃, 滝沢 一泰, 中野 雅人, 永橋 昌幸, 石川 卓, 坂田 純, 小林 隆, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 乳癌ゲノム医療の推進に向けた取り組み 当科における乳癌ゲノム医療の推進に向けた取り組み

    永橋 昌幸, 土田 純子, 遠藤 麻巳子, 諸 和樹, 庭野 稔之, 山浦 久美子, 利川 千絵, 長谷川 美樹, 五十嵐 麻由子, 中島 真人, 小山 諭, 神林 智寿子, 金子 耕司, 佐藤 信昭, 市川 寛, 島田 能史, 小林 隆, 坂田 純, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 胆道癌において脂質メディエーターS1Pの産生は亢進しリンパ行性進展に寄与する TCGAデータと自施設データ解析による検討

    廣瀬 雄己, 永橋 昌幸, 坂田 純, 小林 隆, 滝沢 一泰, 三浦 宏平, 堅田 朋大, 峠 弘治, 油座 築, 安藤 拓也, 土田 純子, 諸 和樹, 田島 陽介, 中野 雅人, 市川 寛, 羽入 隆晃, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 遠位胆管癌におけるAJCC第8版のT分類(depth of invasion)の検証

    峠 弘治, 坂田 純, 油座 築, 安藤 拓也, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 滝沢 一泰, 小林 隆, 土田 純子, 諸 和樹, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 食道癌術後の内頸静脈血栓症発症の危険因子に関する検討

    根本 万理子, 市川 寛, 小杉 伸一, 石川 卓, 羽入 隆晃, 臼井 賢司, 酒井 剛, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 田島 陽介, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 生体肝移植後de novo悪性腫瘍発症例の検討

    三浦 宏平, 小林 隆, 安藤 拓也, 油座 築, 土田 純子, 諸 和樹, 峠 弘治, 廣瀬 雄己, 堅田 朋大, 田島 陽介, 市川 寛, 滝沢 一泰, 羽入 隆晃, 中野 雅人, 永橋 昌幸, 島田 能史, 坂田 純, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 食道胃接合部腺癌における術前内視鏡検査による食道浸潤長評価の精度

    酒井 剛, 市川 寛, 羽入 隆晃, 石川 卓, 臼井 賢司, 根本 万理子, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 田島 陽介, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 乳腺外科医を目指す若手女性外科医にとってのロールモデルとキャリア形成

    土田 純子, 遠藤 麻巳子, 諸 和樹, 庭野 稔之, 山浦 久美子, 利川 千絵, 長谷川 美樹, 五十嵐 麻由子, 永橋 昌幸, 中島 真人, 小山 諭, 市川 寛, 羽入 隆晃, 島田 能史, 小林 隆, 坂田 純, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 当科における高齢者胃癌手術症例の検討

    羽入 隆晃, 市川 寛, 石川 卓, 酒井 剛, 根本 万理子, 臼井 賢司, 安藤 拓也, 油座 築, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 田島 陽介, 滝沢 一泰, 中野 雅人, 永橋 昌幸, 島田 能史, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 直腸間膜全割標本を用いた直腸癌の肛門側癌進展の臨床的意義

    小柳 英人, 島田 能史, 阿部 馨, 田中 花菜, 田島 陽介, 中野 雅人, 亀山 仁史, 廣瀬 雄己, 三浦 宏平, 市川 寛, 羽入 隆晃, 滝沢 一泰, 永橋 昌幸, 坂田 純, 小林 隆, 野上 仁, 丸山 聡, 瀧井 康公, 石川 卓, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 胆嚢癌におけるAJCC第8版のN分類の妥当性の検証

    油座 築, 坂田 純, 安藤 拓也, 峠 弘治, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 滝沢 一泰, 小林 隆, 土田 純子, 諸 和樹, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 島田 能史, 永橋 昌幸, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • Stage III大腸癌における大腸癌取扱い規約第9版の検証 第8版との比較から

    中野 雅人, 島田 能史, 田中 花菜, 小柳 英人, 田島 陽介, 中野 麻恵, 亀山 仁史, 廣瀬 雄己, 三浦 宏平, 市川 寛, 羽入 隆晃, 滝沢 一泰, 永橋 昌幸, 坂田 純, 小林 隆, 野上 仁, 丸山 聡, 瀧井 康公, 石川 卓, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 乳頭部癌における根治切除後再発 再発率、再発形式、危険因子、再発治療

    堅田 朋大, 坂田 純, 安藤 拓也, 油座 築, 峠 弘治, 廣瀬 雄己, 三浦 宏平, 滝沢 一泰, 小林 隆, 土田 純子, 諸 和樹, 田島 陽介, 市川 寛, 羽入 隆晃, 中野 雅人, 永橋 昌史, 島田 能史, 石川 卓, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • Stage IV大腸癌におけるRASおよびBRAF遺伝子変異同時検索の臨床的意義

    阿部 馨, 島田 能史, 永橋 昌幸, 市川 寛, 田中 花菜, 小柳 英人, 田島 陽介, 中野 雅人, 亀山 仁史, 野上 仁, 丸山 聡, 瀧井 康公, 油座 築, 廣瀬 雄己, 羽入 隆晃, 滝沢 一泰, 石川 卓, 坂田 純, 小林 隆, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 食道胃接合部腺癌における肉眼的近位切離断端距離の臨床的意義

    市川 寛, 羽入 隆晃, 石川 卓, 臼井 賢司, 根本 万理子, 酒井 剛, 廣瀬 雄己, 堅田 朋大, 三浦 宏平, 田島 陽介, 滝沢 一泰, 中野 雅人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2019年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2019年4月

    記述言語:日本語  

    researchmap

  • 当科における残胃癌切除症例の検討

    羽入 隆晃, 市川 寛, 石川 卓, 臼井 賢司, 根本 万理子, 酒井 剛, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2019年2月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2019年2月

    記述言語:日本語  

    researchmap

  • 巨大食道胃接合部癌における治療戦略

    羽入 隆晃, 市川 寛, 石川 卓, 須藤 翔, 大渓 隆弘, 根本 万理子, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会雑誌  2018年11月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2018年11月

    記述言語:日本語  

    researchmap

  • 胃癌における相同組換え修復機構の破綻と予後

    市川 寛, 羽入 隆晃, 石川 卓, 加納 陽介, 宗岡 悠介, 堅田 朋大, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 中川 悟, 若井 俊文

    日本消化器外科学会雑誌  2018年11月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2018年11月

    記述言語:日本語  

    researchmap

  • 魚骨による消化管穿孔の3例

    山井 大介, 市川 寛, 根本 万理子, 臼井 賢司, 酒井 剛, 羽入 隆晃, 石川 卓, 三浦 宏平, 滝沢 一泰, 永橋 昌幸, 島田 能史, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2018年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2018年10月

    記述言語:日本語  

    researchmap

  • 多発外傷に対する集学的治療後に生じた腸管気腫症が保存的に軽快した1例

    酒井 剛, 羽入 隆晃, 市川 寛, 石川 卓, 根本 万理子, 臼井 賢司, 三浦 宏平, 滝沢 一泰, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2018年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2018年10月

    記述言語:日本語  

    researchmap

  • 食道扁平上皮癌術前化学療法施行例におけるAJCC第8版ypTNM Stageの臨床的意義

    須藤 翔, 市川 寛, 小杉 伸一, 羽入 隆晃, 石川 卓, 番場 竹生, 中川 悟, 藪崎 裕, 坂田 純, 若井 俊文

    日本消化器外科学会総会  2018年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2018年7月

    記述言語:日本語  

    researchmap

  • 食道癌術後乳び胸発症例の臨床病理学的特徴

    大渓 隆弘, 市川 寛, 小杉 伸一, 須藤 翔, 羽入 隆晃, 石川 卓, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2018年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2018年7月

    記述言語:日本語  

    researchmap

  • 胃癌術後縫合不全例における術前栄養状態の評価と発症予測因子についての検討

    角田 知行, 石川 卓, 佐藤 敦, 根本 万理子, 宗岡 悠介, 須藤 翔, 加納 陽介, 三浦 宏平, 田島 陽介, 市川 寛, 羽入 隆晃, 滝沢 一泰, 中野 雅人, 中島 真人, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • 肝細胞癌患者における脂質メディエーター・スフィンゴシン-1-リン酸及びセラミドの定量とその意義

    永橋 昌幸, 廣瀬 雄己, 三浦 宏平, 油座 築, 相馬 大輝, 安藤 拓也, 峠 弘治, 石川 博輔, 堅田 朋大, 坂田 純, 小林 隆, 中島 真人, 羽入 隆晃, 市川 寛, 石川 卓, 島田 能史, 亀山 仁史, 高部 和明, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • 経口摂取困難な食道癌に対する術前化学療法の意義

    根本 万理子, 市川 寛, 小杉 伸一, 石川 卓, 羽入 隆晃, 角田 知行, 佐藤 優, 須藤 翔, 臼井 賢司, 加納 陽介, 宗岡 悠介, 大渓 隆弘, 酒井 剛, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • 消化器手術患者における周術期リハビリテーション介入と地域包括ケアシステム構築に向けた取り組み

    亀山 仁史, 島田 能史, 坂田 純, 須藤 翔, 三浦 宏平, 田島 陽介, 中野 麻恵, 角田 知行, 市川 寛, 羽入 隆晃, 滝沢 一泰, 中野 雅人, 永橋 昌幸, 中島 真人, 石川 卓, 小林 隆, 小杉 伸一, 木村 慎二, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • 食道扁平上皮癌リンパ行性進展におけるphospho-sphingosine kinase 1発現の意義

    市川 寛, 根本 万理子, 永橋 昌幸, 中島 真人, 廣瀬 雄己, 油座 築, 田島 陽介, 石川 卓, 羽入 隆晃, 角田 知行, 加納 陽介, 須藤 翔, 臼井 賢司, 宗岡 悠介, 三浦 宏平, 島田 能史, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • 食道癌術後肺炎に対する早期気管吸引痰培養の有用性

    須藤 翔, 市川 寛, 石川 卓, 根本 万理子, 宗岡 悠介, 加納 陽介, 三浦 宏平, 角田 知行, 羽入 隆晃, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • 食道癌術後患者における健康関連QOLの長期的な推移

    大渓 隆弘, 市川 寛, 羽入 隆晃, 石川 卓, 角田 知行, 佐藤 優, 加納 陽介, 臼井 賢司, 宗岡 悠介, 酒井 剛, 根本 万理子, 須藤 翔, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • リン酸化スフィンゴシンキナーゼ1の発現と胃癌の進行についての関連

    羽入 隆晃, 永橋 昌幸, 市川 寛, 石川 卓, 小杉 伸一, 角田 知行, 須藤 翔, 根本 万理子, 加納 陽介, 宗岡 悠介, 中島 真人, 田島 陽介, 三浦 宏平, 廣瀬 雄己, 油座 築, 島田 能史, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • StageIV大腸癌における原発巣の治療戦略 Stage IV大腸癌における原発巣の局在のバイオマーカーとしての有用性

    島田 能史, 田島 陽介, 永橋 昌幸, 市川 寛, 八木 亮磨, 中野 雅人, 亀山 仁史, 石川 卓, 坂田 純, 小林 隆, 瀧井 康公, 小杉 伸一, 若井 俊文

    日本外科学会定期学術集会抄録集  2018年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2018年4月

    記述言語:日本語  

    researchmap

  • 当科における胃癌根治切除後S-1補助化学療法症例の検討

    羽入 隆晃, 市川 寛, 石川 卓, 須藤 翔, 加納 陽介, 宗岡 悠介, 根本 万理子, 永橋 昌幸, 島田 能史, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本胃癌学会総会記事  2018年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2018年3月

    記述言語:日本語  

    researchmap

  • 胃癌術後縫合不全例における長期化・重症化因子についての検討

    角田 知行, 石川 卓, 根本 万理子, 宗岡 悠介, 加納 陽介, 須藤 翔, 市川 寛, 羽入 隆晃, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本胃癌学会総会記事  2018年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2018年3月

    記述言語:日本語  

    researchmap

  • HER2陽性胃癌におけるゲノム解析の有用性についての検討(Genomic sequencing as a clinical application for detecting HER2 alterations in gastric cancer)

    宗岡 悠介, 市川 寛, 島田 能史, 根本 万理子, 須藤 翔, 羽入 隆晃, 石川 卓, 永橋 昌幸, 坂田 純, 小林 隆, 會澤 雅樹, 松木 淳, 中川 悟, 藪崎 裕, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2018年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2018年3月

    記述言語:英語  

    researchmap

  • 特発性食道破裂8例の臨床的検討

    須藤 翔, 市川 寛, 根本 万理子, 大渓 隆弘, 羽入 隆晃, 石川 卓, 亀山 仁史, 若井 俊文

    日本腹部救急医学会雑誌  2018年2月  (一社)日本腹部救急医学会

     詳細を見る

    開催年月日: 2018年2月

    記述言語:日本語  

    researchmap

  • 酸・アルカリ性洗剤の同時飲用により胃穿孔をきたした1例

    根本 万理子, 羽入 隆晃, 宗岡 悠介, 須藤 翔, 田島 陽介, 角田 知行, 市川 寛, 中野 雅人, 島田 能史, 石川 卓, 小林 隆, 永橋 昌幸, 坂田 純, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2017年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2017年10月

    記述言語:日本語  

    researchmap

  • 異時性多発大腸癌および十二指腸癌に対して計5回の切除手術を施行したLynch症候群の1例

    堀田 真之介, 島田 能史, 山田 沙季, 田中 花菜, 田島 陽介, 中野 麻恵, 中野 雅人, 亀山 仁史, 市川 寛, 羽入 隆晃, 永橋 昌幸, 坂田 純, 小林 隆, 石川 卓, 若井 俊文

    日本臨床外科学会雑誌  2017年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2017年10月

    記述言語:日本語  

    researchmap

  • 併存症を有す胃癌患者に対する胃切除後の手術成績と予後についての検討

    羽入 隆晃, 市川 寛, 石川 卓, 宗岡 悠介, 大渓 隆弘, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2017年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2017年7月

    記述言語:日本語  

    researchmap

  • 食道癌手術症例における腸瘻造設に関連した合併症に関する検討

    宗岡 悠介, 市川 寛, 羽入 隆晃, 大渓 隆弘, 石川 卓, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2017年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2017年7月

    記述言語:日本語  

    researchmap

  • 当院における食道胃管三角吻合の導入と成績

    市川 寛, 羽入 隆晃, 石川 卓, 小杉 伸一, 宗岡 悠介, 大渓 隆弘, 臼井 賢司, 根本 万理子, 亀山 仁史, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2017年6月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2017年6月

    記述言語:日本語  

    researchmap

  • 当科における残胃癌切除症例の検討

    羽入 隆晃, 石川 卓, 市川 寛, 小杉 伸一, 宗岡 悠介, 大渓 隆弘, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2017年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2017年4月

    記述言語:日本語  

    researchmap

  • 次世代シーケンサーを基盤とした癌遺伝子解析パネルを用いたHER2陽性胃癌に併存する遺伝子異常の解明

    市川 寛, 永橋 昌幸, 羽入 隆晃, 石川 卓, 宗岡 悠介, 大渓 隆弘, 島田 能史, 坂田 純, 亀山 仁史, 小林 隆, 會澤 雅樹, 松木 淳, 藪崎 裕, 中川 悟, 本間 慶一, 川崎 隆, 井筒 浩, 兒玉 啓輔, 中田 光隆, 若井 俊文

    日本外科学会定期学術集会抄録集  2017年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2017年4月

    記述言語:日本語  

    researchmap

  • 初発消化管間質腫瘍手術症例の遺伝子変異

    石川 卓, 廣田 誠一, 神田 達夫, 羽入 隆晃, 市川 寛, 角田 知行, 佐藤 優, 加納 陽介, 須藤 翔, 臼井 賢司, 宗岡 悠介, 大渓 隆弘, 永橋 昌幸, 島田 能史, 坂田 純, 亀山 仁史, 小林 隆, 若井 俊文

    日本外科学会定期学術集会抄録集  2017年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2017年4月

    記述言語:日本語  

    researchmap

  • 胃癌におけるマイクロサテライト不安定性とアクチビン受容体遺伝子変異の検討

    油座 築, 永橋 昌幸, 市川 寛, 羽入 隆晃, 石川 卓, 中島 真人, 島田 能史, 坂田 純, 亀山 仁史, 小林 隆, 中川 悟, 井筒 浩, 兒玉 啓輔, 高部 和明, 若井 俊文

    日本外科学会定期学術集会抄録集  2017年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2017年4月

    記述言語:日本語  

    researchmap

  • 膵癌切除例におけるMacrophage migration inhibitory factorの発現と治療成績

    高野 可赴, 滝沢 一泰, 坂田 純, 安藤 拓也, 油座 築, 峠 弘治, 石川 博補, 三浦 宏平, 大橋 拓, 市川 寛, 羽入 隆晃, 永橋 昌幸, 石川 卓, 亀山 仁史, 小林 隆, 若井 俊文

    日本外科学会定期学術集会抄録集  2017年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2017年4月

    記述言語:日本語  

    researchmap

  • 食道癌術後の呼吸機能の推移

    大渓 隆弘, 羽入 隆晃, 市川 寛, 宗岡 悠介, 永橋 昌幸, 石川 卓, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本外科学会定期学術集会抄録集  2017年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2017年4月

    記述言語:日本語  

    researchmap

  • StageII/III胃癌の根治切除後再発予後予測因子の探索(Prognostic factors for stage II/III gastric cancer patients who underwent curative gastrectomy)

    宗岡 悠介, 石川 卓, 市川 寛, 羽入 隆晃, 梨本 篤, 藪崎 裕, 田中 典生, 赤澤 宏平, 若井 俊文

    日本胃癌学会総会記事  2017年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2017年3月

    記述言語:英語  

    researchmap

  • 無治療で経過観察を行った消化管間質腫瘍の3例(Gastrointestinal stromal tumor observed without treatment: a report of three cases)

    石川 卓, 羽入 隆晃, 市川 寛, 大渓 隆弘, 宗岡 悠介, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2017年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2017年3月

    記述言語:英語  

    researchmap

  • 胃癌の浸潤能とリン酸化スフィンゴシンキナーゼ1の関連性について(Expression of phosphorylated sphingosine kinase 1 is associated with invasiveness of gastric cancer)

    羽入 隆晃, 永橋 昌幸, 市川 寛, 石川 卓, 小杉 伸一, 中島 真人, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2017年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2017年3月

    記述言語:英語  

    researchmap

  • 当院における食道癌術後再建胃管癌症例の検討(Gastric Tube Cancer After Curative Esophagectomy for Esophageal Cancer)

    大渓 隆弘, 市川 寛, 小杉 伸一, 橋本 哲, 宗岡 悠介, 羽入 隆晃, 石川 卓, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2017年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2017年3月

    記述言語:英語  

    researchmap

  • 食道癌術後早期の経腸栄養に際し低脂質栄養剤は乳び胸の予防に有用か?

    小山 諭, 小杉 伸一, 石川 卓, 市川 寛, 羽生 隆晃, 宗岡 悠介, 諸 和樹, 遠藤 麻巳子, 土田 純子, 辰田 久美子, 五十嵐 麻由子, 中島 真人, 永橋 昌幸, 庭野 稔之, 利川 千絵, 三浦 宏平, 坂田 純, 亀山 仁史, 小林 隆, 若井 俊文

    日本創傷治癒学会プログラム・抄録集  2016年12月  (一社)日本創傷治癒学会

     詳細を見る

    開催年月日: 2016年12月

    記述言語:日本語  

    researchmap

  • 若手外科医による腹腔鏡下大腸切除術の安全性の検討

    中野 雅人, 亀山 仁史, 大渓 隆弘, 宗岡 悠介, 田島 陽介, 市川 寛, 岡村 拓磨, 中野 麻恵, 滝沢 一泰, 羽入 隆晃, 石川 卓, 島田 能史, 坂田 純, 小林 隆, 若井 俊文

    日本内視鏡外科学会雑誌  2016年12月  (一社)日本内視鏡外科学会

     詳細を見る

    開催年月日: 2016年12月

    記述言語:日本語  

    researchmap

  • 当科における腹腔鏡下幽門側胃切除の検討と定型化の取り組み

    羽入 隆晃, 市川 寛, 石川 卓, 宗岡 悠介, 大渓 隆弘, 田島 陽介, 岡村 拓磨, 中野 雅人, 滝沢 一泰, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本内視鏡外科学会雑誌  2016年12月  (一社)日本内視鏡外科学会

     詳細を見る

    開催年月日: 2016年12月

    記述言語:日本語  

    researchmap

  • 術前分割DCS療法の治療効果に相違を認めた同時性多発胃癌の1例

    酒井 剛, 市川 寛, 石川 卓, 小杉 伸一, 羽入 隆晃, 臼井 賢司, 宗岡 悠介, 大渓 隆弘, 日紫喜 万理子, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    癌と化学療法  2016年11月  (株)癌と化学療法社

     詳細を見る

    開催年月日: 2016年11月

    記述言語:日本語  

    症例は63歳、男性。上腹部痛を主訴に近医を受診した。精査にて、胃体上部小彎に2型腫瘍(低分化型腺癌充実型)、胃体下部前壁に0-IIc型腫瘍(高分化型管状腺癌)を認め、胃小彎側と大彎側に合計4個のリンパ節腫大を認めた。同時性多発胃癌、MU、cT4aN2M0、cStage IIIBおよびL、Ant、cT1aの診断で、術前分割docetaxel/CDDP/S-1療法を2コース施行後、胃全摘術、D2(-No.10)リンパ節郭清を施行した。進行胃癌の病変および転移の痕跡のあるNo.4dリンパ節に腫瘍の遺残は認められず、組織学的治療効果はGrade 3と判定された。一方、早期胃癌の病変に治療効果は認められず、Grade 0と判定された。術後10ヵ月現在、無再発生存中である。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J00296&link_issn=&doc_id=20161222480318&doc_link_id=%2Fab8gtkrc%2F2016%2F004312%2F318%2F2377-2379%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2016%2F004312%2F318%2F2377-2379%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 胃癌の腫瘍出血に対する緩和的放射線治療後に再出血を来し胃切除を要した1例

    宗岡 悠介, 市川 寛, 石川 卓, 羽入 隆晃, 佐藤 優, 加納 陽介, 臼井 賢司, 大渓 隆弘, 日紫喜 万理子, 三浦 宏平, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    癌と化学療法  2016年11月  (株)癌と化学療法社

     詳細を見る

    開催年月日: 2016年11月

    記述言語:日本語  

    近年、胃癌の腫瘍出血に対する緩和的放射線治療の報告が散見される。今回われわれは、胃癌出血に対する緩和的放射線治療後に再出血を来し、胃切除術を要した症例を経験した。症例は74歳、男性。Stage IV胃癌に対し化学療法を施行し、stable diseaseを維持していた。しかし、化学療法開始から23ヵ月後に腫瘍の再増大と出血を認め、止血目的の緩和的放射線治療を施行した。いったん止血が得られたが、1ヵ月半後に再出血を来した。入院後に出血性ショックを来し、緊急で姑息的胃切除術を施行した。腫瘍出血に対する緩和的放射線治療は安全かつ有効な治療として選択されることが多い。しかし、再出血を来した際には緊急での胃切除術が避けられないことがある。本症例では迅速な手術治療により救命が得られた。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J00296&link_issn=&doc_id=20161222480172&doc_link_id=%2Fab8gtkrc%2F2016%2F004312%2F172%2F1936-1938%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2016%2F004312%2F172%2F1936-1938%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 門脈体循環シャントに対する経皮的コイル塞栓術が著効し化学療法を継続し得た胃癌の1例

    臼井 賢司, 羽入 隆晃, 市川 寛, 石川 卓, 宗岡 悠介, 佐藤 優, 加納 陽介, 大渓 隆弘, 日紫喜 万理子, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    癌と化学療法  2016年11月  (株)癌と化学療法社

     詳細を見る

    開催年月日: 2016年11月

    記述言語:日本語  

    胃癌肝転移による門脈腫瘍栓により、門脈体循環シャント(portosystemic shunt:PSS)・門脈体循環性脳症(Portal systemic encephalopathy:PSE)を来したまれな1例を経験した。症例は57歳、男性。多発肝転移を伴うStage IV胃癌に対し、出血制御目的に幽門側胃切除術を行った。術後S-1+cisplatin療法を導入したが、7コース施行後に肝S7の新規病変と門脈腫瘍栓が出現した。weekly paclitaxel療法に変更して化学療法を継続した。術後1年1ヵ月ごろより意識障害が出現し、術後1年3ヵ月には血中アンモニア濃度296μg/dLと高アンモニア血症を呈した。腹部CT検査で下腸間膜静脈-左腎静脈シャントを認め、PSSによるPSEの診断に至った。経皮的コイル塞栓術で短絡路の遮断を行い、脳症・高アンモニア血症は改善し、化学療法の継続が可能になった。その後、吻合部局所再発に対して残胃全摘術を施行し、以降も化学療法を継続したが、初回手術後3年5ヵ月に死亡した。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J00296&link_issn=&doc_id=20161222480166&doc_link_id=%2Fab8gtkrc%2F2016%2F004312%2F166%2F1917-1919%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2016%2F004312%2F166%2F1917-1919%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 遠隔リンパ節、肝転移を伴うHER2陽性切除不能胃癌に対して化学療法後にconversion surgeryをし得た1例

    三浦 要平, 羽入 隆晃, 市川 寛, 石川 卓, 大渓 隆弘, 宗岡 悠介, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2016年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2016年10月

    記述言語:日本語  

    researchmap

  • 胃癌穿孔症例に対する治療戦略 当院における胃癌穿孔症例の検討

    宗岡 悠介, 羽入 隆晃, 石川 卓, 市川 寛, 大渓 隆弘, 日紫喜 万里子, 佐藤 優, 加納 陽介, 臼井 賢司, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2016年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2016年10月

    記述言語:日本語  

    researchmap

  • 分子標的薬は消化管癌患者の予後を改善しているか? 切除不能・転移性GISTに対するイマチニブ治療 10年間の長期追跡データ

    神田 達夫, 石川 卓, 若井 俊文

    日本消化器病学会雑誌  2016年9月  (一財)日本消化器病学会

     詳細を見る

    開催年月日: 2016年9月

    記述言語:日本語  

    researchmap

  • 食道癌根治治療後の初発肺転移に対する外科切除

    市川 寛, 石川 卓, 小杉 伸一, 中川 悟, 羽入 隆晃, 臼井 賢司, 宗岡 悠介, 亀山 仁史, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2016年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2016年7月

    記述言語:日本語  

    researchmap

  • 食道癌術前cisplatin+5-FU療法施行症例の非腫瘍性扁平上皮におけるNQO1発現の臨床的意義

    市川 寛, 石川 卓, 小杉 伸一, 羽入 隆晃, 臼井 賢司, 宗岡 悠介, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2016年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2016年7月

    記述言語:日本語  

    researchmap

  • 新旧食道癌取扱い規約における、胸部食道癌手術症例の予後の比較検討

    宗岡 悠介, 市川 寛, 石川 卓, 小杉 伸一, 羽入 隆晃, 臼井 賢司, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2016年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2016年7月

    記述言語:日本語  

    researchmap

  • 術前CF療法を施行された胸部食道癌患者における腸腰筋断面積の臨床的意義

    臼井 賢司, 市川 寛, 石川 卓, 小杉 伸一, 羽入 隆晃, 宗岡 悠介, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2016年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2016年7月

    記述言語:日本語  

    researchmap

  • 食道胃接合部腺癌に対する治療戦略

    羽入 隆晃, 石川 卓, 小杉 伸一, 市川 寛, 臼井 賢司, 宗岡 悠介, 亀山 仁史, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2016年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2016年7月

    記述言語:日本語  

    researchmap

  • 残胃進行癌に対する外科的治療戦略 残胃進行癌切除症例の臨床病理学的特徴と遠隔成績についての検討

    羽入 隆晃, 石川 卓, 小杉 伸一, 市川 寛, 臼井 賢司, 宗岡 悠介, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2016年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2016年7月

    記述言語:日本語  

    researchmap

  • 当院における早期胃癌に対するESD非治癒切除症例の検討

    羽入 隆晃, 橋本 哲, 石川 卓, 市川 寛, 臼井 賢司, 宗岡 悠介, 田中 亮, 角田 知行, 若井 淳宏, 佐藤 優, 加納 陽介, 須藤 翔, 大渓 隆弘, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本外科学会定期学術集会抄録集  2016年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2016年4月

    記述言語:日本語  

    researchmap

  • 内視鏡的切除後pT1b胃癌における簇出はリンパ節転移と関連するか?

    岡村 拓磨, 島田 能史, 亀山 仁史, 酒井 剛, 松本 瑛生, 諸 和樹, 八木 亮磨, 田島 陽介, 大渓 隆弘, 宗岡 悠介, 臼井 賢司, 須藤 翔, 市川 寛, 羽入 隆晃, 石川 卓, 小杉 伸一, 小林 隆, 若井 俊文

    日本外科学会定期学術集会抄録集  2016年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2016年4月

    記述言語:日本語  

    researchmap

  • NCD手術死亡リスクモデルによる予測死亡率と当院における胃癌幽門側胃切除患者の周術期因子との関連に関する後方視的検討

    宗岡 悠介, 市川 寛, 石川 卓, 臼井 賢司, 羽入 隆晃, 大渓 隆弘, 須藤 翔, 加納 陽介, 佐藤 優, 角田 知行, 田中 亮, 若井 淳宏, 島田 能史, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本外科学会定期学術集会抄録集  2016年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2016年4月

    記述言語:日本語  

    researchmap

  • 胃癌術後肺転移に対して外科切除を施行した3例

    宗岡 悠介, 市川 寛, 石川 卓, 臼井 賢司, 羽入 隆晃, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2016年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2016年3月

    記述言語:日本語  

    researchmap

  • 胃癌術後再発症例に対する外科的切除の意義

    羽入 隆晃, 石川 卓, 市川 寛, 臼井 賢司, 宗岡 悠介, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2016年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2016年3月

    記述言語:日本語  

    researchmap

  • 高齢者消化管間質腫瘍に対するイマチニブ治療

    石川 卓, 神田 達夫, 羽入 隆晃, 市川 寛, 宗岡 悠介, 臼井 賢司, 亀山 仁史, 小林 隆, 若井 俊文

    日本胃癌学会総会記事  2016年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2016年3月

    記述言語:日本語  

    researchmap

  • 上部胃癌に対する胃切除後の腸腰筋面積変化の検討

    臼井 賢司, 石川 卓, 羽入 隆晃, 宗岡 悠介, 市川 寛, 亀山 仁史, 若井 俊文

    日本胃癌学会総会記事  2016年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2016年3月

    記述言語:日本語  

    researchmap

  • 腹腔鏡補助下噴門側胃切除後早期に内ヘルニアを生じた1例

    松本 瑛生, 羽入 隆晃, 石川 卓, 酒井 剛, 宗岡 悠介, 臼井 賢司, 市川 寛, 田中 亮, 角田 知行, 小杉 伸一, 永橋 昌幸, 坂田 純, 亀山 仁史, 小林 隆, 若井 俊文

    日本臨床外科学会雑誌  2015年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2015年10月

    記述言語:日本語  

    researchmap

  • サイトメガロウイルス感染による直腸潰瘍の1例

    諸 和樹, 島田 能文, 八木 亮磨, 田島 陽介, 岡村 拓磨, 市川 寛, 羽入 隆晃, 滝沢 一泰, 永橋 昌幸, 高野 可赴, 石川 卓, 坂田 純, 小林 隆, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2015年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2015年10月

    記述言語:日本語  

    researchmap

  • 高齢GIST患者のイマチニブ耐性肝転移に対する肝動脈塞栓療法(TAE)の経験

    宗岡 悠介, 市川 寛, 石川 卓, 高野 徹, 臼井 賢司, 佐藤 優, 角田 知行, 田中 亮, 羽入 隆晃, 永橋 昌幸, 坂田 純, 小林 隆, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本臨床外科学会雑誌  2015年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2015年10月

    記述言語:日本語  

    researchmap

  • 当科におけるセンチネルリンパ節生検、色素法単独と色存・RI併用法の再検討

    辰田 久美子, 永橋 昌幸, 土田 純子, 諸 和樹, 庭野 稔之, 利川 千絵, 長谷川 美樹, 萬羽 尚子, 五十嵐 麻由子, 小山 諭, 坂田 純, 小林 隆, 石川 卓, 亀山 仁史, 若井 俊文

    日本臨床外科学会雑誌  2015年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2015年10月

    記述言語:日本語  

    researchmap

  • 胸部食道癌に対する食道切除後反回神経麻痺に関する検討

    佐藤 優, 小杉 伸一, 石川 卓, 加納 陽介, 羽入 隆晃, 平島 浩太郎, 番場 竹生, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2015年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 食道癌の術前補助療法の功罪 補助療法無効例の選別と周術期の対策 胸部食道扁平上皮癌における治療前臨床病理学的因子を用いた術前CF療法無効例の予測

    市川 寛, 中川 悟, 小杉 伸一, 石川 卓, 番場 竹生, 羽入 隆晃, 藪崎 裕, 松木 淳, 會澤 雅樹, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2015年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 高齢者に対する胃癌手術の安全性の検討

    平島 浩太郎, 小杉 伸一, 石川 卓, 亀山 仁史, 坂田 純, 加納 陽介, 佐藤 優, 羽入 隆晃, 番場 竹生, 若井 俊文

    日本消化器外科学会総会  2015年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 早期食道胃接合部癌に対する治療戦略

    羽入 隆晃, 石川 卓, 小杉 伸一, 番場 竹生, 平島 浩太郎, 佐藤 優, 加納 陽介, 小林 隆, 亀山 仁史, 若井 俊文

    日本消化器外科学会総会  2015年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 食道切除を施行した表在型食道類基底細胞癌4例の検討

    番場 竹生, 小杉 伸一, 石川 卓, 羽入 隆晃, 平島 浩太郎, 佐藤 優, 加納 陽介, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2015年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 食道癌化学放射線療法後、膵転移をきたした1例

    山田 沙季, 平島 浩太郎, 石川 卓, 加納 陽介, 佐藤 優, 羽入 隆晃, 番場 竹生, 小杉 伸一, 若井 俊文

    日本臨床外科学会雑誌  2015年7月  日本臨床外科学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 周術期管理 食道 食道癌切除再建術後の空腸瘻留置期間に関する検討

    小杉 伸一, 石川 卓, 番場 竹生, 羽入 隆晃, 平島 浩太郎, 市川 寛, 小林 隆, 亀山 仁史, 坂田 純, 若井 俊文

    日本消化器外科学会総会  2015年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 術前内視鏡検査による食道胃接合部癌の局在と食道浸潤長の診断精度に関する検討

    番場 竹生, 小杉 伸一, 石川 卓, 羽入 隆晃, 平島 浩太郎, 佐藤 優, 加納 陽介, 坂田 純, 小林 隆, 若井 俊文

    日本消化器外科学会総会  2015年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2015年7月

    記述言語:日本語  

    researchmap

  • 骨盤リンパ節郭清後、外腸骨血管に腸管が絞扼されたイレウスの2例

    西野 幸治, 安達 聡介, 西川 伸道, 関根 正幸, 榎本 隆之, 山田 沙季, 佐藤 優, 石川 卓, 若井 俊文

    日本婦人科腫瘍学会雑誌  2015年6月  (公社)日本婦人科腫瘍学会

     詳細を見る

    開催年月日: 2015年6月

    記述言語:日本語  

    researchmap

  • 上部消化管 E-PASS scoring systemによる胃切除術の検討

    平島 浩太郎, 小杉 伸一, 石川 卓, 田中 花菜, 加納 陽介, 市川 寛, 羽入 隆晃, 番場 竹生, 日紫喜 万理子, 永橋 昌幸, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 基礎研究・移植再生 PgR高発現のER陽性HER2陰性乳癌は、タンパク質レベルで性質の違いがあるのか

    長谷川 美樹, 小山 諭, 永橋 昌幸, 利川 千絵, 土田 純子, 辰田 久美子, 萬羽 尚子, 五十嵐 麻由子, 石川 卓, 亀山 仁史, 小杉 伸一, 小林 隆, 坂田 純, 滝沢 一泰, 島田 能史, 羽入 隆晃, 番場 竹生, 皆川 昌広, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 上部消化管 食道癌術後の重篤な合併症は腫瘍学的予後不良因子である Clavien-Dindo分類による術後合併症重症度評価の臨床的意義

    市川 寛, 小杉 伸一, 石川 卓, 番場 竹生, 羽入 隆晃, 平島 浩太郎, 加納 陽介, 田中 花菜, 日紫喜 万理子, 皆川 昌広, 小林 隆, 亀山 仁史, 坂田 純, 永橋 昌幸, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 上部消化管 E-PASS scoring systemにおける高齢者胃癌手術の検討

    田中 花菜, 平島 浩太郎, 小杉 伸一, 石川 卓, 加納 陽介, 市川 寛, 羽入 隆晃, 番場 竹生, 日紫喜 万理子, 永橋 昌幸, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 上部消化管 NCDデータによる食道切除術後死亡リスクモデルを用いた施設間比較 その実践と問題点

    日紫喜 万理子, 小杉 伸一, 市川 寛, 中川 悟, 石川 卓, 番場 竹生, 羽入 隆晃, 平島 浩太郎, 加納 陽介, 田中 花菜, 皆川 昌広, 小林 隆, 亀山 仁史, 坂田 純, 永橋 昌幸, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 上部消化管 CY1胃腺癌症例における胃切除例の検討

    加納 陽介, 小杉 伸一, 石川 卓, 番場 竹生, 羽入 隆晃, 平島 浩太郎, 市川 寛, 田中 花菜, 日紫喜 万理子, 永橋 昌幸, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 下部消化管 初発消化管間質腫瘍の手術成績

    石川 卓, 市川 寛, 羽入 隆晃, 日紫喜 万理子, 田中 花菜, 加納 陽介, 平島 浩太郎, 番場 竹生, 小杉 伸一, 永橋 昌幸, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 上部消化管 胸部食道癌cT3sT4症例の治療成績

    番場 竹生, 小杉 伸一, 石川 卓, 羽入 隆晃, 平島 浩太郎, 市川 寛, 加納 陽介, 田中 花菜, 日紫喜 万理子, 永橋 昌幸, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本外科学会定期学術集会抄録集  2015年4月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2015年4月

    記述言語:日本語  

    researchmap

  • 当科における4型胃癌の治療成績

    加納 陽介, 小杉 伸一, 石川 卓, 佐藤 優, 市川 寛, 羽入 隆晃, 番場 竹生, 若井 俊文

    日本胃癌学会総会記事  2015年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2015年3月

    記述言語:日本語  

    researchmap

  • ESD後遺残・再発病変の現状とその対応 早期胃癌に対するESD非治癒切除症例に関する検討

    羽入 隆晃, 橋本 哲, 小杉 伸一, 石川 卓, 番場 竹生, 平島 浩太郎, 加納 陽介, 若井 俊文

    日本胃癌学会総会記事  2015年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2015年3月

    記述言語:日本語  

    researchmap

  • イマチニブ治療中止によるGIST再燃症例の検討

    石川 卓, 神田 達夫, 加納 陽介, 市川 寛, 羽入 隆晃, 平島 浩太郎, 番場 竹生, 小杉 伸一, 若井 俊文

    日本胃癌学会総会記事  2015年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2015年3月

    記述言語:日本語  

    researchmap

  • 胃癌同時性肝転移に対して肝切除を行い長期生存が得られた2例

    番場 竹生, 加納 陽介, 佐藤 優, 市川 寛, 平島 浩太郎, 羽入 隆晃, 石川 卓, 小杉 伸一, 若井 俊文

    日本胃癌学会総会記事  2015年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2015年3月

    記述言語:日本語  

    researchmap

  • ESD後の追加外科切除で脾門部リンパ節転移を認めた粘膜下層浸潤胃癌の1例

    田中 花菜, 石川 卓, 市川 寛, 羽入 隆晃, 小杉 伸一, 若井 俊文, 渡邉 玄, 谷 優佑

    日本臨床外科学会雑誌  2014年12月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年12月

    記述言語:日本語  

    researchmap

  • 腺癌成分がリンパ節転移をきたした神経内分泌細胞混在胃癌の1例

    日紫喜 万里子, 羽入 隆晃, 小杉 伸一, 石川 卓, 若井 俊文, 渡邉 玄, 渡邉 佳緒里

    日本臨床外科学会雑誌  2014年12月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年12月

    記述言語:日本語  

    researchmap

  • 十二指腸潰瘍瘢痕狭窄に対する2手術例

    日紫喜 万理子, 石川 卓, 加納 陽介, 平島 浩太郎, 羽入 隆晃, 永橋 昌幸, 番場 竹生, 島田 能史, 亀山 仁史, 坂田 純, 小林 隆, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • CY1胃癌における胃切除例の検討

    加納 陽介, 石川 卓, 小杉 伸一, 羽入 隆晃, 平島 浩太郎, 番場 竹生, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • 胆管原発小細胞癌の1例

    相馬 大輝, 坂田 純, 廣瀬 雄己, 三浦 宏平, 佐藤 良平, 永橋 昌幸, 滝沢 一泰, 島田 能史, 石川 卓, 亀山 仁史, 小林 隆, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • 食道アカラシアに表在癌7病変を合併した1例

    阿部 馨, 番場 竹生, 小杉 伸一, 加納 陽介, 平島 浩太郎, 羽入 隆晃, 永橋 昌幸, 石川 卓, 島田 能史, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • ホルモン療法が奏功した肝硬変併存広範なDCISの1例

    土田 純子, 小山 諭, 利川 千絵, 長谷川 美樹, 永橋 昌幸, 諸 和樹, 滝沢 一泰, 石川 卓, 島田 能史, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小杉 伸一, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • 肝転移で発症しカプセル内視鏡によって診断し得た小腸神経内分泌腫瘍の1例

    油座 築, 皆川 昌広, 滝沢 一泰, 高野 可赴, 安藤 拓也, 三浦 宏平, 永橋 昌幸, 石川 卓, 島田 能史, 坂田 純, 亀山 仁史, 小林 隆, 小杉 伸一, 小山 諭, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • 乳管腺腫との鑑別に苦労した微小浸潤アポクリン癌の1例

    諸 和樹, 小山 諭, 長谷川 美樹, 永橋 昌幸, 利川 千絵, 土田 純子, 羽生 隆晃, 石川 卓, 島田 能史, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌弘, 小杉 伸一, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • メッケル憩室炎によるイレウスを来した腎移植後患者の1例

    田中 花菜, 石川 卓, 加納 陽介, 平島 浩太郎, 羽入 隆晃, 永橋 昌幸, 番場 竹生, 島田 能史, 亀田 仁史, 坂田 純, 小林 隆, 小杉 伸一, 小山 論, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • 大腸癌における壁内転移の臨床的意義

    山田 沙季, 島田 能史, 八木 亮磨, 中野 麻恵, 中野 雅人, 永橋 昌幸, 羽入 隆晃, 石川 卓, 坂田 純, 小林 隆, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • Pagetoid spreadで発見された直腸癌術後再発の1例

    岩城 孝和, 亀山 仁史, 中野 雅人, 阿部 馨, 山田 沙季, 八木 亮磨, 中野 麻恵, 島田 能史, 石川 卓, 坂田 純, 小林 隆, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本臨床外科学会雑誌  2014年10月  日本臨床外科学会

     詳細を見る

    開催年月日: 2014年10月

    記述言語:日本語  

    researchmap

  • 胆道癌における術前胆道ドレナージが手術部位感染症に与える影響とその対策

    坂田 純, 小林 隆, 皆川 昌広, 市川 寛, 羽入 隆晃, 島田 能史, 石川 卓, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 食道胃接合部扁平上皮癌の臨床病理学的特徴

    小杉 伸一, 石川 卓, 羽入 隆晃, 市川 寛, 皆川 昌広, 小林 隆, 亀山 仁史, 坂田 純, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2014年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 胸部食道癌術後反回神経麻痺の危険因子と自然経過に関する検討

    佐藤 優, 小杉 伸一, 市川 寛, 羽入 隆晃, 石川 卓, 皆川 昌広, 小林 隆, 亀山 仁史, 坂田 純, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2014年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • NAFLD-NASH関連肝細胞癌に対する肝切除術の周術期合併症および遠隔成績

    廣瀬 雄己, 坂田 純, 滝沢 一泰, 島田 能史, 石川 卓, 亀山 仁史, 小林 隆, 皆川 昌広, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 進行胆嚢癌に対する局所進展度別の術式選択

    須藤 翔, 坂田 純, 小林 隆, 皆川 昌宏, 羽入 隆晃, 島田 能史, 石川 卓, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 食道胃接合部癌リンパ節転移分布からみた手術戦略

    羽入 隆晃, 小杉 伸一, 石川 卓, 市川 寛, 皆川 昌広, 小林 隆, 亀山 仁史, 坂田 純, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2014年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 穿孔・縦隔炎を来した食道炎に対し、二期的にY字胃管によるバイパス術を施行した1例

    宗岡 悠介, 石川 卓, 小杉 伸一, 市川 寛, 羽入 隆晃, 坂本 薫, 小林 隆, 皆川 昌広, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2014年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 食道癌術前補助化学療法抵抗性におけるNQO1発現の関与

    市川 寛, 小杉 伸一, 松田 康伸, 皆川 昌広, 小林 隆, 亀山 仁史, 坂田 純, 羽入 隆晃, 石川 卓, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2014年7月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 進行胃癌に対する術前化学療法の栄養状態に与える影響

    宗岡 悠介, 石川 卓, 市川 寛, 羽入 隆晃, 小杉 伸一, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 良性胆道狭窄症例の治療経験

    齋藤 敬太, 坂田 純, 小林 隆, 皆川 昌広, 羽生 隆晃, 島田 能史, 石川 卓, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 食道胃接合部扁平上皮癌の臨床病理学的特徴

    小杉 伸一, 石川 卓, 羽入 隆晃, 市川 寛, 皆川 昌広, 小林 隆, 亀山 仁史, 坂田 純, 小山 諭, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • Stage II/III胃癌における転移陰性リンパ節個数の長期成績に与える影響

    田中 亮, 小杉 伸一, 市川 寛, 羽入 隆晃, 石川 卓, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 術前補助化学療法を施行した食道癌患者における小野寺Prognostic nutritional indexの臨床的意義

    市川 寛, 小杉 伸一, 石川 卓, 羽入 隆晃, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 食道・胃接合部癌に対する治療戦略 食道胃接合部癌のリンパ節転移分布からみた手術戦略

    羽入 隆晃, 石川 卓, 小杉 伸一, 市川 寛, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 当科におけるBlumgart変法の導入とその根拠

    皆川 昌広, 高野 可赴, 滝沢 一泰, 仲野 哲矢, 石川 卓, 亀山 仁史, 小林 隆, 坂田 純, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 膵癌切除例におけるsecreted protein acidic and rich in cysteine(SPARC)の発現意義

    高野 可赴, 皆川 昌広, 滝沢 一泰, 坂田 純, 小林 隆, 石川 卓, 島田 能史, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 表層拡大進展を伴う広範囲胆管癌に対する術前評価と外科治療戦略

    若井 俊文, 永橋 昌幸, 市川 寛, 島田 能史, 石川 卓, 亀山 仁史, 坂田 純, 小林 隆, 小杉 伸一, 皆川 昌広

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 肝外胆管癌における再発巣切除例の検討

    丸山 智宏, 坂田 純, 小林 隆, 皆川 昌広, 羽入 隆晃, 島田 能史, 石川 卓, 亀山 仁史, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 生体肝移植後胆管結石症例の検討

    小林 隆, 坂田 純, 皆川 昌広, 三浦 宏平, 島田 能史, 亀山 仁史, 小杉 伸一, 石川 卓, 羽入 隆晃, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 当科における腹腔鏡補助下噴門側胃切除術の短期成績

    石川 卓, 小杉 伸一, 羽入 隆晃, 市川 寛, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本消化器外科学会総会  2014年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2014年7月

    記述言語:日本語  

    researchmap

  • 細胞周期調節因子p27はNASH関連肝細胞癌再発の予測因子である

    廣瀬 雄己, 松田 康伸, 滝沢 一泰, 島田 能史, 石川 卓, 亀山 仁史, 坂田 純, 小林 隆, 皆川 昌広, 小杉 伸一, 若井 俊文

    日本肝胆膵外科学会・学術集会プログラム・抄録集  2014年6月  (一社)日本肝胆膵外科学会

     詳細を見る

    開催年月日: 2014年6月

    記述言語:日本語  

    researchmap

  • イマチニブ治療で長期生存を得られたGIST患者の検討

    石川 卓, 神田 達夫, 内藤 哲也, 小杉 伸一, 宗岡 悠介, 田中 亮, 市川 寛, 羽入 隆晃, 坂田 純, 亀山 仁史, 小林 隆, 皆川 昌広, 小山 諭, 若井 俊文

    日本癌治療学会誌  2014年6月  (一社)日本癌治療学会

     詳細を見る

    開催年月日: 2014年6月

    記述言語:日本語  

    researchmap

  • 大腸癌において免疫組織化学染色によって同定される神経侵襲の臨床的意義

    木戸 知紀, 島田 能史, 伏木 麻恵, 中野 雅人, 亀山 仁史, 野上 仁, 滝澤 一泰, 羽入 隆晃, 新田 正和, 高野 可赴, 石川 卓, 小林 隆, 坂田 純, 皆川 昌広, 小杉 伸一, 小山 論, 若井 俊文, 味岡 洋一

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 食道癌における好中球リンパ球比の臨床的意義

    小杉 伸一, 石川 卓, 羽入 隆晃, 市川 寛, 皆川 昌広, 小林 隆, 野上 仁, 亀山 仁史, 坂田 純, 小山 諭, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • タンパク質プロファイルと遺伝子プロファイルの違いによる個別化治療の可能性

    長谷川 美樹, 小山 諭, 坂田 英子, 辰田 久美子, 利川 千絵, 萬羽 尚子, 五十嵐 麻由子, 野上 仁, 小杉 伸一, 皆川 昌広, 坂田 純, 亀山 仁史, 石川 卓, 高野 可赴, 小林 隆, 吉田 豊, 山本 格, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 噴門側胃切除術、空腸間置再建後の内視鏡検査

    石川 卓, 小杉 伸一, 市川 寛, 羽入 隆晃, 坂田 純, 亀山 仁史, 小林 隆, 野上 仁, 皆川 昌広, 小山 諭, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 潰瘍性大腸炎に合併する大腸腫瘍におけるサーベイランス内視鏡検査の臨床的意義

    伏木 麻恵, 島田 能史, 木戸 知紀, 中野 雅人, 亀山 仁史, 野上 仁, 羽入 隆晃, 滝沢 一泰, 高野 可赴, 新田 正和, 石川 卓, 小林 隆, 坂田 純, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 併存疾患を有する胸部食道癌患者における食道切除術の短期及び長期成績

    市川 寛, 小杉 伸一, 羽入 隆晃, 石川 卓, 坂田 純, 亀山 仁史, 小林 隆, 野上 仁, 皆川 昌広, 小山 諭, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 食道癌根治術後の呼吸機能およびQOLの推移

    坂本 薫, 羽入 隆晃, 市川 寛, 佐藤 優, 加納 陽介, 石川 卓, 亀山 仁史, 小林 隆, 野上 仁, 皆川 昌広, 小山 諭, 小杉 伸一, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 潰瘍性大腸炎に合併した大腸腫瘍に対する手術術式の選択 回腸嚢肛門吻合術かそれとも回腸嚢肛門管吻合術か

    島田 能史, 伏木 麻恵, 木戸 知紀, 中野 雅人, 亀山 仁史, 野上 仁, 羽入 隆晃, 滝沢 一泰, 新田 正和, 高野 可赴, 石川 卓, 小林 隆, 坂田 純, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 潰瘍性大腸炎手術における回腸嚢作製に関与する因子

    亀山 仁史, 中野 雅人, 島田 能史, 伏木 麻恵, 木戸 知紀, 野上 仁, 羽入 隆晃, 滝沢 一泰, 高野 可赴, 新田 正和, 石川 卓, 小林 隆, 坂田 純, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 潰瘍性大腸炎におけるLoop ileostomy造設時のoutlet obstructionの発症状況と危険因子の検討

    中野 雅人, 亀山 仁史, 木戸 知紀, 伏木 麻恵, 島田 能史, 野上 仁, 羽入 隆晃, 滝沢 一泰, 高野 可赴, 新田 正和, 石川 卓, 小林 隆, 坂田 純, 皆川 昌広, 小杉 伸一, 小山 諭, 若井 俊文

    日本外科学会雑誌  2014年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • GIST診療の治療最前線 イマチニブ二次耐性GIST肝転移に対する肝動脈塞栓・化学塞栓療法(TAE・TACE)

    市川 寛, 石川 卓, 羽入 隆晃, 坂本 薫, 小杉 伸一, 若井 俊文

    日本胃癌学会総会記事  2014年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • リンパ節転移を伴う粘膜下層浸潤胃癌の予後に関する検討

    羽入 隆晃, 松木 淳, 小杉 伸一, 石川 卓, 梨本 篤, 薮崎 裕, 會澤 雅樹, 市川 寛, 若井 俊文

    日本胃癌学会総会記事  2014年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 術前化学療法が有効であった胃扁平上皮癌の1例

    坂本 薫, 小杉 伸一, 市川 寛, 羽入 隆晃, 石川 卓, 坂田 純, 亀山 仁史, 小林 隆, 野上 仁, 皆川 昌広, 小山 諭, 若井 俊文

    日本胃癌学会総会記事  2014年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 胃癌に対する腹腔内三部位洗浄細胞診の有用性

    石川 卓, 坂本 薫, 小杉 伸一, 市川 寛, 羽入 隆晃, 若井 俊文

    日本胃癌学会総会記事  2014年3月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2014年3月

    記述言語:日本語  

    researchmap

  • 胃切除術後患者の栄養指導拡大の取り組み

    植木 明, 石川 卓, 黒崎 ひとみ, 吉原 喬, 曽根 あずさ, 佐藤 陽子, 佐藤 真帆, 村山 稔子, 小山 諭, 若井 俊文

    日本病態栄養学会誌  2013年12月  (一社)日本病態栄養学会

     詳細を見る

    開催年月日: 2013年12月

    記述言語:日本語  

    researchmap

  • 内視鏡外科学会のE-ラーニングの内容、題材としてどのようなものが適当か? E-ラーニングによる熟練者から若手外科医へ伝える創意と熱意 新潟内視鏡外科研究会より

    皆川 昌広, 野上 仁, 亀山 仁史, 石川 卓, 若井 俊文, 黒崎 功, 酒井 靖夫

    日本内視鏡外科学会雑誌  2013年11月  (一社)日本内視鏡外科学会

     詳細を見る

    開催年月日: 2013年11月

    記述言語:日本語  

    researchmap

  • 幽門側胃切除、R-Y再建後の悪性狭窄に対する消化管ステントの使用経験

    臼井 賢司, 矢島 和人, 加納 陽介, 若井 淳宏, 坂本 薫, 石川 卓, 小杉 伸一, 神田 達夫, 若井 俊文

    日本消化器外科学会総会  2013年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2013年7月

    記述言語:日本語  

    researchmap

  • 組織学的T1食道胃接合部腺癌症例の内視鏡的・外科的治療成績

    矢島 和人, 神田 達夫, 竹内 学, 小林 正明, 石川 卓, 坂本 薫, 小杉 伸一, 味岡 洋一, 若井 俊文

    日本消化器外科学会総会  2013年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2013年7月

    記述言語:日本語  

    researchmap

  • 85歳以上超高齢者胃癌患者に対する胃切除術の短期および長期成績

    坂本 薫, 矢島 和人, 臼井 賢司, 加納 陽介, 若井 淳宏, 石川 卓, 小杉 伸一, 神田 達夫, 若井 俊文

    日本消化器外科学会総会  2013年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2013年7月

    記述言語:日本語  

    researchmap

  • 食道胃接合部癌の外科治療戦略 食道浸潤胃癌に対する経裂孔的アプローチによる切除および胸腔内吻合術の手術成績と遠隔成績

    加納 陽介, 矢島 和人, 神田 達夫, 臼井 賢司, 若井 淳宏, 坂本 薫, 石川 卓, 小杉 伸一, 若井 俊文

    日本消化器外科学会総会  2013年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2013年7月

    記述言語:日本語  

    researchmap

  • 開胸食道切除後胸腔ドレーン排液量に影響を与える因子

    小杉 伸一, 神田 達夫, 矢島 和人, 石川 卓, 坂本 薫

    日本消化器外科学会総会  2013年7月  (一社)日本消化器外科学会

     詳細を見る

    開催年月日: 2013年7月

    記述言語:日本語  

    researchmap

  • 疼痛緩和のために時期に応じて複数種の神経ブロックを行った婦人科悪性腫瘍の一症例

    生駒 美穂, 清水 大喜, 川島 寛之, 石川 卓, 小野 信, 澁澤 幸子

    日本緩和医療学会学術大会プログラム・抄録集  2013年6月  (NPO)日本緩和医療学会

     詳細を見る

    開催年月日: 2013年6月

    記述言語:日本語  

    researchmap

  • 胸部下部食道癌および食道胃接合部癌に対する経裂孔的根治的食道切除術の治療成績

    坂本 薫, 小杉 伸一, 神田 達夫, 臼井 賢司, 加納 陽介, 若井 淳宏, 石川 卓, 矢島 和人, 鈴木 力, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2013年6月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2013年6月

    記述言語:日本語  

    researchmap

  • 食道癌術後縫合不全・縦隔膿瘍に対し、経鼻的膿瘍ドレナージが有効であった3例

    臼井 賢司, 小杉 伸一, 矢島 和人, 加納 陽介, 若井 淳宏, 坂本 薫, 石川 卓, 神田 達夫, 若井 俊文

    日本食道学会学術集会プログラム・抄録集  2013年6月  (NPO)日本食道学会

     詳細を見る

    開催年月日: 2013年6月

    記述言語:日本語  

    researchmap

  • 緩和ケアチームが関与した婦人科悪性腫瘍患者の現状

    生駒 美穂, 川島 寛之, 石川 卓, 小野 信, 澁澤 幸子

    日本緩和医療学会学術大会プログラム・抄録集  2013年6月  (NPO)日本緩和医療学会

     詳細を見る

    開催年月日: 2013年6月

    記述言語:日本語  

    researchmap

  • GISTの治療における分子標的薬の位置づけ 局所進行消化管間質腫瘍に対する臓器・機能温存を企図した術前イマチニブ治療

    神田 達夫, 石川 卓, 小杉 伸一, 矢島 和人, 野上 仁, 黒崎 功, 廣田 誠一

    日本外科学会雑誌  2013年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2013年3月

    記述言語:日本語  

    researchmap

  • 臨床的粘膜下層浸潤食道癌における鎖骨上リンパ節郭清の省略可能性についての検討

    小杉 伸一, 河口 賀彦, 神田 達夫, 矢島 和人, 石川 卓, 坂本 薫, 赤池 英憲, 藤井 秀樹

    日本外科学会雑誌  2013年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2013年3月

    記述言語:日本語  

    researchmap

  • 臨床的大動脈周囲リンパ節転移陽性胃癌に対する化学療法後胃切除の治療成績

    矢島 和人, 神田 達夫, 小杉 伸一, 佐藤 優, 角田 知行, 坂本 薫, 石川 卓, 味岡 洋一

    日本外科学会雑誌  2013年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2013年3月

    記述言語:日本語  

    researchmap

  • 食道癌切除後長期生存患者の予後因子

    角田 知行, 小杉 伸一, 佐藤 優, 坂本 薫, 石川 卓, 矢島 和人, 神田 達夫, 鈴木 力

    日本外科学会雑誌  2013年3月  (一社)日本外科学会

     詳細を見る

    開催年月日: 2013年3月

    記述言語:日本語  

    researchmap

  • スキルス胃癌に対する審査腹腔鏡の臨床的意義

    坂本 薫, 矢島 和人, 神田 達夫, 佐藤 優, 角田 知行, 石川 卓, 小杉 伸一, 畠山 勝義

    日本胃癌学会総会記事  2013年2月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2013年2月

    記述言語:日本語  

    researchmap

  • TS-1+CDDPによる術前化学療法中に穿孔した胃癌の1例

    岡部 康之, 矢島 和人, 石川 卓, 小杉 伸一, 坂本 薫, 角田 知行, 佐藤 優, 神田 達夫, 味岡 洋一

    日本胃癌学会総会記事  2013年2月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2013年2月

    記述言語:日本語  

    researchmap

  • 早期上部胃癌に対する手術術式の選択 切除術式は?再建術式は? 早期上部胃癌に対する噴門側胃切除術、空腸間置法の有用性

    石川 卓, 神田 達夫, 矢島 和人, 佐藤 優, 角田 知行, 坂本 薫, 小杉 伸一, 鈴木 力

    日本胃癌学会総会記事  2013年2月  (一社)日本胃癌学会

     詳細を見る

    開催年月日: 2013年2月

    記述言語:日本語  

    researchmap

  • 進行胃癌に対するNACの現状と展望 大動脈周囲リンパ節転移陽性胃癌に対する術前化学療法の治療成績

    矢島 和人, 神田 達夫, 小杉 伸一, 佐藤 優, 角田 知行, 坂本 薫, 石川 卓, 味岡 洋一

    日本胃癌学会総会記事  2013年2月  (一社)日本胃癌学会

     詳細を見る